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Abstract 
Cerebellar ataxia affects 68% of adult patients with mitochondrial disease and is associated 
with progressive loss of co-ordination, impaired balance, and speech difficulties. In these 
patients, the cerebellum shows numerous neuropathological changes, and a prominent feature 
is the appearance of axonal torpedoes which represent swollen axons from Purkinje cells.   
Axonal torpedoes occur in the proximal portion of the Purkinje cell axon projecting into the 
granular cell layer and are mainly comprised of hyper phosphorylated neurofilament H. 
Although they have been reported in mitochondrial disease, their significance and 
contribution to disease is not known.  
Immunohistochemistry and immunofluorescence was used to characterise and quantify axonal 
torpedoes in the cerebellums of ten patients with mitochondrial disease and fourteen controls.  
A triple immunofluorescent assay was developed to reliably quantify the level of respiratory 
chain protein expression in axonal torpedoes compared to Purkinje cell bodies and their 
axons.   
A major limitation of current immunofluorescent techniques is the ability to use very thin 
brain sections (5µm) due to the intrinsic properties of the tissue causing scattering of light 
emitted from the fluorophores reducing the resolution of the image. To overcome this 
limitation, I have optimised the novel clearing technique known as CLARITY (Clear, Lipid-
exchanged, Acrylamide-hybridized Rigid, Imaging/immunostaining compatible, Tissue 
hYdrogel) to use on both mouse and human cerebellar sections from both control individuals 
and patients. The optimisation of CLARITY has allowed for the use of 250µm thick 
cerebellar sections to further characterise the morphology of axonal torpedoes in 3D volume 
as well as determining the degree of axonal changes between patients and controls on a global 
scale.  
This study provides a detailed characterisation of axonal pathology that occurs in the 
cerebellum of patients with mitochondrial disease. The success in optimising the clearing 
method that produces quality staining of neuronal structures in thick (250µm) cerebellar tissue 
from both mouse and human tissue will allow for further investigation of changes in the 
vascular, dendritic or axonal networks in 3D volume on a global scale. 
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The central nervous system (CNS) contributes to only 2% of the total body mass, however it 
consumes 20% of total oxygen of which 95% is utilised by mitochondria to produce 
adenosine triphosphate (ATP) via oxidative phosphorylation (OXPHOS) (Mink et al., 1981). 
The dependence of the CNS on mitochondria for the production of cellular energy makes it 
vulnerable to impaired ATP production.  
1.1. Mitochondria  
Originally mitochondria and eukaryotic cells existed as independent organisms until 
environmental pressures lead to the formation of a favourable endosymbiotic relationship. 
This relationship was able evolve due to mitochondria’s capacity to readily generate ATP by 
OXPHOS. Eventually the two organisms became reliant on one another for survival as a 
result all eukaryotic cells are dependent on mitochondria for energy, while the majority of 
mitochondrial proteins have become nuclear encoded (Margulies et al., 1976). 
Mitochondria are intracellular double membrane organelles 1-4μm in length and 0.3-0.7μm in 
diameter (Palade, 1953). In the outer mitochondrial membrane (OMM), voltage dependent 
anion channels (VDAC) form hydrophilic pores that regulate the movement of ions and 
molecules (<10kDa) between the cytoplasm and the inter-membrane space (IMS) (Shoshan-
Barmatz et al., 2010). Unlike the OMM, the inner mitochondrial membrane (IMM) is highly 
impermeable, restricting passive ion movement into the matrix, allowing for the creation of 
proton gradients, a step pivotal to the OXPHOS process. As both membranes are 
impermeable to large proteins, polypeptides and proteins that have mitochondrial targeting 
sequences are transported across the membranes by the protein complexes; translocase of the 
outer mitochondrial membrane (TOM) and translocase of the Inner mitochondrial Membrane 
(TIM) (Wagner et al., 2009). 
The mitochondrial cristae are invaginations of distinct membrane that are connected to the 
intermembrane space through cristae junctions creating a large surface area within the 
mitochondrial matrix (Frey and Mannella, 2000). The large surface area of the cristae 
membrane makes it suitable for the site of OXPHOS as well as iron-sulphur cluster biogenesis 
and the synthesis of mitochondrial DNA(mtDNA)-encoded and transport proteins (Vogel et 
al., 2006). The mitochondrial matrix contains the mitochondrial genome as well as a large 
number of enzymes required for β-oxidation and the tricarboxylic acid cycle. The 
mitochondrial genome (mtDNA) encodes for a number of subunits that constitute a series of 
protein complexes that are pivotal to OXPHOS, the electron transport chain.   
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1.2. Functions of Mitochondria 
As well as their essential role in the production of ATP, mitochondria are also involved in the 
production of reactive oxygen species (ROS) and iron-sulphur clusters, and are crucial for the 
modulation of calcium dynamics and apoptosis. 
1.2.1. Oxidative Phosphorylation 
The multi-subunit polypeptide complexes (I-IV) that form the respiratory chain are located in 
the IMM and are vital to the efficient biochemistry of OXPHOS. ATP is produced by the 
condensation of inorganic phosphate (Pi) and adenosine diphosphate (ADP) through a series 
of oxido-reduction reactions along the respiratory chain and is assisted by a number of 
molecules such as copper ions, cytochromes, nicotinamides, flavins and iron-sulphur centres. 
The oxido-reduction reactions result in the transport of protons across the inner membrane by 
NADH oxidoreductase (complex I), ubiquinol cytochrome c reductase (complex III) and 
cytochrome c oxidase (complex IV) and the transverse movement of electrons through the 
respiratory chain. The movement of protons and elections creates an electrochemical gradient 
that facilitates the generation of ATP through the hypothesised chemiosmosis process 
(Mitchell, 1961), where the electrochemical gradient drives the protons through complex V 
(ATP synthase) converting kinetic energy to stored chemical energy (Figure 1.1). 
Approximately 45 genes encode subunits for Complex I (NADH oxidoreductase), 7 of which 
are mtDNA encoded (Ugalde et al., 2004). The subunits form three modules (N, Q and P), 
which have distinct functions. In module N, the donation of two electrons from NADH to 
complex I, reduces the attached prosthetic group flavin mononucleotide (FMNH) to FMNH2, 
to begin the process of ATP production. The electrons produced from this reaction are passed 
via iron sulphur (Fe-S) clusters to ubiquinone (Q), resulting in its reduction to ubiquinol 
(QH2). The transfer of electrons, causes a conformational change in module P, opening a pore 
and allowing for four protons to be pumped across the IMM into the IMS 
The next step is the reduction of succinate to fumarate occurring at complex II (succinate 
dehydrogenase). Complex II is also involved in the tricarboxylic acid (TCA) cycle. Complex 
II is composed of 4 subunits which are completely nuclear encoded. The catalytic subunit 
SDHB is located in the matrix, while SDHC and SDHD anchor complex II to the IMM 
(Hagerhall, 1997). Subunit SDHA is involved in catalysing the deprotonation of succinate to 
fumarate. The generation of fumarate, produces reduced flavin adenine dinucleotide (FADH2) 
which when oxidised to flavin adenine dinucleotide (FAD) releases electrons that are passed 
through Fe-S clusters to converge at Complex III with electrons produced from Complex I 
(Cecchini, 2003).  
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Of the 11 subunits that make up complex III (ubiquinol cytochrome c reductase), it is the 
cytochrome b subunit that is encoded by the mitochondrial genome. Electrons are transferred 
through the two step Q cycle, which is coupled with the oxidation and reduction of ubiquinol-
ubiquinone resulting in two protons being pumped across for every electron that is transferred 
(Trumpower, 1990). The electrons are transferred from complex III to the CuA site of 
complex IV via the Rieske heme group of cytochrome c (Mathews, 1985).  
Complex IV (cytochrome c oxidase) is comprised of 13 subunits of which the mtDNA 
encodes for subunits I-III. Once complex IV receives the electrons at the CuA site, they are 
moved on to the catalytic site haema3 and CuB (Faxen et al., 2005). At complex IV, H2O is 
formed through the reduction of O2 by four electrons from cytochrome c. The transfer of the 
first two electrons from cytochrome b results in the reduction of haema3 and CuB forming a 
peroxide bridge once a molecular oxygen is added. The next round of electron transfer results 
in two protons being bound to the metal groups and releasing the peroxide bridge. The further 
addition of two proton ions results in the formation of two molecules of water (H2O) and the 
transfer of four protons into the intermembrane space. (Yoshikawa et al., 2006).  
All the protons that have been pumped into the intermembrane space generates an 
electrochemical gradient which Complex V (ATP synthase) utilises to convert ADP and Pi 
into ATP. There are two distinct structural domains of complex V; FO and F1. FO forms a c-
ring in the membrane through 8 hydrophobic subunits which allows the protons to pass 
through. While F1 extends into the matrix and is composed of 5 subunits forming a stationary 
ring and a central rotatory stalk (Wittig and Schagger, 2008). As protons are moved through 
the c-ring of the FO domain, glutamate residues are protonated and deprotonated causing the 
rotation of subunits ε and γ of the stationary ring. The continued rotation generates energy 
that is used to convert ADP and Pi into ATP (Yoshida et al., 2001). It takes eight protons to 
cause 360˚ of rotation producing three ATP molecules.  
 
 
Chapter 1    Introduction 
5 
 
   
 F
ig
u
re
 1
.1
: 
G
ra
p
h
ic
a
l 
d
ep
ic
ti
o
n
 o
f 
th
e 
re
sp
ir
a
to
ry
 c
h
a
in
 a
n
d
 t
h
e 
g
en
et
ic
 o
ri
g
in
s 
o
f 
th
e 
su
b
u
n
it
s.
  
T
h
e 
fi
v
e 
p
ro
te
in
 c
o
m
p
le
x
es
 i
n
v
o
lv
ed
 i
n
 o
x
id
at
iv
e 
p
h
o
sp
h
o
ry
la
ti
o
n
 (
O
X
P
H
O
S
) 
ar
e 
lo
ca
te
d
 i
n
 t
h
e 
in
n
er
 m
it
o
ch
o
n
d
ri
al
 m
em
b
ra
n
e.
 T
h
e 
m
o
v
em
en
t 
o
f 
el
ec
tr
o
n
s 
fr
o
m
 c
o
m
p
le
x
 I
 a
n
d
 I
I 
v
ia
 c
o
m
p
le
x
 I
II
 a
n
d
 c
y
to
ch
ro
m
e 
c 
to
 c
o
m
p
le
x
 I
V
 c
re
at
es
 e
n
er
g
y
 t
h
at
 e
x
tr
u
d
es
 p
ro
to
n
s 
in
to
 t
h
e 
in
te
rm
em
b
ra
n
e 
sp
ac
e 
g
en
er
at
in
g
 a
n
 e
le
ct
ro
ch
em
ic
al
 g
ra
d
ie
n
t.
 T
h
e 
k
in
et
ic
 e
n
er
g
y
 o
f 
p
ro
to
n
s 
m
o
v
in
g
 b
ac
k
 d
o
w
n
 t
h
is
 g
ra
d
ie
n
t 
in
to
 t
h
e 
m
at
ri
x
 i
s 
u
ti
li
se
d
 b
y
 c
o
m
p
le
x
 V
 t
o
 c
o
n
v
er
t 
A
D
P
 a
n
d
 i
n
o
rg
an
ic
 p
h
o
sp
h
at
e 
in
to
 A
T
P
. 
A
t 
th
e 
b
o
tt
o
m
 o
f 
th
e 
fi
g
u
re
, 
th
e 
n
u
m
b
er
 
o
f 
su
b
u
n
it
s 
en
co
d
ed
 b
y
 t
h
e 
n
u
cl
ea
r/
m
it
o
ch
o
n
d
ri
al
 g
en
o
m
es
 a
re
 s
h
o
w
n
. 
Im
a
g
e 
m
o
d
if
ie
d
 a
n
d
 t
a
ke
n
 f
ro
m
 M
a
n
d
a
vi
ll
i 
et
 a
l.
 (
2
0
0
2
) 
Chapter 1    Introduction 
6 
 
1.2.2. Reactive Oxygen Species 
Reactive oxygen species (ROS) are reactive molecules that have an oxygen atom with a ‘free 
radical’ pair of electrons attached to it. In the cell, mitochondria along with the endoplasmic 
reticulum and peroxisomes are a major source of ROS (Brown and Borutaite, 2012). In 
mitochondria, it is complexes I and III that are the main producers of ROS such as superoxide 
(O2-). Both complexes release ROS into the mitochondrial matrix, but Complex III also 
releases ROS into the intermembrane space (Muller et al., 2004).  
ROS has been shown to be involved in a number of cellular processes such as cell 
differentiation, autophagy and signalling cascades through reversible post translational protein 
modifications (Rhee et al., 2000; Sena and Chandel, 2012). However an overabundance of 
ROS can lead to cellular damage, apoptosis, and de novo mtDNA mutations, therefore the 
tight regulation of ROS is imperative. There a number of mechanisms present to detoxify 
ROS, for example within mitochondria O2- detoxification occurs through the reduction of 
O2- to H2O2 by the different isoforms of superoxide dismutase (SOD).  
1.2.3. Iron-Sulphur clusters 
Mitochondria play an important role in the biogenesis of iron-sulphur (Fe-S) clusters and iron 
regulation in the cell. Fe-S clusters are essential for OXPHOS as they are present within 
complexes I, II and III where they function to facilitate electron transfer by repeatedly 
changing the redox status of iron from Fe2+ to Fe3+. In addition to their role in OXPHOS, 
Fe-S clusters are important cofactors in a number of cellular process such as DNA repair and 
maintenance, enzyme catalysis and gene expression (Lill et al., 1999). Therefore the efficient 
formation of Fe-S clusters in the mitochondria is paramount to survival.  
1.2.4. Calcium Dynamics 
The internal concentration of calcium has to be tightly controlled as it is involved in 
numerous processes essential to cellular viability ranging from roles in excitatory 
neurotransmission to the activation of enzymes involved in both cell signalling and apoptosis. 
Mitochondria are vital to the regulation of intracellular Ca2+ concentration, so when cytosolic 
concentration exceeds 10μM, there is massive influx of calcium down a steep electrochemical 
gradient through the voltage-dependent anion channel (VDAC) in the outer membrane, and 
the Mitochondrial Calcium Uniporter (MCU) (Baughman et al., 2011) and MCUR1 
(mitochondrial calcium uniporter regulator 1) (Mallilankaraman et al., 2012) in the inner 
membrane(Bernardi, 1999). The subsequent increase in matrix calcium concentration causes 
an increase in ATP production by increasing respiratory rate and the rate of proton extrusion 
(McCormack and Denton, 1989). 
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The regulation of Ca2+ in neurons is more imperative than other cell types, as Ca2+ plays an 
integral role in a number of neuronal processes such as synaptic plasticity and 
neurotransmitter release as well as determining the location of mitochondria along the axon of 
a neuron (MacAskill et al., 2009). Ca2+ is involved in the regulation of mitochondrial 
mobility, where there is a increase in Ca2+ mitochondria become concentrated. This allows 
for an increased density of mitochondria at sites where calcium influx is dynamic such as 
presynaptic terminals and postsynaptic dendritic spines (Yi et al., 2004). Mutations of 
mtDNA not only disrupt the mitochondrion’s ability to produce ATP but also its ability to 
handle Ca2+, for example mature neurons derived from embryonic stem cells harbouring 
mtDNA mutations have been shown to exhibit progressive deficits in Ca2+ transients when a 
repeated glutamate stimuli was applied (Trevelyan et al., 2010).  
1.2.5. Apoptosis 
Not only do mitochondria produce the molecule that is essential for life but they also play a 
crucial role in programmed cell death through the release of cytochrome c during apoptosis. 
Apoptosis is a form of cell death, whereby death is caused by a general process of blebbing of 
the cell membrane, cell shrinkage, condensation of chromosomes and nuclear fragmentation. 
Apoptosis can be initiated either intrinsically through a cell damage mediated pathway or 
extrinsically by a cell receptor mediated pathway. 
A mitochondrion’s role in apoptosis is initiated when a ligand specific to a death receptor 
such as (FAS) binds to it, resulting in procaspase 8 being cleaved into the active caspase 8 
through the Fas-associated death domain (FADD). Caspase 8 initiates the mitochondrial 
pathway of apoptosis by cleaving the BH-3 protein Bid into truncated Bid (tBID). It is 
disputed whether tBid activates the pro-apoptotic proteins Bax (Wang et al., 1996) and Bak or 
prevents these proteins from forming heterodimers (Willis et al., 2007), either way tBid 
allows for the monomers of Bax or Bak to homo-oligomerise into proteolipid pores in the 
outer mitochondrial membrane resulting in the permeabilisation of the outer mitochondrial 
membrane (Renault et al., 2013). The permeabilisation of the membrane results in the release 
of cytochrome c and pro-apoptotic proteins such as SMAC/Diablo and apoptosis inducing 
factor (AIF). The permeabilisation of the mitochondrial outer membrane does not affect the 
structural integrity of mitochondria (von Ahsen et al., 2000). Cytochrome c binds to 
apoptosis- protease-activating factor 1 (APAF-1) forming the apoptosome, which cleaves 
procaspase 9 into caspase 9 which activates downstream effector caspases that leads to 
chromogen condensation and DNA fragmentation. While nuclear DNA undergoes 
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fragmentation during apoptosis, mtDNA has been observed to remain intact (Murgia et al., 
1992). 
Mitochondrial dynamics as explained in section 1.3 have also been shown to regulate 
apoptosis, for example an overexpression of mitochondrial fission proteins like hFis1, leads to 
an increase in apoptosis (James et al., 2003). This is negated when those mitochondrial fission 
proteins are inhibited or fusion proteins like OPA1 are over expressed (Lee et al., 2004; 
Frezza et al., 2006). 
1.3. Mitochondrial Dynamics 
Mitochondria are highly mobile and do not always exist as single organelles. Through the 
process of fission and fusion they form dynamic networks facilitating the appropriate 
distribution of mitochondria within the cell and as a method of mitochondrial quality control 
(Campello and Scorrano, 2010).  
Mitochondrial fission is a way of isolating damaged portions of mitochondria preventing 
further oxidative damage to the network therefore preserving the integrity of mtDNA and the 
functioning capabilities of the remaining mitochondria (Parone et al., 2008). While 
mitochondrial fusion allows nuclear encoded mitochondrial proteins to be exchanged between 
two individual mitochondria as well as functional complementation (Gilkerson et al., 2008; 
Kowald and Kirkwood, 2011). Functional complementation occurs when mitochondria 
carrying a mtDNA mutation fuse, allowing for the mixing of mtDNA transcripts keeping the 
levels of mtDNA mutations low and tolerable and subsequently maintaining a higher quality 
of mitochondria throughout the mitochondrial population (Nakada et al., 2001).  
1.3.1. Fission  
The process of mitochondrial fission is mediated by the large guanosine triphosphatase 
(GTPase) DRP-1, a dynamin-related protein (Smirnova et al., 2001). DRP-1 is a cytosolic 
protein that is recruited to the mitochondrial membrane through receptors anchored on the 
outer mitochondrial membrane (Loson et al., 2013). There are four receptors known to be 
involved in the recruitment of DRP-1; mitochondrial fission protein 1 (Fis1) (Yoon et al., 
2003), mitochondrial fission factor (Mff) (Gandre-Babbe and van der Bliek, 2008), and 
mitochondrial dynamics proteins of 49 and 51 kDa (MiD49 and MiD51) (Palmer et al., 2011; 
Zhao et al., 2011). Recently it has been shown that the role of Fis1 in fission is only a minor 
role and that it has a more significant role in the degradation of mitochondria through 
mitophagy (Otera et al., 2010; Shen et al., 2014). Mff is seen as the main recruiter of DRP-1 
as an overexpression of mff results in the fragmentation of the mitochondrial network due to 
an increase in fission rates while a knockdown or knockout of mff reduces the recruitment of 
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DRP-1 as shown by a reduction in the numbers of mitochondrial DRP-1 puncta (Otera et al., 
2010; Loson et al., 2013). As with Mff, both MiD49 and MiD51 have been shown to recruit 
DRP-1 to the mitochondria independently of Mff (Palmer et al., 2013). However when 
MiD49 and MiD51 are overexpressed there is an inhibition of fission, this has been attributed 
to MiD49 and MiD51 binding to DRP-1 dimers that are inactive (Palmer et al., 2013; Liu and 
Chan, 2015).  
DRP-1 molecules oligomerise to form active helices that have the same dimensions as the 
mitochondrial constriction sites and wrap around the mitochondrion (Ingerman et al., 2005). 
As the constriction point at which DRP-1 wraps around the mitochondria has a dimension of 
129nm (Ingerman et al., 2005) and the normal diameter of mitochondria is 500-1000nm, 
DRP-1 relies on the endoplasmic reticulum (ER) to wrap tightly around the mitochondrial 
network causing it to constrict and allowing for the DRP-1 helices to wrap round (Friedman et 
al., 2011). The recruitment proteins Mff, MiD49 and MiD51 have been observed at the ER-
mitochondria contact sites, indicating that these are the primary sites of mitochondrial fission 
(Elgass et al., 2015).  Hydrolysis of GTP by DRP-1 is thought to provide the force to scission 
the outer and inner membranes (Ingerman et al., 2005).  
Disruption of fission can have devastating effects, as exemplified by a neonate case where a 
dominant-negative mutation to the DRP-1 gene caused abnormal brain development, optic 
atrophy and persistent lactic acidemia (Waterham et al., 2007). In mice, knocking out DRP-1 
has been shown to be embryonic lethal (Wakabayashi et al., 2009). While in adult mouse 
forebrain neurons, inducible DRP-1 ablation was shown to cause deficits in synaptic 
transmission and memory function with hippocampal atrophy (Oettinghaus et al., 2016). 
Using a Drp1flox/flox::L7-Cre mouse model, Kageyama and colleagues knocked out DRP-1 
in mouse post mitotic Purkinje cells which resulted in the mitochondria becoming elongated 
due to the inhibition of fission. There was also an increase in oxidative stress leading to a loss 
of respiratory function, an accumulation of ubiquitin and mitophagy markers ultimately 
leading to Purkinje cell degeneration (Kageyama et al., 2012).This phenotype was rescued 
when the DRP1 KO Purkinje cells were treated with anti-oxidants. These findings indicate 
that mitochondrial fission is critical for the functioning of mitochondria and the survival of 
neurons.  
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1.3.2. Fusion 
Unlike mitochondrial fission, mitochondrial fusion involves the co-ordinated fusion of both 
the OMM and IMM. The OMM is fused together through the activity of mitofusin 1 (Mfn 1) 
and mitofusin 2 (Mfn2), two large GTPases (Chen et al., 2003). Both proteins contain two 4,3 
hydrophobic heptad repeats (HR2) and through the interaction of HR2 repeats the mitofusins 
form stable complexes (Koshiba et al., 2004). Two transmembrane regions within the 
mitofusin proteins anchor the proteins to the OMM leaving the C and N terminal projecting 
into the cytosol and their interaction promotes mitochondrial fusion (Rojo et al., 2002). 
Mutations within Mfn2 are known to be the primary cause of Charcot-Marie-Tooth 
neuropathy type 2A, a disease characterised by axonopathy resulting in weakness and atrophy 
of distal muscles and mild sensory loss (Zuchner et al., 2004; Grandis and Shy, 2005). 
Knockout of Mfn1 and Mfn2 in murine dopaminergic neurons results in motor deficits (Pham 
et al., 2012), in addition Mfn2 KO mice showed reduced mitochondrial mass and transport 
within dopaminergic terminals in the striatum. 
OPA1, a GTPase located in the intermembrane space is essential for the fusion of the IMM 
(Chen et al., 2005). OPA1 requires the presence of Mfn 1 to regulate fusion (Cipolat et al., 
2004). Mutations within OPA1 result in Optic atrophy type 1, a dominantly inherited optic 
neuropathy that occurs in 1 in 50,000 individuals (Delettre et al., 2000). A downregulation of 
OPA1 in Hela cells caused the fragmentation of the mitochondrial network along with the loss 
of the mitochondrial membrane potential, disorganization of the cristae and the release of 
cytochrome c (Olichon et al., 2003). As shown, when there is a disruption to mitochondrial 
dynamics there can be serve consequences for the cell and the correct functioning of the 
proteins involved is required for the neurons survival. 
1.3.3. Mitochondrial Motility 
Biogenesis of mitochondria takes place in the soma of the neuron and with neurons being 
polar cells with extensive axons (Hirokawa, 1993), the efficient transport of mitochondria to 
areas of high energy demand such as the synapses and Nodes of Ranvier is imperative 
(Grafstein and Forman, 1980). This is shown by mitochondria being highly motile organelles 
with one third being mobile at any given point and 70% of those are undergoing anterograde 
transport at a rate of rate of 0.1-2μM Sec-1 (Ligon and Steward, 2000). Through the rapid 
transition from anterograde motor proteins to retrograde motor proteins, mitochondria achieve 
bidirectional movement (Figure 1.2A). 
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The kinesin motor protein superfamily are the main motor proteins to provide the kinetic 
energy for anterograde transportation, with the isoform KIF5β being the main motor protein 
for the transport of mitochondria (Tanaka et al., 1998). KIF5β binds to mitochondria through 
the recruitment of a protein complex composed of Miro and Milton. Milton was shown to be 
important for this interaction as overexpressed kinesin would only bind to mitochondria when 
Milton was co-expressed in rat cultured hippocampal neurones (Wang and Schwarz, 2009). 
Miro provides the link between Milton and kinesin, and also is pivotal to in the role of 
stopping the anterograde transport of mitochondria. 
Miro contains a calcium binding EF hand motif composed of 29 residues (Fransson et al., 
2003), when calcium binds to the helix-loop-helix structure formed from the EF motif 
(Nelson and Chazin, 1998), it promotes an interaction between the heavy chain of kinesin and 
Miro subsequently arresting anterograde transport (Figure 1.2B (Cai and Sheng, 2009). The 
cessation of transport by calcium would enable an increase in mitochondrial density in areas 
with a high cytosolic calcium concentration such as the synaptic terminals especially 
following an action potential and increasing the availability of ATP for processes such as 
neurotransmitter uptake and rebalancing of ionic gradient and calcium handling (MacAskill et 
al., 2009).  
Retrograde transport is minus-end microtubule directed and the kinetic energy for this is 
provided by the multi-subunit complex Dynein. The interaction between mitochondria and 
Dynein is dependent on the accessory factor Dynactin. Prevention of Dynactin binding 
through antibodies and pharmacological agents caused a termination in retrograde transport 
(Hafezparast et al., 2003). Retrograde transport becomes important when mitochondria 
become dysfunctional are transported to the soma to be selectively degraded in a process 
known as mitophagy.  
Correct functioning of the mitochondria and the respiratory chain has been shown to 
have important effects on the rate and direction of mitochondrial transport. When 
100μM antimycin, a complex III inhibitor is applied, an increase in retrograde 
transport of mitochondria was observed (Miller and Sheetz, 2004). When the 
mitochondrial uncoupler carbonyl cyanide m-chlorophenylhydrazone (CCCP) was 
applied, there was a complete termination of all mitochondrial transport with transport 
recovering once the CCCP had been washed from the cells (Miller and Sheetz, 
2004). The application of Annonacin, a lipohillic inhibitor of complex I, to striatal 
neurons derived from embryos of Wistar rats resulted in an expected decrease in 
ATP but also an increase in retrograde transport of mitochondria (Escobar-Khondiker 
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et al., 2007). The application of pharmacological agents show that the correct 
functioning of mitochondria is required for the efficient transport of these organelles 
and that a disruption to the respiratory chain arising from mtDNA mutation is likely to 
impair axonal transport (Brini et al., 1999).  
    
 
Figure 1.2: Axonal transport of mitochondria. 
A) Anterograde transport of mitochondria in the axons (towards plus end 
of microtubules in the axon tips) is facilitated by Kinesin, a motor protein 
composed of two heavy chains and two light chains. Retrograde transport 
is completed by the dynein complex, which is composed of the dynein 
heavy, intermediate, intermediate light and light chains and several 
dynactin subunits (such as DCTN1 and DCTN2). B) The proteins Miro 
and Milton mediates the connection of kinesin to the mitochondria and is 
involved in the cessation of anterograde transport.  When there is an 
increase in cytosolic Ca2+, Ca2+ binds to the EF hand motif in Miro 
causing a conformational change resulting in an interaction between the 
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heavy chain of kinesin and Miro subsequently arresting anterograde 
transport. Figure was adapted from Millecamps and Julien (2013) 
 
 
1.4. Mitochondrial Biogenesis 
A cell’s requirement for ATP can fluctuate in response to environmental and metabolic 
stimuli such as exercise. Biogenesis of mitochondria is initiated to increase mitochondrial 
number and activity to ensure the ATP demands are met (Kelly and Scarpulla, 2004). The 
main protein involved in the regulation of biogenesis is the peroxisome proliferator activated 
receptor  coactivator 1 (PGC-1) (Puigserver and Spiegelman, 2003). Through its 
interactions with transcription factors such as Nuclear respiratory factor 1 (NRF1), nuclear 
respiratory factor 2 (NRF2) and oestrogen related receptor  (ERRα) (Wu et al., 1999; 
Scarpulla, 2002), PGC-1 can regulate the expression of genes involved in the function of 
mitochondria. For example, the activation of NRF1 and NRF2 by PGC-1 results in 
downstream activation of other factors and proteins which include mitochondrial transcription 
factor A (TFAM), mitochondrial transcription factor B2 (TFBM2) and a number of nuclear 
encoded respiratory chain proteins such as cytochrome c (Evans and Scarpulla, 1989; Gleyzer 
et al., 2005). Additionally TFAM is involved in the transcription of mtDNA, resulting in a 
further increase in respiratory chain protein production. The increase in production of proteins 
through the activity of PGC-1 results in an increase in mitochondrial activity and production 
of ATP.  
It was originally believed that all synthesis of proteins and organelles was completed in the 
soma of the neuron before being transported to the distal regions. However recent evidence 
has shown a repertoire of mRNA’s in both the axons and growth cones of neurons (Gumy et 
al., 2011; Deglincerti and Jaffrey, 2012). mRNAs that encode nuclear transcribed 
mitochondrial proteins have been located in the axons and presynaptic terminal (Gioio et al., 
2001; Hillefors et al., 2007; Taylor et al., 2009). When translation of the mRNA or 
mitochondrial protein import was inhibited in the axons of cultured sympathetic neurons, 
there was a decrease in mitochondrial membrane potential in cultured sympathetic neurons 
(Hillefors et al., 2007). These findings and the observation of mRNA in axons suggests that 
nuclear-encoded mitochondrial proteins are synthesised and imported into the mitochondria 
locally at the axon, allowing axonal mitochondria to respond quickly to a change in local 
energy demands.  
 
Chapter 1    Introduction 
14 
 
 
 
1.5. Mitochondrial Mitophagy 
Mitophagy is the process of selective destruction of mitochondria via autophagosomes to 
either control the number of mitochondria or to remove damaged mitochondria from the cell. 
One comprehensively characterised pathway for the clearance of dysfunctional or depolarised 
mitochondria via mitophagy is the ubiquitin-dependent PINK1/Parkin pathway (Figure 1.3). 
This pathway first gained major interest following the discovery that mutations to the Parkin 
gene (PARK2) accounted for almost 50% of all familial autosomal recessive juvenile 
Parkinson’s Disease (PD) (Lucking et al., 2000). Pink1 mutations have also be attributed to be 
the cause of a rare familial form of PD (Valente et al., 2004).  
PINK1 is a Ser/Thr kinase that is found partially inserted into the OMM that has its C-
terminal kinase domain exposed to the cytosol (Zhou et al., 2008). When a mitochondrion is 
healthy (Figure 1.3A), PINK1 is imported across the OMM and IMM via a N-terminal 
mitochondrial targeting sequence (MTS) which is immediately cleaved by a mitochondrial 
processing peptidase (MPP) in the matrix and then the remaining PINK1 protein is further 
cleaved by the IMM protease, Presenilin-associated rhomboid like protein (PARL) (Deas et 
al., 2011; Greene et al., 2012). When mitochondria become damaged or depolarised 
(Figure1.3B), PINK1 is no longer imported or cleaved by MPP or PARL, resulting in an 
accumulation of PINK1 on the OMM (Jin et al., 2010). The accumulation of PINK1 on the 
OMM results in its interaction with MOM translocase (TOMM) complex, then 
homodimerisation and self-phosphorylation, causing PINK1 to become a highly active kinase 
which  subsequently recruits Parkin, an E3 ubiquitin ligase from the cytosol to the 
mitochondria (Narendra et al., 2008; Okatsu et al., 2013; Aerts et al., 2015). PINK1 then 
phosphorylates Parkin and ubiquitin, resulting in phosphor-Parkin which undergoes a 
conformational change allowing for phosphor-ubiquitin to bind to it creating a maximally 
activated phosphor-Parkin (Shiba-Fukushima et al., 2012; Koyano et al., 2014). The activated 
Parkin then ubiquitinates a number of proteins on the OMM such as mfn1(Glauser et al., 
2011). These ubiquitin chains are further phosphorylated by PINK1, promoting the 
recruitment of more Parkin to the mitochondria and accelerating the process of Parkin 
recruitment, activation and ubiquitination of mitochondria (Shiba-Fukushima et al., 2014; 
Okatsu et al., 2015). The formation of a ubiquitin chain causes the recruitment of p62 and 
HDAC6 (Lee et al., 2010b). Both are key regulatory components of the autophagy machinery, 
with p62 binding to the key autophagosome component LC3, while cortactin-dependent actin-
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remodelling machinery that promotes the recruitment of autophagosome and lysosomes is 
activated by HDAC6 (Lee et al., 2010a; Lee et al., 2010b). Once mitochondria have been 
recruited into the autophagosome/lysosome they then undergo enzymatic degradation. In 
addition to its role in activating Parkin, PINK1 also phosphorylates MIRO, causing its 
degradation in a Parkin dependent manner with the loss of MIRO causing a dissociation of 
mitochondria from kinesin and a cessation of movement (Wang et al., 2011). It has been 
postulated that the reason MIRO is targeted by PINK1 is so that the arrest of mitochondrial 
motility prevents further fusion, helping to quarantine depolarised or damaged mitochondria 
within a defined location and before promoting engulfment by an autophagosome (Wang et 
al., 2011).  
The majority of the work characterising the PINK1/Parkin pathway of mitophagy was 
completed on immortalized and non-neuronal cell lines with results being controversial as the 
levels of mitochondrial damage induced to initiate the PINK1/Parkin pathway of mitophagy is 
viewed as non-physiological (Grenier et al., 2013).  It is important to understand the 
physiological role of mitophagy in neurons especially axons as most neuronal mitochondria 
reside in distal dendritic and axonal processes while axonal degeneration is known to precede 
the loss of soma in PD (Burke and O'Malley, 2013). Lysosomes have been observed in the 
axons of primary dorsal root ganglion neurons (Maday et al., 2012). In a recent study, a 
genetically encoded photosensitizer targeted to mitochondria (mt-KR), was expressed in rat 
hippocampal neurons which when induced by light caused local ROS-mediated damage to 
mitochondria (Ashrafi et al., 2014). When distal axonal mitochondria were selectively 
damaged, the study showed that mt-KR created fragmented or rounded mitochondria and 
there was an accumulation of both Parkin and LC3 on those mitochondria, indicating that the 
autophagosomes had formed around the mitochondria. This accumulation of Parkin and LC3 
was also observed when antimycin A was applied to distal axonal mitochondria to cause 
depolarisation, and the colocalization of Parkin and LC3 at the mitochondria was inhibited 
when completed in either  Parkin-/- or PINK1 -/- axons (Ashrafi et al., 2014). This study 
along with earlier experiments by Cai et al. (2012), which showed in mature cortical neurons 
that a dissipation of the mitochondrial membrane potential induced Parkin-mediated 
mitophagy in somatodendritic regions, highlighted that in neurons the PINK1/Parkin pathway 
of mitophagy is a used method to remove damaged mitochondria.  
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1.6. Mitochondrial Genome 
Mitochondria are semi-autonomous organelles that uniquely contain their own DNA in the 
matrix. Mitochondrial DNA (mtDNA) exists in multiple copies of a circular, double stranded 
genome. mtDNA is observed as discrete nucleoids, composed of 1-2 mtDNA molecules 
(Wang and Bogenhagen, 2006; Kukat et al., 2011). The mtDNA genome is 16,569 base pairs 
(bp) long, encoding 37 genes for 22 tRNA’s, 13 proteins for subunits of respiratory chain 
complexes, 12S and 16S rRNA (Figure 1.4 (Nass et al., 1965)).  There is very little non-
coding capacity in the mitochondrial genome, with only the strand-displacement loop (D-
loop), which contains elements necessary for mtDNA transcription, the only known non-
coding region in the mtDNA (Arnberg et al., 1971; Kasamatsu et al., 1971) . This lack of 
introns makes mtDNA a very compact and concise molecule (Anderson et al., 1981).   
MtDNA has a guanine-rich heavy chain that encodes two rRNAs, 12 mRNAs and 14 tRNAs 
while the cytosine-rich light chain encodes 1 mRNA and 8 tRNAs (Figure 1.4 (Bestwick and 
Shadel, 2013)). As mentioned in section 1.2.1, genes within mtDNA encode for subunits 
within complex I, complex III, complex IV and complex V while complex II is entirely 
nuclear encoded (Grossman, 1990). 
 It is widely accepted that mtDNA is solely inherited through the maternal lineage as 
mitochondria within the sperm are destroyed by a ubiquitin-dependent mechanism (Sutovsky 
and Schatten, 2000). However there is one case of paternal mitochondrial inheritance, where 
paternal mtDNA was identified in the skeletal muscle of an individual (Schwartz and Vissing, 
2002).  
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    Figure 1.4: The mitochondrial DNA genome.  
The mitochondrial genome is found as discreet circular pieces of DNA within 
the matrix of mitochondria. The mtDNA genome is 16,569 bp long and 
encodes 37 genes; 22 tRNAs, 13 subunits of complexes, 12S and 16S rRNA. 
The majority of genes are located on the guanine rich heavy strand rather than 
the cytosine-rich light chain. The 22 tRNA’s are depicted by black lines with 
each letter representing the amino acid that it encodes for. The 13 subunits are 
colour coded for each complex; complex I (blue), Complex III (green), 
complex IV (red) and complex V (yellow). MtDNA replication begins on the 
heavy chain at OH before being initiated at OL site. Image taken from Taylor 
and Turnbull (2005). 
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1.6.1.Heteroplasmy, Homoplasmy and Threshold 
As mentioned, there are multiple copies of mtDNA in each mitochondrion, ranging from 100 
of copies in sperm to hundreds of thousands of mitochondria in the unfertilized oocyte 
(Stewart and Chinnery, 2015). As each copy of mtDNA replicates independently and the 
mtDNA repair mechanism is less efficient compared to nuclear DNA, mutated or wild type 
mtDNA can coexist within the same mitochondria. When all copies of mtDNA have the same 
sequence (whether mutated or wild type), the cell is deemed to be homoplasmic. However 
when there is small genetic variation within a number of the mtDNA molecules the cell is 
deemed to be heteroplasmic.  
If the cell contains a pathogenic mutation, depending on the cell type, it can normally tolerate 
a high percentage of mutated mtDNA and must pass a threshold before a biochemical defect 
is observed (Figure 1.5). For a point mutation involving tRNA genes a typical threshold level 
is around ~90% , while the threshold for a mtDNA deletion is ~70-80% (Sciacco et al., 1994; 
Wallace et al., 1995; Yoneda et al., 1995; Durham et al., 2007). The threshold frequency is 
dependent on the tissue and mutation type, for example neuronal mitochondria were more 
vulnerable to complex I deficiencies when compared to isolated mitochondria from the heart, 
kidney, liver or muscle (Rossignol et al., 1999).  
    Figure 1.5: Mitochondrial DNA heteroplasmy and Biochemical threshold effect.  
As there are multiple copies of mtDNA in a single mitochondria, both wild 
type (green) and mutated (red) mtDNA can co-exist in the same mitochondria 
resulting in heteroplasmy. The cell can tolerate high levels of a pathogenic 
mutations, typically the threshold is ~90% for a point mutation involving a 
tRNA gene or for a mtDNA deletion it is ~70-80% and needs to be exceeded 
before a biochemical defect is observed. 
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1.6.2. Replication of mtDNA 
MtDNA replication is continually occurring and is independent of nuclear DNA replication 
(‘relaxed replication’). However expression of both nuclear and mitochondrial DNA must be 
closely co-ordinated as all the proteins involved in mtDNA replication are nuclear encoded 
and imported into the mitochondria. The machinery involved in the replication of mtDNA is 
composed of DNA polymerase γ (POLG), a DNA helicase (Twinkle), mitochondrial single 
stranded binding (mtSSB) proteins and a mitochondrial RNA polymerase (POLRMT) 
(Spelbrink et al., 2001; Fuste et al., 2010). 
POLG is a nuclear encoded protein that is translated from 23 exons on chromosome 15q25 
(Walker et al., 1997). It is a heterodimer, composed of the 140kDa catalytic subunit POLG-A, 
and two copies of the accessory protein POLG-B. POLG-A is the catalytic component that 
contains the DNA polymerase site and a 3’-5’ exonuclease for proof reading, while POLG-B 
improves the rate of DNA synthesis by improving the ground state nucleotide binding and 
increasing the rate of reaction (Johnson et al., 2000; Lee et al., 2009). While Twinkle, 
separates the two strands of DNA in a 5′–3′ direction, allowing for the mtDNA to be 
replicated (Spelbrink et al., 2001). 
The first method of mtDNA replication proposed was the strand displacement model 
(Clayton, 1982). In this model, replication begins unidirectionally on the heavy (H) strand at 
the origin of heavy strand synthesis (OH), the progression of replication displaces the heavy 
strand. The H strand is progressively replicated, leading to the eventual exposure of the origin 
of light-strand synthesis (OL) on the light strand. Exposure of the OL, results in the formation 
of a stem loop structure which initiates the replication of the light strand (Wong and Clayton, 
1985). For the first 25 nucleotides,  human mitochondrial RNA polymerase (POLRMT) is 
bound to the light strand before being displaced by POLG commencing the replication of the 
light strand in the opposite direction (Fuste et al., 2010). Replication will continue until both 
strands have been replicated creating a daughter mtDNA molecule (Brown et al., 2005). 
650 nucleotides away from the OH is a series of DNA sequence motifs know as termination 
associated sequences (TAS) that result in the termination of 95% of replication initiated at OH 
(Doda et al., 1981). Premature termination at these sites, results in a strand of DNA being 
formed known as 7S DNA which remains bound to the parental L strand creating a triple-
stranded displacement loop (D-loop). It is thought that the 3’ end of the D loop, can initiate 
termination, allowing for a regulatory mechanism of mtDNA replication and the subsequent 
control over copy number (Jemt et al., 2015). 
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However an alternative method has been proposed, a synchronous model of replication where 
by replication of both the leading and lagging strands are coupled together (Holt et al., 2000). 
Further investigation into this model has established the incorporation of ribonucleotides 
along the displaced lagging strand (Yasukawa et al., 2006). The ribonucleotides role in 
initiating the lagging strand replication was confirmed when it was shown, in vitro, that OL-
dependent initiation of replication was achieved using only POLRMT and DNA replication 
factors (Fuste et al., 2010). POLRMT and ribonucleotides are likely to generate RNA primers, 
which initiates lagging strand replication by POLG (Holt, 2009). The benefit of this model 
over the strand displacement model is that it prevents long repeats of DNA being exposed, as 
this exposure in bacteriophages is associated with increased frequency of DNA damage (Bron 
et al., 1991). The models of mtDNA replication are depicted in Figure 1.6. 
1.6.3. Transcription of mtDNA 
The three promoter sites for the initiation of transcription of mtDNA are Heavy strand 
promoter 1 (HSP1) and 2 (HSP2) and light strand promoter (LSP) on the light strand 
(Bestwick and Shadel, 2013). Transcription from the initiation sites LSP and HSP2 results in 
a full genome length polycistronic copy of the mtDNA (Bonawitz et al., 2006). Bi-directional 
transcription is completed by POLRMT, human mitochondrial transcription factor B2 
(TFB2M) and the mitochondrial transcription factor A (TFAM) (Rebelo et al., 2011). TFAM 
preferentially activates transcription at LSP and HSP1 by binding downstream of the 
promoter and causing a 90˚ bend in the DNA, opening the promoter up and allowing 
enhanced interaction of the c-terminal of TFAM  with TFB2M (Ngo et al., 2011).  
When transcription is initiated at HSP1, it is prematurely terminated due to the termination 
factor, MTERF, binding to a 22bp termination site in the sequence of tRNA Leu (UUR) 
producing a transcript containing two rRNA genes and two tRNA genes (Yakubovskaya et 
al., 2010).  
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    Figure 1.6: Models of mtDNA replication.  
In the strand displacement model (a-c), replication begins unidirectional at the 
OH within the D-loop displacing the heavy strand from the light strand (a). 
Replication of the H strand progresses until, it eventually expose the origin of 
light-strand synthesis (OL) on the light strand (b). Following exposure of the 
OL, replication of the light strand begins in the opposite direction, replication 
continues in both directions until both strands have been fully replication. In 
the synchronous model (d), mtDNA replication begins at a zone of replication 
(OriZ), where replication occurs bi-directionally. The ribonucleotide 
incorporation throughout the lagging strand (RITOLS) model (e-g) is similar to 
the strand displacement model, in that replication begins at OH. However as 
the heavy strand is displaced, RNA intermediates are produced (dashed lines) 
on the light strand before being converted to DNA. The inclusion of RNA 
intermediates prevents long repeats of DNA being exposed, reducing the 
chance of DNA damage (Krishnan et al., 2008). Image taken from Krishnan et 
al. (2008)  
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1.6.4. Translation of mtDNA 
The mRNA produced from the mtDNA has a number of unusual features which includes that 
they have a poly(A) tail that may form a part of the stop codon (Ojala et al., 1981), are 
uncapped (Grohmann et al., 1978) and they contain very few 5’ untranslated nucleotides 
(Montoya et al., 1981).   
The translation of mtDNA is completed by the mitoribosome which is comprised of two 
subcomplexes; the small and the large complexes which contain 81 nuclear encoded proteins 
and two mitochondrially-encoded rRNAs (12S RNA and 16S RNA). The 16S RNA and 48 
proteins make up the larger 39S subunit while the smaller 28S subunit is assembled of 12S 
RNA and 33 proteins (Anderson et al., 1981; O'Brien, 2003). 
There are three phases of mtDNA translation; initiation, elongation and termination. AUG is 
the main codon for the initiation of translation but AUA and AUU have been shown to initiate 
protein synthesis (Anderson et al., 1981). These codons are recognised by two initiation 
factors: mtIF1 and mtIF3, and recruit the mitoribosome (Koc and Spremulli, 2002). As the 
mitoribosome proceeds along the mRNA, three elongation factors: mtEF-Tu, mtEF-Ts and 
mtEF-G1, support and regulate translation (Ling et al., 1997).  
Termination of translation is driven by the typical stop codons of UAA and UAG and is 
facilitated by the mitochondrial release factor 1a (mtRF1a) (Soleimanpour-Lichaei et al., 
2007). In addition to the typical stop codons, it is postulated that the codons AGA and AGG, 
could represent stop codons since there are no tRNAs are encoded by these codons in the 
mtDNA. However, it was shown that the codons are not stop codons but initiate translation 
termination through the induction of a -1 frameshift due to mitorobosome stalling. The 
consequence of the frameshift, is for the mitoribosome to read a UAA or UAG codon, 
initiating the termination of translation (Temperley et al., 2010).  
 
 
 
 
 
 
 
Chapter 1    Introduction 
24 
 
1.6.5. Mutations to mtDNA 
The mutation rate in mtDNA is 10-20 fold higher than that of nuclear DNA (Brown et al., 
1979). This susceptibility arises due to a number of factors. Firstly, nucleoids in mitochondria 
do not contain protective histones therefore making mtDNA vulnerable to damage by ROS. 
This was confirmed in human fibroblasts where mtDNA damage by H2O2 and ROS was 3x 
and 16x higher compared to nuclear DNA (Corral-Debrinski et al., 1992). Another factor is 
that ROS production is a by-product of OXPHOS and the location of mtDNA in the matrix 
increases its exposure to ROS therefore increasing the chance of oxidative damage to 
mtDNA. Oxidative damage to the mtDNA includes oxidised bases, abasic (AP) sites and 
DNA strand cleavage due to oxidation products from the AP sites (Sung and Demple, 2006). 
Additionally as mtDNA is relatively compact with no introns or non-coding regions, any base 
change will potentially lead to a pathological mutation.  
It was originally believed that the DNA repair mechanisms in mitochondria were limited in 
comparison to those in the nucleus, as pyrimidine dimers that were induced by UV radiation 
had not been removed from mtDNA (Clayton et al., 1974). However it was shown that 
although mitochondria lack the machinery to repair mtDNA as a result of UV damage, they 
do contain isoforms of enzymes that are utilised in the base excision repair (BER) pathway, 
providing an efficient mechanism for the repair of oxidative damage (Bogenhagen et al., 
2001). BER is initiated by a DNA glycosylase like uracil glycosylase (Slupphaug et al., 
1996), 8oxoG-glycosylase (Nishioka et al., 1999), or thymine glycosylase (Miller et al., 2004) 
completing a base excision that removes the damaged base leaving an apurinic/apyrimidine 
site. An AP endonuclease then cleaves the DNA strand at the AP site creating a break in the 
strand allowing polymerase-γ, to repair the break. Taken with the observation that oxidative 
damage to mtDNA in both rats (Driggers et al., 1993) and Chinese hamster ovarian cells 
(Taffe et al., 1996) had undergone some repair, it shows that base excision repair is the 
favoured DNA repair mechanism for the mitochondrial genome. It is likely that the BER 
mechanism is sufficient to remove oxidative damage from mtDNA when the level of ROS 
production is normal, however if the equilibrium moves towards an increase in ROS 
production, for whatever reason then the BER would not be able to keep up and mutations 
would accumulate.   
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1.6.6. Types of mutations 
The mitochondrial genome can undergo a number changes that include point mutations, and 
deletions while the total copy number can become depleted in the cell. As mentioned these 
mutations can either occur sporadically or be inherited through the maternal germ cell 
resulting in impaired oxidative phosphorylation and manifest as a clinical disorder that are 
grouped under the name mitochondrial disease.  
1.6.6.1. Point Mutations 
Point mutations are single nucleotide changes within the mtDNA sequence. The mutations 
can be within a region that encodes for a tRNA. For example one of the most common point 
mutations is the m.3243A>G mutation, which is the primary cause of ~80% of mitochondrial 
encephalomyopathy with lactic acidosis and stroke like episodes (MELAS) cases (Goto et al., 
1990). The m.3243A>G mutation reduces the rate of translation by preventing 5- 
taurinomethyluridine modification of the uridine wobble-position in tRNALeu(UUR) (Kirino 
et al., 2004). As explained by the “wobble hypothesis”, a wobble position is the site where the 
third base in mRNA forms a non-Watson-Crick base pairing with the first base of a tRNA 
anticodon (Crick, 1965; Barrell et al., 1980) . 
Other point mutations may affect a gene that encodes an OXPHOS protein, for example the 
point mutation m.8993T>G in ATPase subunit 6. This point mutation causes an amino acid 
change from leucine to arginine. This amino acid change causes a loss of function by limiting 
the ability of the c- ring of complex V to rotate therefore no rotational torque is produced and 
the F1 subunit of complex V is unable to generate ATP (Sgarbi et al., 2006). The m.8993T>G 
mutation is known to cause neuropathy, ataxia, retinitis pigmentosa  (NARP) disease (Holt et 
al., 1990) as well as maternally inherited Leigh’s syndrome (MILS) (Tatuch et al., 1992). 
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1.6.6.2. Rearrangements of mtDNA 
In addition to point mutations, the mitochondrial genome can also undergo sporadic 
rearrangements that include duplication, micro-deletions and large-scale deletions.  
Normal mtDNA becomes duplicated when a section is duplicated in tandem creating a 
genome larger than the normal 16,569-bp genome. The first observation of mtDNA 
duplication was observed in a patient with Kearns–Sayre syndrome (KSS) (Zeviani et al., 
1988). Duplication has also been implicated in other diseases such as a patient with myopathy 
where a 21.1 kbp duplication was observed (Manfredi et al., 1997) or a patient with diabetes 
mellitus that had a tandem duplication of approximately 6 kbp (Dunbar et al., 1993). It is not 
certain how duplications of mtDNA become pathogenic but it has been suggested that the 
duplications results in aberrant translation products by the fusion of genes at the duplication 
breakpoint or cause an imbalance of mitochondrial tRNAs or proteins (Poulton et al., 1989; 
Poulton, 1992).  
There are two forms of mtDNA deletions; microdeletions (<5bp) or large-scale deletions. 
Large-scale deletions are mainly sporadic (Chinnery et al., 2004) and found in the major arc 
between the OH and OL, flanked by short direct repeats (Samuels et al., 2004; Bua et al., 
2006). Large scale deletions are thought to arise either during mtDNA replication or during 
repair of damaged mtDNA. Single large scale deletions are most commonly associated with 
KSS (Zeviani et al., 1988). While multiple mtDNA deletions can arise due to mutations in 
nuclear encoded proteins such as Polγ which can result in Polymerase γ encephalopathies.  
1.6.6.3. mtDNA depletions.  
In addition to point mutations, duplications and deletions, the total mtDNA copy number can 
become depleted within a cell. mtDNA depletion is the consequence of mutations in genes 
that are involved in either the replication of mtDNA, its maintenance or production of 
nucleotides. A mutation to the gene that encodes POLG has been shown to cause a depletion 
of mtDNA in Alpers’ syndrome (Naviaux et al., 1999). While a mutation to TYMP which 
encodes for a Thymidine Phosphorylase, results in a depletion of copy number through 
impaired thymidine metabolism, leading to impaired mtDNA replication or maintenance 
resulting in mitochondrial neurogastrointestinal encephalomyopathy (MNGIE) (Nishino et al., 
1999). 
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1.7. Mitochondrial diseases and their neurological manifestations 
Mitochondrial disease is defined as a genetic human disorder which leads to a defect in the 
mitochondrial OXPHOS. Originally believed to be a rare disorder, mitochondrial disease has 
recently been shown to be a common human genetic disorder. Gorman et al. (2015) have 
shown that mitochondrial disease affects up to 1 in 4,300 adults in the United Kingdom. 
Mitochondrial diseases are very heterogeneous disorders as they can manifest at birth or in 
old age, they affect multiple organs and the severity can vary widely (DiMauro et al., 2013).  
The CNS is particularly vulnerable to mitochondrial disorders, as exemplified by the 
prominent neurological disorders observed in patients with mitochondrial disease (Figure 1.7 
(McFarland et al., 2010)). The vulnerability of the CNS arises due to its high metabolic 
demand, reduced antioxidant abilities and finally as neurons are post-mitotic they are 
generally unable to divide, with the exception of neurons in the subventricular zone, 
hippocampus and olfactory epithelium. In addition to the neurological symptoms associated 
with mitochondrial disease, the susceptibility of the CNS to mitochondrial disease is 
exemplified by a common feature of brain atrophy. In eighteen post-mortem brains from 
patients with genetically and clinically diverse mitochondrial disease, it was shown that all 
but two had a reduced brain weight compared to age matched controls. The average reduction 
in weight was ~16% (Lax and Jaros, 2012). 
As mentioned, neurological features are very prominent in mitochondrial disorders and 
include cerebellar ataxia, seizures, stroke-like episodes and neuronal deafness (DiMauro et al., 
2013). Patients can manifest with a multitude of symptoms and are not typically restricted to 
those required for a clinical definition of a specific syndrome.  
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1.7.1. Kearns Sayre Syndrome  
Kearns Sayre Syndrome (KSS) is a mitochondrial disorder caused by a single sporadic large-
scale deletion or complex rearrangement of the mtDNA. Two thirds of KSS patients harbour a 
deletion of 4,977 bp but the deletions can range from 2.0 to 7.0 kbp in size (Zeviani et al., 
1988).The deletions are most commonly found between the two proposed origins of 
replication (OH and OL) in the major arc. 
KSS typically manifests before the age of 20 years with retinitis pigmentosa and progressive 
external opthalmoplegia (Kearns and Sayre, 1958). Other neurological symptoms associated 
with KSS are subclinical neuropathy, cerebellar ataxia, cognitive impairments in visuospatial 
attention and executive function, deafness and raised cerebrospinal fluid (CSF) protein levels. 
As with other mitochondrial diseases, KSS is a multi-system disorder and symptoms that are 
also observed are proximal myopathy, dysphagia, complete heart block and endocrinopathies.  
1.7.2. Leber Hereditary Optic Neuropathy 
First described by Theodore Leber in 1871 (Leber, 1871), Leber hereditary optic neuropathy 
(LHON) is one of  most common mitochondrial diseases affecting 1 in 25,000 individuals in 
the north of east of England (Chinnery et al., 2000). 95% of LHON cases are caused by either 
of three point mutations to subunits of complex I; m.3460G>A (MT-ND1), m.11778G>A 
(MT-ND4) and m.14484T>C (MT-ND6) (Mackey et al., 1996). It has been demonstrated that 
the mutations involved in LHON cause a decrease in the rate of complex I driven ATP 
synthesis while the production of ROS is chronically increased (Vergani et al., 1995; Ghelli et 
al., 2003; Floreani et al., 2005).   
The age of onset in LHON is typically 20-40 years of age, with males being more afflicted 
than females. The disorder is clinically characterised by a centrocecal scotoma due to the 
degeneration of cells in the retinal ganglion cell layer and optic nerve (Man, 2002).  
1.7.3. Mitochondrial encephalomyopathy with lactic acidosis and stroke like episodes 
(MELAS) 
As mentioned in section 1.6.6.1, the m.3243A>G mutation, found in the MT-TL1 gene 
encoding for tRNALeu, is the most common cause of MELAS. A number of other point 
mutations within the MT-TL1gene have been identified as a cause of MELAS phenotype and 
this includes the point mutations; m.3251A>G (Morten et al., 1993), m.3271T>C (Goto et al., 
1992), and m.3291T>C (Hess et al., 1991). Point mutations at m.1642G>A (tRNAVal) and 
m.9957T>C (subunit III of cytochrome oxidase c) have also been shown to cause a MELAS 
phenotype (Manfredi et al., 1995; Taylor et al., 1996).  
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The MELAS phenotype associated with the m.3243A>G mutation is characterised by a triad 
of symptoms; seizures, lactic acidosis and stoke-like episodes. Patients with the m.3243A>G 
mutation can also present with cerebellar ataxia, cognitive decline, deafness, hemianopia, 
hemiparesis, migraine and peripheral neuropathy (Nesbitt et al., 2013; Mancuso et al., 2014). 
In addition to causing the MELAS syndrome, the m.3243A>G mutation is also responsible 
for other clinical syndromes that include maternally inherited deafness and diabetes (MIDD) 
and progressive external ophthalmoplegia (PEO) (Nesbitt et al., 2013). The variability of the 
symptoms exemplifies how heterogeneous the phenotypes associated with the m.3243A>G 
mutation can be.  
1.7.4. m.8344A>G 
The m.8344A>G mutation is found in the TѱC loop of mitochondrial tRNALys  (Yasukawa 
et al., 2000) and the most common clinical disorder associated with the mutation is myoclonic 
epilepsy ragged red fibres (MERRF). MERRF can also be caused by a less common mutation 
in the same gene (m.8356T>C) (Silvestri et al., 1992). Patients harbouring the m.8344A>G 
mutation clinically present in childhood and adolescence, and their symptoms include 
deafness cerebellar ataxia, myoclonic epilepsy, myoclonus and myopathy but may also 
present with cognitive impairment, migraine, neuropathy and optic neuropathy (Mancuso et 
al., 2013; Whittaker et al., 2015). 
1.7.5. POLG encephalopathies 
Polymerase γ (POLG) encephalopathies are caused by mutations to the POLG gene, POLG, 
resulting in depletion, multiple deletions and multiple point mutations of mtDNA (Hudson 
and Chinnery, 2006). To date there are over 200 mutations reported in POLG, with 90 
mutations confirmed to cause a disease phenotype. POLG mutations may lead to a number of 
clinical entities including Alpers’ syndrome, autosomal dominant and recessive progressive 
external ophthalmoplegia (rPEO), mitochondrial inherited recessive ataxia syndrome without 
ophthalmoplegia (MIRAS) (Hakonen et al., 2008), Parkinsonism (Davidzon et al., 2006) and 
sensory ataxia, neuropathy dysarthria and ophthalmoplegia (SANDO) (Van Goethem et al., 
2003).  
POLG encephalopathies have variable age of onset, clinical picture, genotype and severity but 
there are common features to all the syndromes in that the nervous system  and liver are 
selectively involved. For example, Alpers’ syndrome is an early onset neurodegenerative 
disorder that is caused by an autosomal recessive mutation to Polγ gene, POLG. The 
mutations p.Ala467Thr, p.Trp748Ser, and p.Gly848Ser are commonly thought to be the 
primary cause of Alpers’ syndrome (Naviaux et al., 1999). The mutations result in impaired 
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mtDNA replication and repair, which typically leads to mtDNA depletion and subsequently 
impaired OXPHOS in patients with Alpers’ syndrome (Wong et al., 2008). Alpers’ syndrome 
is typically defined by a tetrad of clinical symptoms; 1) Refractory seizures, 2) Episodic 
psychomotor regression, 3) cortical blindness, 4) Liver disease with micronodular cirrhosis 
(Naviaux and Nguyen, 2004). Additionally, individuals may also present with ataxia, 
dementia, hypotonia and spasticity eventually leading to death from status epilepticus or 
hepatic failure (Harding, 1990). 
The progression of POLG encephalopathies typically follows episodes of progressive decline 
that includes loss of consciousness, severe epilepsy and the development of acute cerebral 
lesions which are predominately found in the posterior parts of the brain (Tzoulis et al., 2010). 
1.8. Neurodegeneration in Mitochondrial Disease 
The advent of neuro-radiological imaging technologies such as computed tomography (CT) 
scans and Magnetic Resonance Imaging (MRI), has been very beneficial in improving the 
clinical diagnosis of primary mitochondrial disease. The diagnosis of MELAS through the 
observation of non-vascular distributed focal stroke-like lesions that are located 
predominantly in the occipital lobe with MRI imaging, exemplifies the benefit of these 
technologies (Allard et al., 1988). A recent study looked at 33 patients with genetically and 
clinically defined mitochondrial disease and found that the major findings on the MRI images 
were cerebellar atrophy, cerebral atrophy, basal ganglia lesions, brainstem signal changes, 
stroke like lesions and white matter lesions (Bindu et al., 2015).  
In patients with MELAS, the typical MRI findings are signal changes that mimic infarcts 
(stroke-like lesions) in the grey and white matter predominantly in the occipital and parietal 
lobes. However, these lesions do not follow vascular territories. Imaging studies using MRI, 
diffusion-weighted imaging (DWI) on MRI, perfusion imaging on MRI, and 1H magnetic 
resonance spectroscopy (1H-MRS) provide evidence that the stroke-like episodes are related 
to vasogenic edema, hyperperfusion, and neuronal damage (Yoneda et al., 1999; Ito et al., 
2008a). MRI imaging has also shown that calcification of the basal ganglia is a common 
observation in m.3243A>G patients (Sue et al., 1998). Atrophy to the cerebral cortex, 
cerebellum, pallidal and superior cerebellar peduncles were observed in patients with the 
m.8344A>G point mutation (Ito et al., 2008b). In addition to the atrophy, T2 hyperintensities 
were observed in the striatum and cerebral white matter. Demyelination in the thalamus has 
also been observed in one individual with the m.8344A>G mutation but they did not have the 
classical phenotype of MERRF (Erol et al., 2009).     
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Typical findings in patients with KSS were high-signal lesions on T2-weighted images in the 
subcortical white matter with cerebral and cerebellar atrophy (Chu et al., 1999). Occasionally 
hyperintensities in the basal ganglia, midbrain, peripheral white matter and thalami (Haas and 
Dietrich, 2004). Proton Magnetic Resonance Spectroscopy (MRS) showed that resting 
pyruvate levels were increased in KSS patients compared to controls (Kuwabara et al., 1994). 
MRS imaging one month after the treatment of Co-enzyme Q (CoQ) in a patient returned the 
lactate baseline to normal levels, however sequential imaging at 10 months and 16 months 
showed the lactate levels had once again become elevated (Choi et al., 2000).  
MRI imaging of 26 patients with a combined mitochondrial spinocerebellar ataxia and Alpers 
phenotype due to mutations in POLG (homozygous or compound heterozygotes for A467T 
and W748S) found lesions in the basal ganglia, deep cerebellar nuclei, occipital lobe and 
thalamus (Tzoulis et al., 2006). One patient received sequential imaging, and the evolution of 
lesions in the left occipital lobe, right motor and prefrontal cortex could be observed. Another 
study completed cerebral MR imaging of two patients with compound heterozygous POLG 
mutations and observed bilateral signal abnormalities and hyperatrophy of the inferior olives 
(Kinghorn et al., 2013). Imaging of the cerebellum in thirteen patients with POLG-associated 
ataxia found that the majority of patients (85%) had no or only mild atrophy visible in the 
cerebellum (Synofzik et al., 2012). In patients with Mitochondrial Neurogastrointestinal 
Encephalopathy (MNGIE), diffuse white matter lesions are observed along with 
demyelination of sensory neurons ((Hirano et al., 1994; Nishino et al., 1999; Labauge et al., 
2002) 
A common observation reported in all of the mentioned syndromes is intracerebral 
calcification, predominantly calcification of the basal ganglia (Chu et al., 1999; Ito et al., 
2008b). Calcification appears as a common feature, 54% of patients with the m.3243A>G 
mutation were shown to have calcification in the caudate, globus pallidus, putamen and 
thalamus in a study in 1998 (Sue et al., 1998). The calcification of the basal ganglia is not 
associated with atrophy and there appears to be no correlation between clinical symptoms and 
degree of basal ganglia calcification (Brannan et al., 1980; Wider et al., 2009).  
A multitude of changes can occur in the different brain regions that are undetectable through 
neuro-radiological imaging technologies. Therefore, microscopic investigations are required 
to help understand the course of degeneration in patients with mitochondrial disease.  
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1.9. Neuropathological studies. 
The microscopic analysis of post-mortem tissue from patients with mitochondrial disease has 
allowed for a deeper understanding of which regions and more specifically the type of 
neurons that are more susceptible to perturbed energy supply. The results from those studies 
have shown that deficits in the expression of complex I and complex IV are the most 
prominent, while neuronal loss, astrogliosis, and microgliosis are a typical feature in observed 
lesions.  
1.9.1. Kearns Sayre Syndrome 
The neuropathological hallmark of KSS is spongiform encephalopathy in the white matter 
tracts of the basal ganglia, cerebellum, cerebrum, spinal cord and thalamus (Oldfors et al., 
1990; Sparaco et al., 1993; Tanji et al., 1999). The main site of pathology in KSS is the white 
matter, where there is a preferential loss of myelin associated glycoprotein (MAG) (Figure 
1.8A) and a reduction in oligodendrocyte lineage cells (Lax et al., 2012a). Investigation into 
respiratory chain deficiency, found a marked reduction in cytochrome c oxidase subunit I in 
astrocytes and oligodendrocytes while axonal mitochondria remained intact (Lax et al., 
2012a) . In addition to white matter pathology, the cerebellum is shown to have a moderate 
loss of Purkinje cells and formation of axonal torpedoes in the granular cell layer, while 
spongiform degeneration and capillary proliferation was observed in the dentate nucleus 
(Tanji et al., 1999).  Remaining Purkinje cells and neurons of the dentate nucleus (Figure 
1.8B and 1.8C) was observed to have a decrease in complex I and IV protein expression 
deficiencies (Lax et al., 2012b). In a KSS patient, there was a loss of GABAergic interneurons 
in the temporal cortex, while the remaining neurons displayed a severe reduction in the 
expression of complex I and IV protein expression (Lax et al., 2016). Accompanying the 
respiratory chain deficient interneurons were COX deficient blood vessels. Changes to the 
blood brain barrier and vascular network have been observed with vascular proliferation, 
fibronectin extravasation in the cerebral cortex and capillary and arterial walls were observed 
to have iron and calcium deposits in and around them (Oldfors et al., 1990; Sparaco et al., 
1993; Tanji et al., 1999)  
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Figure 1.8: Examples of neuropathology in the cerebellum of patients with Kearns Sayre 
syndrome (KSS). 
There is a loss of myelin-associated glycoprotein (A and Ai) in the cerebellum of 
a KSS patient. Immunohistochemical analysis shows there is a loss of porin (B) 
and complex II (C) in the dentate nucleus white matter of KSS patients (Bi and 
Ci) compared to controls (Bii and Cii). Image modified from Lax et al. (2012a). 
  
Ai) 
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1.9.2. Leber Hereditary Optic Neuropathy 
The primary neuropathological feature of LHON, is the degeneration of retinal ganglion cells 
and axonal loss in the optic nerve (Milesi et al., 2012). During the initial stages of the disease, 
it is the small calibre axon fibres of the papillomacular bundle that are selectively lost 
resulting in optic nerve atrophy during advanced stages of the disease (Sadun et al., 2000). 
Surviving retinal ganglion cells, were observed to have calcium deposits and the mitochondria 
within those cells appeared enlarged and swollen (Kerrison et al., 1995). The spinal cord has 
been observed to be involved in a number of LHON cases, with axonal loss observed in the 
cuneate fasciculus, posterior spinal cord roots and gracile fasciculus. Alongside axonal loss, 
neuropil vacuolation and disintegration, neuron loss, capillary proliferation and macrophage 
accumulation has been observed in the gracile fasciculus (Jaros et al., 2007). Small intra-
cytoplasmic hematoxylinophilic bodies were observed in the remaining neurons in the gracile 
fasciculus, indicating the cells are undergoing apoptosis (Jaros et al., 2007).  
1.9.3. m.3243A>G 
The classical neuropathological features of MELAS, are the presence of micro-infarcts or 
“stroke-like” lesions in the cerebellar cortex, occipital, parietal and temporal lobes 
(Figure1.9A) (Tanji et al., 2001; Lax et al., 2012b). The microvasculature in the cerebellum of 
patients with the m.3234A>G mutation has been shown to undergo a number of changes; with 
the mineralisation of arterioles in deep cerebellar white matter, an increase in collagen IV 
deposition, thinning of the smooth muscle cell layer and with COX deficiency (Figure 1.9B) 
observed in the vascular smooth muscle and endothelial cell layers (Lax et al., 2012c). The 
study by Lax et al. (2012c) also found evidence of a breakdown to the blood-brain barrier, 
with thinning and fragmentation of the tight junction proteins ZO-1 and occludin in 
m.3243A>G patients compared to controls (Lax et al., 2012c). Blood vessels walls in the 
basal ganglia, globus pallidus and thalamus have been shown to be undergoing calcification 
even though these regions are spared of neuronal degeneration (Sue et al., 1998). Electron 
microscopy has shown that in the smooth muscle and endothelial cell layers of cerebral and 
cerebellar arterioles and small arteries there is an aggregation of enlarged mitochondria 
(Ohama et al., 1988; Mizukami et al., 1992; Tanahashi et al., 2000). The presence of stroke 
like lesions and vascular pathology in the brains of m.3243A>G is likely to be associated but 
it is unclear if the mitochondrial impairment observed in the blood vessels is sufficient to 
cause lesions.  
In the cerebellum, atrophy of the molecular layer and granular cells results in the increased 
inter-folia spacing. Additionally, there was a decrease in neuronal cell densities in the dentate 
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nucleus, inferior olive and Purkinje cell layer with the remaining neurons displaying a 
deficiency in complex I expression (Lax et al., 2012b). When the heteroplasmy of the 
remaining neurons in the Purkinje cell layer, inferior olive and dentate nucleus was 
investigated, it was shown that the percentage of the m.3243A>G mutation was typically 
greater than 73%, however there was no correlation between cell loss and mutation load (Lax 
et al., 2012b). The morphology of surviving Purkinje cells has been observed to undergo a 
number of changes with an increase in dendritic arborisation, mitochondria becoming trapped 
in thickened axons, and the formation of axonal torpedoes (Figure 1.9C) (Tanahashi et al., 
2000; Lax et al., 2012b). In the dentate nucleus there are signs of a change to the synaptic 
input with the observations of decreased synaptophysin immunoreactivity and grumose 
degeneration in the close vicinity of dentate nucleus neurons (Tanahashi et al., 2000; Lax et 
al., 2012b). Moreover, Chrysostomou et al. (2016)  has observed a loss on inhibitory synaptic 
contact on the dentate nucleus and the remaining GABAergic presynaptic terminals were 
deficient for complex I deficiency (Figure 19.D). GABAergic interneuron densities in the 
frontal, occipital and temporal lobes were reduced while the remaining interneurons were 
shown to be deficient for complex I (Lax et al., 2016). 
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Figure 1.9: Cerebellar neuropathology in patients harbouring the m.3243A>G mutation. 
A) The degeneration of the white matter, granular cell layer, Purkinje cell layer 
and molecular layer can be observed in the stroke-like lesion (Outlined). B) COX 
II immunodeficiency is clearly observable in the epithelial cells (arrow) of the 
choroid plexus. C) A axonal torpedo has formed in the granule cell layer. D) In 
the inhibitory presynaptic terminals (Ci, white circle) there is a decrease in the 
expression of complex I expression (Cii, white arrow) compared to the 
mitochondrial marker (Ciii, white arrow) indicating mitochondrial dysfunction. 
Images modified from; A and C) Lax and Jaros (2012)  B) Tanji et al. (2001)  D) 
Chrysostomou et al. (2016)  
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1.9.4. m.8344A>G 
The neuropathological changes observed in patients harbouring the m.8344A>G mutation are 
astrocytosis, demyelination and neuronal loss, found prominently in the cerebellum, spinal 
cord and inferior olive, red nuclei and substantia nigra of the brain stem (Takeda et al., 1988; 
Fukuhara, 1991). In the cerebellum, the dentate nucleus (Figure 1.10A) and inferior olive 
have severe neuronal loss, while there is a mild loss of Purkinje cell numbers (Tanji et al., 
2001; Lax et al., 2012b). In the spinal cord, there is a mild loss of neurons to the anterior and 
posterior horns while in the Clark’s nucleus there is a significant reduction in neuronal 
numbers (Sparaco et al., 1993). Investigations into respiratory chain deficiency have shown 
that dopaminergic neurons in the substantia nigra in a MERRF patient had a 22% and 16.3% 
reduction in NDUFB8 and NDUFA13 respectively (Reeve et al., 2013). This observation was 
confirmed by Grunewald et al. (2014), who observed a 32% reduction in NDUFB8 compared 
to VDAC1 in substantia nigra neurons of a patient harbouring the m.8344A>G mutation when 
compared to control substantia nigra neurons. A immunofluorescent study has shown that 
surviving GABAergic interneurons in the frontal, temporal and occipital cortices from 
patients harbouring the m.8344A>G mutation were deficient for NDUFA13 and COX I 
(Figure 1.10C) (Lax et al., 2016). It was also shown that the level of NDUFA13 was 
decreased in the Purkinje cell soma when compared to COX4, additionally there was a loss of 
GABAergic presynaptic terminals innervating dentate nucleus neurons in one of the patients 
harbouring the m.8344A>G mutation which correlated with the observed reduction in 
Purkinje cell density (Chrysostomou et al., 2016).  
Abnormalities are not restricted to the neurons, cerebellar blood vessels were shown to have a 
high level of high heteroplasmy (86%), and the smooth muscle and endothelial cell layers of 
the arterioles were COX-deficient (Figure 1.10C) (Lax et al., 2012c). The presence of 
immunoreactivity against plasma proteins in Purkinje cell and dentate nucleus neurons 
indicates a breakdown of the blood brain barrier (BBB), this observation is further supported 
by the decrease in expression of tight junction proteins (Lax et al., 2012c). 
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Figure 1.10: Neuropathology in patients harbouring the m.8344A>G mutation. 
There is a clear loss of neurons in the dentate nucleus of a patient harbouring 
the m.8344A>G mutation (Ai) when compared to the dentate nucleus of a 
control individual (Aii). In GABAergic interneurons from the inferior temporal 
lobe (highlighted by dashed line), there is a reduction in the expression of 
complex I (NDUFB8, Bi) and complex IV (COX1, Bii) when compared to the 
expression of a mitochondrial protein (porin, Biii). The smooth muscle and 
endothelial cell layers of cerebellar arterioles are COX-deficient. Images used 
are modified from; A) Turnbull et al. (2010) B) Lax et al. (2016) C) Lax et al. 
(2012c). 
  
Chapter 1    Introduction 
40 
 
1.9.5. POLG-related encephalopathy 
Pathology in POLG patients can be varied with either acute focal lesions or diffuse 
progressive changes with intraregional distributions. Focal demarcated lesions have been 
observed in the neocortex, hippocampus, cerebellum (Figure 1.11A) and thalamus and the 
lesions are characterised by neuronal loss, eosinophilic neuronal necrosis, vacuolation of the 
neuropil, astrocytosis (Figure 1.11B) and diffuse microglia activation (Figure 1.11C) (Tzoulis 
et al., 2014).  
In patients with Alpers syndrome, neuropathological examination showed that predominantly 
the occipital and temporal lobe of the cerebral cortex, but also the cerebellum, hippocampus 
and olfactory lobe, had symmetrical but multifocal ischaemic encephalopathy with laminar 
necrosis and neuronal degeneration (Khan et al., 2012). Other pathology has also been 
observed with gliosis reported in the basal ganglia, brainstem and most prominently the 
occipital lobe (Wiltshire et al., 2008). In a recent study by Tzoulis et al. (2014), showed that 8 
patients with POLG-related encephalopathy, all had focal lesions in the cerebellar cortex, 
where there was severe loss of Purkinje cells and granule cells with Bergman gliosis. In the 
dentate nucleus there was severe neuronal loss and the surviving neurons had a pronounced 
accumulation of lipofuscin. In those patients, neuronal loss and gliosis was also observed in 
the thalamus and locus coeruleus and inferior olivary nucleus of the brainstem. While focal 
lesions in the neocortex, hippocampus, thalamus and cerebellum showed astrocytosis, diffuse 
microglial activation, eosinophilic neuronal necrosis, neuronal loss and vacuolation of the 
neuropil (Tzoulis et al., 2014). When expression levels of components of the ETC were 
investigated, the remaining neurons in the regions with chronic changes and higher neuronal 
density had the greatest level of deficiency when compared to sites of focal degeneration. The 
substantia nigra, red, olivary and pontine nucleus were shown to have the greatest reduction in 
expression of ETC proteins (Tzoulis et al., 2014).  
The midbrain has also been shown to be susceptible in POLG encephalopathies, with the 
observation of significant loss of the dopaminergic neurons (Figure 1.11D), astrogliosis and 
microglia activation in the red nucleus and the substantia nigra pars compacta. The remaining 
neurons in these regions were shown to have complex I deficiency and had 50-60% less 
mtDNA than control neurons (Tzoulis et al., 2013).  
Microinfarcts with astrogliosis were observed in the cerebellums of patients with 
heterozygous POLG mutations, (Lax et al., 2012b). The study also observed neuronal loss and 
demyelination in the dentate nucleus which was surprising as the heteroplasmic levels of 
deleted mtDNA deletion were low in those regions. In a more recent study by the same 
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colleagues, the occipital, temporal and frontal cortices were shown to have a significant 
reduction in inhibitory interneurons while a quadruple immunofluorescent assay showed the 
remaining inhibitory interneurons to be complex I deficient (Lax et al., 2016). 
A study by Lax et al. (2012d), investigating pathology in the spinal cord of 11 patients with 
compound heterozygous mutations in POLG, found evidence of myelin and axonal loss in the 
posterior spina funiculus. While in the dorsal root ganglion, posterior and anterior horn there 
was a reduction in neuronal density. The surviving neurons in the posterior horn were 
deficient for NDUFB8, NDUFS3 and NDUFA9. A similar observation in the dorsal root 
ganglion was also observed, with a 33% and 34% reduction in the presence of NDUFS1and 
NDUFB8, respectively. In addition to the complex I deficiency, there was abnormal 
distribution of mitochondria in the cytoplasm in the dorsal root ganglion (Figure 1.11E). 
When investigating the mtDNA copy number in the remaining neurons of the dorsal root 
ganglion it was shown that MT-ND1 was markedly reduced compared to control neurons, 
inferring that in addition to the mtDNA deletions associated with the POLG mutation, the 
neurons also have a reduction in wild type copy number.  
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Figure 1.11: Neuropathology in POLG-related encephalopathy. 
A) Microscopic focal, sharply demarcated lesions can be observed in the 
cerebellum. B) Increased immunohistochemical reactivity to glial fibrillary 
acidic protein shows the presence of astrocytosis C) Diffuse microglial 
activation can be observed in cortical acute lesions. D) The profound loss of 
dopaminergic neurons in ventrolateral tier of the substantia nigra in POLG 
encephalopathy (Di) is made evident when compared to the substantia nigra in a 
control individual (Dii). E) In dorsal root ganglions there was abnormal 
clustering of mitochondria (arrow heads). Images modified from; A, B and 
C)Tzoulis et al. (2014) D) Lax et al. (2012d) 
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1.10. Mitochondrial dysfunction and axonal pathology 
In mitochondrial disease, it is predominantly the grey matter that is observed to be 
degenerating, however the white matter is also susceptible to degeneration or changes. 
Typically white matter involvement in primary mitochondrial disease is not a prominent 
feature but in the case of individuals with KSS, demyelination along with spongiform 
degeneration predominantly in the cerebral white matter and basal ganglia and to a lesser 
degree in the cerebellar white matter and spinal cord is characteristic of the disease 
mechanism (Sparaco et al., 1993; Lax et al., 2012a). In individuals with MELAS and MERRF 
necrotic lesions of cerebral and cerebellar white matter show a decrease in myelin and axon 
number (Sparaco et al., 1993; Terauchi et al., 1996). MRI studies on patients with MELAS 
have observed bilateral deep white matter changes in the frontal and occipital lobes (Fujii et 
al., 1990), changes to the parieto-occipital white matter (Barkovich et al., 1993), both diffuse 
and focal changes to the periventricular white matter (Castillo et al., 1995) and cerebral and 
cerebellar white matter lesions in located the border zones between two major cerebral 
arteries (Apostolova et al., 2005). Diffuse axonal loss was observed in the medulla oblongata 
and cerebral white matter while in the deep white matter there were multiple necrotic lesions 
in a MELAS case (Yokoyama et al., 2010). Severe demyelination and axonal degeneration 
was observed in the spinal cord and to a lesser degree in the cerebellar white matter and 
thalamus of a patient with the m.8344A>G mutation (Sparaco et al., 1993; Erol et al., 2009). 
In LHON, electron microscopy (EM) studies found degenerating optic nerve axons with 
varying levels of myelination and some axons were completely demyelinated (Sadun et al., 
1994; Carelli et al., 1999). In the myelinated post-laminar portion of the optic nerve, 
accumulated swollen mitochondria were observed while cytoskeletal molecules accumulated 
in the axons (Sadun et al., 1994; Carelli et al., 1999). 
An additional observation in the cerebellum of individuals with mitochondrial disease is the 
presence of large swellings in the Purkinje cell axons, known as axonal torpedoes (Mori et al., 
2000b; Lax et al., 2012b), which will be further described in chapter 3. In addition to causing 
white matter disturbances in mitochondrial diseases, mitochondrial dysfunction has been 
involved in the pathogenesis of axonal injury in other neurological disorders such as Multiple 
Sclerosis (MS) (Trapp and Stys, 2009). In a study by Mahad et al. (2009), mitochondrial 
changes were observed in chronic active lesions, where there was a decrease in COXIV 
activity in demyelinated axons. While in demyelinated axons from inactive areas of chronic 
lesions mitochondrial respiratory chain complex IV activity and mitochondrial mass were 
increased. Additionally, the activity of complex I and III were observed to be decreased in 
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mitochondria-enriched fractions from the motor cortex of tissue isolated from post-mortem 
MS motor cortex (Dutta et al., 2006). 
With the demonstration of axonal loss preceding neuronal death in MS, where axonal 
degeneration is associated with the progressive neurological decline (Bjartmar et al., 2000) 
and PD (Burke and O'Malley, 2013) as well as the observation of mitochondrial dysfunction 
in association with white matter disturbances and demyelination. The investigation of 
respiratory chain deficiency on axons and the subsequent changes in axonal morphology, like 
the formation of axonal torpedoes in the cerebellum of patients, may allude to the mechanisms 
leading to cerebellar ataxia.  
1.11. The Cerebellum 
As described above the cerebellum is commonly afflicted in mitochondrial disease with both 
paediatric and adult’s patients commonly presenting clinically with cerebellar ataxia which is 
defined by a lack of balance, coordination and motor control. Additionally, neuropathological 
abnormalities, including cerebellar atrophy and those described throughout section 1.10 are 
frequently detected (Lebre et al., 2011). The prominent involvement of the cerebellum 
indicates that the cerebellar neurons are particularly vulnerable to disrupted OXPHOS.  
1.11.1. Cerebellar structure 
The cerebellum is located in the posterior region of the brain and is a part of the hind brain 
along with the medulla and pons. The main role of the cerebellum is to process the ascending 
sensory and descending motor signals which are crucial for muscle tone and motor movement 
coordination. In addition to its role in motor coordination recent evidence has shown the 
cerebellum plays a role in cognition and emotion (Ito, 2008; Stoodley, 2012; Buckner, 2013). 
The architecture of the cerebellum is one of the most elaborate in the whole CNS and contains 
over half the mature neurons in the adult CNS.  The cerebellum has a three longitudinal 
regions either side of the midline that run along the rostral to caudal plane. These regions are 
then further folded into 10 lobules (I-X) and then further divided in to folia (figure 1.12A 
(Apps and Hawkes, 2009). In addition to the longitudinal organization, the cerebellum can 
also be divided into traverse zones based on gene expression. The four traverse zones are; 
anterior, posterior, central and nodular zones. Each traverse zone can be further divided into a 
series of stripes or bands that are positioned along the rostrocaudal axis (Apps and Hawkes, 
2009). The stripes are defined by the expression of molecular markers, with the metabolic 
enzyme aldolase C (zebrin II) being the most extensively studied (Brochu et al., 1990; 
Hawkes and Herrup, 1995). 
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The cerebellar cortex has a rather basic histological structure composed of three stratums, the 
Purkinje cell layer (PCL), the granular cell layer (GCL) and the molecular layer (ML) (Figure 
1.12B). The main excitatory neuron in the cerebellum, are the granule cells and are found 
abundantly in the GCL along with the inhibitory Golgi cells. Purkinje cells are inhibitory 
neurons which are the major output neuron of the cerebellum and form a distinct “neuronal 
ribbon” between the GCL and the ML (Martin, 2002). The inhibitory interneurons, Basket 
and stellate cells, reside in the molecular cell layer. Along with the cerebellar cortex there is 
the medullary core of white matter and three deep cerebellar nuclei (DCN); the dentate, the 
fastigial and the interposed nucleus. 
Figure 1.12: The structure of the cerebellum. 
A) A graphical representation of the lobes, lobules and main fissures in the 
unfolded cerebellar cortex. B) The three stratums of the cerebellum. Inhibitory 
interneurons are annotated in blue text, while excitatory neurons are annotated 
in red text. Figure 1.9A is modified from Manni and Petrosini (2004) and 1.9B 
is modified from Butts et al. (2014) 
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1.11.2. Cerebellar circuitry 
The cerebellum receives input from the inferior olive (IO), the brainstem and spinal cord. The 
main input neurons are the climbing fibres and mossy fibres which act upon the main output 
neuron, the Purkinje cell.  
The climbing fibres originate from the inferior olive in the caudal brain stem and project their 
thick ramifications through the GCL and PCL to act directly on the Purkinje cell by forming 
excitatory synapses on the smooth lower branches of the dendritic tree in the ML. Only one 
climbing fibre innervates a single Purkinje cell, but that single climbing fibres makes multiple 
synaptic contact generating the largest depolarising event seen in any neuron (Eccles et al., 
1966). 
Unlike the climbing fibers, Mossy fibers indirectly innervate the Purkinjec cells. Mossy fibers 
originate from the cuneocerebellar, dorsal spinocerebellar, pontocerebellar, and 
vestibulocerebellar tracts and finish in the GCL where glutamatergic synapses innervate 
granule cells and occasionally Golgi cells. Granule cells are excitatory neurons whose 
extending axons bifurcate in a T-fashion in the ML forming parallel fibres that extend 
horizontally along the long axis of the folia and parallel to the PCL (Voogd and Glickstein, 
1998). The parallel fibres intersect the expansive dendrites of the Purkinje cells in the ML, 
where they form excitatory synapse on either the spiny branches of Purkinje cell dendrites or 
the interneurons; stellate and basket cells. A single parallel fibre will innervate several 
hundred Purkinje cells as it traverses along the ML (Napper and Harvey, 1988). An inhibitory 
feed-back loop is formed by the Golgi cells as they receive excitatory input from the mossy 
fibres and granule cells but they also innervate the granule cells and parallel fibres.  
Purkinje cells are large GABAergic inhibitory neurons, whose axons are the sole output of the 
cerebellum and extend through the GCL and white matter tract to the deep cerebellar nuclei 
where the axons terminates with inhibitory synapses.  As Purkinje cells are the main output 
neurons they must integrate both excitatory input from climbing and mossy fibres with 
inhibitory input from basket and stellate cells. Occasionally climbing fibres and mossy fibres 
also innervate the deep cerebellar nuclei. The circuit between the Purkinje cells and the 
dentate nucleus is the main intra-cerebellar circuit. The microcircuit of the cerebellum is 
depicted in Figure 1.13. 
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Figure 1.13: The circuitry of the olivo-cerebellar pathways. 
The two main afferent neurons in the cerebellum are the mossy fibres (MF) and 
the thick ramifications known as climbing fibres (CF). Originating from 
numerous brain stem and spinal cord nuclei, the MF’s make excitatory synaptic 
contacts with granule cells (GrC) and with Golgi cells (GoC) in the Granular 
cell Layer (GCL) as well as neurons in the deep cerebellar nuclei (DCN). 
Bifurication of the GrC ascending axons forms Parallel fibres (PF) in the 
molecular layer. The PF’s form excitatory synapses with Purkinje cells (PC) 
and with interneurons (stellate (SC) and basket cells (BC)) in the molecular 
layer (ML) as well as GoC’s. The second main afferent the CF’s ascend from 
the Inferior Olive (IO) to the PC where it forms a powerful ‘climbing’ multi-
synaptic contact. The PC forms a distinct “neuronal ribbon” known as the 
Purkinje cell layer (PCL) and are the main output neurons of the cerebellum 
which inhibits DCN. It is only the GrC that make excitatory synapses the rest of 
the cerebellar cortical neurons, make inhibitory synaptic connections with their 
target neurons with the end goal being controlling the signal output from the 
DCN. 
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1.13. Aims 
As described above, the cerebellum is commonly affected in patients with mitochondrial 
disease. A common observation in the cerebellum is the presence of axonal torpedoes which 
are explained in detail in chapter 3. As these structures have not been thoroughly 
characterised in mitochondrial disease, the aims of my thesis are to characterise axonal 
torpedoes as well as morphological changes to the Purkinje cell axons in patients with 
mitochondrial disease. This work will aim to provide an insight into how respiratory chain 
deficiency relates to axonal torpedo formation and changes in the Purkinje cell connectivity 
which may provide an insight into the genesis of cerebellar ataxia. The aim of characterising 
the axonal torpedoes further will help understand how the axonal torpedoes are detrimental 
and degenerative to the Purkinje cell and may present a therapeutic target. I aim to answer the 
following questions: 
1. Are axonal torpedoes more prevalent in patients with mitochondrial disease and is 
there evidence that the axonal torpedoes are involved in a degenerative process? 
2. What are the structural abnormalities or changes associated with the presence and 
formation of axonal torpedoes? 
3. Is there any evidence for respiratory chain deficiency in axonal torpedoes, Purkinje 
cell bodies and Purkinje cell axons? 
4. Is there any evidence that respiratory chain deficiency causes a change to the 
morphology of Purkinje cell axons? 
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2.1. Materials 
2.1.1. Equipment 
 
2.1.2. 
Consumables 
Coverslips (22 x 22mm, 22 x 40mm, 22 x 50mm)   VWR 
Equipment Manufacturer 
65˚C Oven Genlab MIN016 
2100 Antigen Retriever Aptum Biologics Ltd 
2511 Dry Vacuum Pump Welch 
Balance Adventurer Ohaus 
Desiccator chamber Scienceware 
Laminar Flow hood Jencons-PLS 
Magnetic Stirrer IKA RCT Basic 
Microwave Sharp R95ST 
Nanopure Water Elga 
Nikon A1R Single photon Confocal  Nikon 
pH meter Jenway 3510 
Rotatest Shaker Luckham R100 
See-Saw Rocker SSL4 
Software 
ImageJ 
Imaris v8 
SAS 
Volocity 3D Image Analysis 
Stuart 
 
National Institute of Health 
Berkin 
SAS Institute Inc. 
PerkinElmer 
Stereology BX51 Light Microscope Olympus 
Water bath 
Hyrax V50 Vibratome 
Grant Subaqua pro 
Zeiss 
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Eppendorf tubes (1.5mL, 2mL)     Biogene 
Falcon Tubes (15mL, 50mL)      BD biosciences 
Glass Pasteur pipettes 230mm     Volac 
Pipette Tips        Star Lab 
Pasteur Pipettes        VWR 
Pipettes 
 p10        Eppendorf  
 p20, p200       Ergone 
 p1000, p5000       Gilson 
Six well plates        Greiner Bio-one 
Whatman grade I filter paper      Merk 
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2.1.3. Solutions 
Unless stated otherwise, all solutions made using nanopure 18 mega Ω activity water.  
Solution      Components  
10 % Normal goat serum (NGS) blocking solution  100µl Normal goat serum 
        1 ml dH2O 
 
Clearing Solution      12.366 g Boric acid 
40 g Sodium dodecyl sulphate 
1 l dH2O 
pH 8.5 
 
3,3′-Diaminobenzidine 2  3,3′-Diaminobenzidine tablet 
5 ml dH2O  
 
EDTA        0.416 g EDTA 
        1 l dH2O 
        pH8  
 
Fructose        Xg Fructose 
(20%,60%,80%, 100% weight/volume)   50 ml dH2O  
  
   
Glycine       1.5 g glycine   
        100 ml dH2O 
pH 7.4 
 
 
Hydrogel solution      20 ml Acrylamide 
        10 ml bis-acrylamide 
1 g VA-044 Initiator 
40 ml PBS 
        310 ml dH2O 
 
3% Hydrogen Peroxide Solution    12 ml Hydrogen Peroxide 
        388 ml dH2O 
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1X Phosphate buffered saline (PBS)    8 g Sodium Chloride 
0.2 g Potassium Chloride 
1.42 g Sodium hydrogen         
phosphate 
0.245 g Potassium dihydrogen 
phosphate 
        1 l dH2O 
pH 7.4 
 
10X Phosphate buffered saline (PBS)   80 g Sodium Chloride 
20 g Potassium Chloride 
   14.2 g Sodium hydrogen 
phosphate 
2.45 g Potassium dihydrogen 
phosphate 
        1 l dH2O 
pH 7.4 
 
Phosphate buffer solution (PB)  0.62 g Sodium dihydrogen 
phosphate 
2.18 g Sodium hydrogen 
phosphate 
1 l dH2O 
pH 7.4 
 
Refractive Index Matching Solution (RIMS)   40 g Histodenze 
        30 ml PB 
        0.1% tween-20 
 
Scotts tap water      20 g Magnesium sulphate 
2 g Sodium bicarbonate 
few crystals of thymol 
1 l dH2O 
 
SeeDB        20.25 g fructose 
        5 ml dH2O 
        100 µl α-thioglycerol 
         
Sodium Borate Buffer      61.83 g boric acid 
        10 g Sodium Hydroxide 
        1 l dH2O 
 
Sudan Black       0.5 g Sudan Black 
        100 ml 70% Ethanol 
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Tris Buffer Saline      1.2 g Trizma Base 
        17 g Sodium Chloride 
        2 l dH2O 
        pH 7.4 
 
Tri-sodium citrate      2.94g tri-sodium citrate 
        1 l dH20 
        pH 6 
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2.1.4. Chemicals 
Chemical      Manufacturer 
α-thioglycerol       Sigma 
Acrylamide       BioRad 
Bis-acrylamide      BioRad 
Boric Acid       Sigma 
3,3′-Diaminobenzidine tablets     Sigma 
DPX Mountant       Sigma 
EDTA        Affymetrix USB Products 
Ethanol       Fisher Chemicals 
Fructose       Sigma 
Glycine       Sigma 
Haemotoxylin       TCS Biosciences Ltd 
Histoclear       National Diagnostics 
Histodenze       Sigma 
Horse-radish peroxidase (HRP)-polymer   CellPath Ltd 
Hydrogen Peroxide      Sigma    
Magnesium sulphate      Sigma 
Normal Goat serum      Sigma 
4% Paraformaldehyde      Santa Cruz 
Potassium dihydrogen phosphate    AnalR 
Potassium Chloride       Sigma 
Prolong Gold Antifade     Life Technologies 
Sodium Bicarbonate      Sigma 
Sodium Chloride       Sigma 
Sodium dihydrogen phosphate    AnalR 
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Sodium Dodecyl sulphate     Sigma 
Sodium hydrogen phosphate      AnalR 
Sodium Hydroxide      AnalR 
Sudan black       Reactifs Ral 
Trizma Base       Sigma 
Tween 20       Sigma 
VA-044 Initiator      Alpha Laboratories  
Universal probe      CellPath Ltd 
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2.1.5. Tissue Details 
2.1.5.1. Human 
Human cerebellum brain tissue was obtained from the Newcastle Brain Tissue Resource 
(NBTR) and Edinburgh Sudden Death Brain Bank and included tissues from 13 patients with 
clinically and genetically well characterised mitochondrial disease (Table2.1) and 16 non-
neurologically affected control individuals (Table 2.2). All patients and their families 
provided informed consent to donate their tissue for research purposes and ethical approval 
for this study was gained from Newcastle and North Tyneside Local Research Ethics 
Committee (LREC 2002/205). 
2.1.5.2. Mice 
For the optimisation of the Clear Lipid-exchanged Acrylamide-hybridized Rigid 
Imaging/Microscopy (CLARITY) method, 12 month old wild type C57BL/6 mice were used. 
These mice were cared for and housed at the Comparative Biology Centre, Newcastle 
University under conditions and regulations in compliance with the Animals (Scientific 
Procedures) Act 1986 and its associated Codes of Practice. 
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Gender Age 
(Years) 
PMI 
(Hours) 
Genetic defect Cause of Death 
Patient 1 F 40 58 m.3243A>G Respiratory Failure 
Patient 2 F 20 187 m.3243A>G Aspiration pneumonia 
with MELAS 
Patient 3 F 36 9 m.3243A>G Myocardial infarction 
Patient 4 M 45 43 m.3243A>G Complications 
associated with 
mitochondrial disease 
Patient 5 M 59 67 POLG 
(p.Gly848Ser and 
p.Ser1104Cys) 
Unknown 
Patient 6 M 30 21 m.3243A>G Unknown 
Patient 8 F 60 10 m.3243A>G Multi-organ failure 
Patient 7 F 42 59 m.8344A>G Respiratory failure 
Patient 9 M 58 66 m.8344A>G Unknown 
Patient 
10 
M 79 85 POLG 
(p.Thr251Ile/p.Pro
587Leu;  
p.Ala467Thr) 
Pneumonia due to 
mitochondrial disease 
Patient 
11 
M 55 112 POLG 
(p.Trp748Ser and 
p.Arg1096Cys) 
Complications 
associated with 
mitochondrial disease 
Patient 
12 
F 60 39 Unconfirmed 
Multiple mtDNA 
deletions due a 
nDNA defect  
Pulmonary embolus 
Patient 
13 
M 47 76 m.3243A>G Myocardial infarction 
   Table 2.1: Summary of patients with mitochondrial disease that were  
used in this project.  
The details of patients include age, gender, post mortem interval (PMI) and 
cause of death from tissue that was supplied by NBTR. 
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   Table 2.2: Summary of control individuals that were used in this  
project.  
The details of controls include age, gender, post mortem interval (PMI) and 
cause of death from tissue that was supplied by NBTR and Edinburgh Sudden 
Death Brain Bank.  
 
 
 
 
 
 
 
 
 
 
 
 
 Gender Age (Years) PMI (Hours) Cause of Death 
Control 1 F 69 16 Gastric Cancer 
Control 2 F 74 53 Heart Failure 
Control 3 M 55 51 Liver Cancer 
Control 4 F 74 67 Lung Cancer 
Control 5 M 70 72 Metastatic Ovarian Cancer 
Control 6 F 77 83 Myocardial Infarction 
Control 7 M 48 46 Coronary Artery Atherosclerosis 
Control 8 M 44 83 Coronary Artery Atherosclerosis 
Control 9 M 45 44 Complications of 
Bronchopneumia and  Coronary 
Artery Atherosclerosis 
Control 10 M 25 53 Hanging 
Control 11 M 61 61 Hanging 
Control 12 M 48 43 Coronary Artery Thrombosis 
Control 13 M 72 17 Oesophageal adenocarcinoma 
Control 14 F 78 34 Metastatic Ovarian Cancer 
Control 15 F 72 27 Pulmonary oedema 
Control 16 F 58 39 Cushings Disease 
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2.2. Methods 
All the primary and secondary antibodies used in this project are summarised in table 2.3 and 
2.4 respectively. The appropriate dilution and antigen retrieval method will be explained in 
chapter when specifically used. 
2.2.1. Immunohistochemistry 
5µm formalin-fixed, paraffin-embedded (FFPE) cerebellar sections cut on the sagittal plane 
were deparaffinised using Histoclear then rehydrated through a graded ethanol series. The 
next step was to complete the appropriate method of antigen retrieval followed by incubation 
of the sections in a 3% hydrogen peroxide solution for 30 minutes to block endogenous 
peroxidase activity. The sections were washed 3x 5 minutes with tris buffered saline (TBS) 
and then the primary antibodies were applied at the optimal dilution for 1 hour. Post primary 
antibody incubation the sections underwent 3x 5minute TBS washes followed by a 30 minute 
incubation with a universal probe. Another 3x 5 minutes TBS washes were applied before a 
30 minute incubation with horse-radish peroxidase (HRP)-polymer. The sections were then 
washed thoroughly with distilled water followed by a 5 minute incubation with 3, 3’-
diaminobenzadine (DAB). A further 5 minute wash with distilled water was applied before 
being counterstained with Mayer’s haematoxylin and using Scott’s tap water. Finally the 
sections were dehydrated and mounted in DPX.  
 
2.2.2. Immunofluoresence 
Immunofluorescence was performed on 5μM FFPE sagittal cerebellar sections. The sections 
were deparaffinised and rehydrated before performing antigen retrieval specific to the primary 
antibodies used (table 2.3). Sections were washed well in distilled water before incubation in 
10% (v/v) normal goat serum for 60 minutes to minimise non-specific binding of the 
secondary antibodies and to give the highest signal to noise ratio. The sections were incubated 
in primary antibodies diluted in PBS at 4˚C overnight. The following day, sections were 
washed with PBS before being incubated with fluorescent secondary antibodies for 120 
minutes at 4˚C.  Sections were incubated in Sudan black solution (0.3% w/v in 70% v/v 
ethanol) 10 minutes and washed well in distilled water. The sections were then mounted in 
prolong gold anti-fade solution and cover slipped before being stored at -20˚C. 
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Table 2.3: Summary of primary antibodies used . 
         Properties of the primary antibodies used throughout the project. 
 
 
 
Primary  antibody Target Host and isotype Supplier 
Anti-GAD65/67 Glutamic acid decarboxylase 65–67 Rabbit IgG Sigma 
Anti-SMI-31R Phosphorylated heavy 
subunit of 
neurofilaments 
Mouse IgG1 Biolegend 
Anti-SMI-32 Non-phosphorylated 
heavy subunit of 
neurofilaments 
Mouse IgG1 Biolegend 
Anti-amyloid 
precursor protein 
Amyloid Precursor Protein Rabbit IgG Thermo 
Fisher 
Scientific 
Anti-synaptophysin Synaptophysin Mouse IgG1 Dako 
Anti-beta III 
Tubulin [TUJ-1] 
β-tubulin (TuJ-1) Mouse IgG2a Abcam 
Anti-Acetylated 
alpha Tubulin 
Acetylated alpha Tubulin Mouse IgG2b Abcam 
Anti-complex I 19 
kDa 
NDUFA13 Mouse IgG2b Abcam 
Anti-neurofilament 
H 200kDa 
neurofilament H (200 kDa) Rabbit  IgG Millipore 
Anti-SMI-94 Myelin Basic Protein Mouse  IgG1 Biolegend 
Anti-SMI-99 Myelin Basic Protein Mouse  IgG2b Abcam 
Anti-Porin porin Mouse IgG2b Abcam 
Anti-MTCO1 Cytochrome C Oxidase subunit I 
(COX1) 
Mouse IgG2a Abcam 
Anti-COX4 + 
COX4L2 
cytochrome C oxidase subunit IV 
(COX4) 
Mouse IgG2a Abcam 
Anti-glut-1 Glut-1 (endothelial) Rabbit IgG Sigma 
Anti-SDHA Succinate Dehydrogenase 
Complex, Subunit A (SDHA) 
Mouse IgG1 Abcam 
Anti-myelin basic 
protein 
Myelin Basic Protein Chicken IgY Aves Lab 
Anti-neurofilament 
H 200kDa 
Neurofilament H (200 kDa) Chicken IgY Aves Lab 
Anti-α smooth 
muscle actin 
α smooth muscle actin Mouse IgG2a Dako 
Anti-parvalbumin Parvalbumin Mouse IgG1 Swant 
Anti-calbindin D-
28k 
Calbindin D-28k Mouse IgG1 Swant 
Anti-NaV1.6 Type VI Sodium Channel Rabbit IgG Alamone 
Labs 
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Table 2.4: Summary of secondary antibodies used . 
Details about all the secondary antibodies that were used throughout the project. 
The host species of each secondary antibody was goat and the dilution used was 
1:100. 
 
 
 
 
 
 
 
Antibody Target Manufacturer 
Alexa Fluor 633 anti-mouse IgG1 Mouse IgG1  
 
 
 
 
 
Thermo Fisher Scientific 
Alexa Fluor 633 anti-mouse IgG2a Mouse IgG2a 
Alexa Fluor 633 anti-mouse IgG2b Mouse IgG2b 
Alexa Fluor 647nm anti-mouse 
IgG1 
Mouse IgG1 
Alexa Fluor 405nm anti-rabbit IgG Rabbit IgG 
Alexa Fluor 405nm anti-mouse 
IgG2a 
mouse IgG2a 
Alexa Fluor 405nm Streptavidin 
Conjugate 
Biotin 
Alexa Fluor 488nm anti-mouse 
IgG1 
Mouse IgG1 
Alexa Fluor 488nm anti-mouse 
IgG2b 
Mouse IgG2b 
Alexa Fluor 488nm anti-mouse 
IgG2a 
Mouse IgG2a 
Alexa Fluor 488nm anti-Rabbit IgG Rabbit IgG 
Fluorescein Goat Anti-Chicken IgY Chicken IgY 
Alexa Fluor 546nm anti-mouse 
IgG1 
Mouse IgG1 
Alexa Fluor 546nm anti-rabbit IgG Rabbit IgG 
Alexa Flour 546nm anti-mouse 
IgG2a 
mouse IgG2a 
Alexa Flour 546nm anti-mouse 
IgG2b 
mouse IgG2b 
Biotinylated anti-Rabbit IgG anti-Rabbit IgG Jackson Laboratories 
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2.2.3. SeeDB 
The SeeDB method is based on the technique described in the study by Ke et al. (2013). 12 
month old wild type C57BL/6 mice were killed humanely and their brains were removed. The 
brains were incubated in 4% paraformaldehyde at 4ºC overnight and then washed with PBS. 
The brains were then sectioned to 250µm using a Hyrax V50 vibratome (Frequency 70Hz, 
Amplitude 0.7m, Zeiss). The sections were then blocked in 10% Normal Goat Serum (NGS) 
in PBS for one hour before having the primary antibodies (anti-SMI-31R, Anti-neurofilament 
H 200kDa and Anti-MTCO1)in PBS applied for 4 days at 4ºC.  The sections were then 
washed the sample in PBS three times for an hour each. The secondary antibodies (Alexa 
Fluor 488nm anti-mouse IgG1, Alexa Fluor 546nm anti-rabbit IgG and Alexa Fluor 633 anti-
mouse IgG2a) were then applied in PBS for 3 days at 4˚C. The sections are then washed again 
with 3x1hour PBS washes. 
The sections then undergo the SeeDB clearing method. Sections are incubated ~20 ml of 20% 
(w/v) fructose solution for 8 hrs at 37 °C. The sections are then incubated in 40% (w/v) 
fructose for 8 hrs at 37 °C. The next step is to incubate the section in 60% (w/v) fructose for 8 
hrs at 37 °C. The sections are then incubated in 80% (w/v) fructose for 12 hrs at 37ºC before 
being incubated in 100% (w/v) fructose for 12 hrs at 37ºC. The sections are finally incubated 
in the SeeDB solution for 24hrs at 37ºC. The sections should be continuously rotated or 
rocked during the incubation steps. The sections are then placed between coverslips imaged 
on the Nikon A1R Single photon Confocal Microscope as described in chapter 2.3.2  
2.2.4. Clear Lipid-exchanged Acrylamide-hybridized Rigid Imaging/Microscopy 
(CLARITY) 
The CLARITY technique is adapted from the method first described in the original study by 
Chung et al. (2013).  
2.2.4.1. Tissue Preparation 
For the optimisation of CLARITY, 12 month old wild type C57BL/6 mice were sacrificed 
using cervical dislocation before the brains were excised and incubated in 4% 
paraformaldehyde at 4ºC overnight. While for the human sections, smaller sub-sections, 
approximately 3cm x 3cm x 1cm (WxLxD) were excised from formalin fixed sagittal 
cerebellar brain sections that contained both cerebellar folia and dentate nucleus were 
collected from the NBTR, where they had been stored in formalin. The cases selected for use 
in the CLARITY chapters all had a fixation time less than six years. The human sections were 
washed in PBS over night before undergoing the CLARITY technique.  
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2.2.4.2. Hydrogel Preparation 
The hydrogel solution was prepared by combining 20mL acrylamide (40%), 10mL bis-
acrylamide (2%), 1 g VA-044 initiator (10% wt) , 40mL 10X PBS and 310mL dH2O. This 
was completed on ice and then stored at -20˚C until needed.  
2.2.4.3. Tissue embedding 
The tissue was placed in 50mL of hydrogel solution and incubated for 3 days (mice) or 7 days 
(human) at 4˚C. Once the incubation was completed, the falcon tubes were opened and placed 
in a desiccator chamber where it was filled with nitrogen for 10mins. A vacuum pump then 
removed all gas from desiccator chamber for 10 minutes before being refilled with nitrogen 
from a tank for another 10 minutes. The falcon tubes were then sealed, ensuring exposure to 
the oxygen is minimal and the falcon tubes were transferred to a 37ºC water bath for 3 hours 
to initiate the polymerisation of the hydrogel.  
2.2.4.4. Passive Clearing of Tissue 
The tissue was removed from the polymerised hydrogel in a fume hood. The tissue was 
washed in PBS overnight and then sectioned to 250µm on a Hyrax V50 vibratome (Frequency 
70Hz, Amplitude 0.7m, Zeiss). The clearing solution was prepared by combining 24.722 g 
boric acid, 80 g sodium dodecyl sulphate, and 2L dH2O and then pH to 8.5 by adding NaOH. 
The 250 µm sections were placed in a 50mL falcon tube and filled with 40ml clearing 
solution before being placed in a 37ºC water bath. The clearing solution was changed every 
other day.  
The length of time for passive clearing was assessed visually but for mouse 250µm thick 
cerebellar sections it was typically 7 days while in human 250 µm thick cerebellar sections it 
was > 4weeks likely due to length of time spent in formalin.  
2.2.4.5. Immunofluorescent staining.  
Once clearing was completed, the sections are washed with PBS 5 times for 30 minutes. The 
sections are then incubated in 10% (v/v) normal goat serum for 1hr 30mins. Once completed, 
the sections were then incubated in 1mL PBS 0.1% tween with the appropriate antibody 
dilution. The sections were incubated in the primary antibody at 4C for 6 days and then 
followed by a round of 5x 30mins PBS wash. The secondary antibodies were diluted in 1mL 
PBS 0.1% Tween and applied to the sections for 4 days at 4˚C. The sections then underwent 
5x 30mins PBS washes before a 30mins incubation in 0.2M glycine and an overnight 
incubation in Refractive Index Matching Solution (RIMS).  
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2.2.4.6. Imaging 
The cleared and stained sections were placed between two coverslips and then imaged on the 
Nikon A1R Single photon Confocal Microscope as described in chapter 2.3.2 
2.3. Microscopy 
2.3.1. Light Microscope 
A light microscope uses visible light in conjunction with a series of lenses to magnify the 
section. The image can then be projected to a charge-coupled device (CCD) camera allowing 
the user to capture a digital image of the magnified section. A modified light microscope 
(Olympus BX51), with a motorised stage and CCD colour video camera were used in 
conjunction with stereological software (Stereo investigator, MBF Bioscience, USA) to 
quantify axonal torpedo and Purkinje cell density. 
2.3.2. Laser scanning confocal microscope 
Confocal microscopy differs from wide-field fluorescence microscopes, in that confocal 
microscopes only excite a very small focal plane, building up an image rather than exciting 
the entire field of interest. By only scanning a small focal point and the use of a spatial 
pinhole which eliminates out of focus emitted light, a laser scanning confocal microscope 
greatly improves the signal-to-noise ratio, therefore, increasing the optical resolution of the 
image.  
In a confocal microscope, the excitatory light source is a laser which is reflected by a beam 
splitter and focused onto the specimen by the objective. The laser excites the fluorophores in 
that focal region, resulting in emitted fluorescence. The emitted light is captured by the 
objective, passes through the beam splitter and pin hole to the photomultiplier (PMT) 
detector. Emitted light from regions that are out of focus are unable to pass through the pin 
hole and are therefore not detected by the PMT detector reducing the amount of noise 
detected. The principles of confocal microscopy is summarised in Figure 2.1.  The ability of a 
confocal microscope to carry out optical sectioning, the process of detecting signal at different 
focal depths to create a 3D image makes confocal microscopy well suited for imaging thick 
tissue sections.  
Imaging of immunofluorescence staining was completed on the Nikon A1R microscope 
(Nikon Corporation, Japan). The Nikon A1R is a point scanning confocal microscope that is 
mounted on a fully automated Nikon inverted microscope with a motorized nosepiece and 
stage and contains a hybrid-scanner (galvano/resonant) and a 4 channel detection (excitation 
wavelengths 405nm, 491, 515, 561 and 640nm). The Nikon A1R microscope was also 
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equipped with six different objectives (air or oil) and a Step-by-step Nikon A1 Piezo Z 
scanner and Nikon TI-S-EJOY (Nikon) which allowed for Z stack images of the regions of 
interest to be imaged.  
Before images were capture, for quantification, the laser settings needed to be set. To achieve 
this, the photomultiplier tube gain (HV), laser power and offset functions were adjusted when 
imaging a neurologically normal control section to ensure that there was no avoiding under or 
over exposure of each channel. For the 5µm thick sections, imaging was completed using the 
x60 oil immersion objective in conjunction with an electronic zoom of x3 using the resonant 
scanning method with a line average of 8 and 1.2AU pin hole. While the passively cleared 
sections were imaged using an x20 objective and a 2.56 zoom on the axonal torpedoes. In the 
instances of the CLARITY cleared sections, galvano was the preferred scanning method with 
a line average of two and 1.2AU pin hole. Images were captured using the intuitive 
NIS:Elements operating software (Nikon corporation, Japan) that is attached with the Nikon 
A1R.  
2.4. Image Analysis 
Analysis of respiratory chain deficiency was achieved using the velocity software (Volocity 
v6.3, Perkin Elvin). While 3D rendering of images was complete using the Imaris software 
(Imaris v8, Bitplane). 
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    Figure 2.1: Schematic diagram detailing the principles of confocal microscopy.  
The light source (red line) passes through the source pinhole and is reflected by 
the beam splitter through the objective, which focuses the light on to the focal 
plane. The emitted excited light is collected by the objective lens and where it 
passes through the beam splitter and detector pinhole to the photomultiplier 
(PMT) detector. The detector pinhole prevents out of focus light from above 
(black line) and below (blue line) from being detected by the P<T detector. 
The image was taken from Wang et al. (2015a) 
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3.1. Introduction 
The cerebellum only occupies 10% of the brain volume but contains 50% of the brain’s total 
neuronal population resulting in a dense network of neurons (Knierim, 1997). This high 
density of neurons results in the cerebellum consuming a vast quantity of energy, with 
computational modelling predicting that Purkinje cells alone require 10 11 molecules of ATP 
per second to maintain neuronal function (Howarth et al., 2010). The cerebellum is therefore 
vulnerable to mitochondrial dysfunction due to its high energy requirements. A common 
clinical manifestation of this in mitochondrial disease is cerebellar ataxia, defined as a lack of 
balance, coordination and motor control. This is present in approximately 70% of the patients 
within the UK MRC Mitochondrial Disease Patient cohort (Lax et al., 2012b; Nesbitt et al., 
2013). 
When investigating the cerebellum in patients with mitochondrial disease, abnormal  
neuroradiological and neuropathological findings are frequently observed (Lax and Jaros, 
2012). In patients with the m.8344A>G point mutation, pronounced cerebellar lesions were 
observed (Fukuhara, 1991) while severe neuronal loss in the dentate nucleus and inferior olive 
and mild loss of Purkinje cell numbers have also been observed (Tanji et al., 2001; Lax et al., 
2012b). In the cerebellum of patients with the m.3243A>G point mutation, there is an 
increase in inter folia spacing due to atrophy of the molecular and granular cell layer and  
neuronal densities were reduced in the dentate nucleus, inferior olive and Purkinje cell layer 
(Lax et al., 2012b). Abnormal Purkinje cell morphology has also been found,  including a loss 
of presynaptic terminals, increase in dendritic arborisation and an increase in the number of 
thickened axons causing trapping of mitochondria (Tanahashi et al., 2000; Lax et al., 2012b). 
Patients with secondary mitochondrial disease due to a mutation in mtDNA maintenance 
genes can also develop cerebellar ataxia, with abnormalities in the cerebellum observed in 
neuroimaging (Tzoulis et al., 2006). A patient that had multiple mtDNA deletions due to a 
recessive POLG mutation was shown to have moderate focal loss of Purkinje cells and mild 
neuronal loss in the dentate nucleus (Betts-Henderson et al., 2009).  
 
 
3.1.1. Axonal Torpedoes in the Cerebellum 
A prominent form of axonal pathology known as axonal torpedoes are commonly observed in 
the cerebellum of patients with mitochondrial disease (Mori et al., 2000a; Tanahashi et al., 
2000; Lax et al., 2012b). Axonal torpedoes are fusiform swellings of the proximal portion of 
the Purkinje cell axon in the Granular cell layer (GCL) (Figure 3.1 (Lax et al., 2012b)). 
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Immunofluorescent labelling confirms that the axonal torpedoes belong to the Purkinje cell 
body through the positive staining with calbindin and the highly phosphorylated 
neurofilaments found within the axonal torpedoes (Louis et al., 2009b; Redondo et al., 2015) 
 
Figure 3.1: Axonal Torpedoes in the Cerebellum of Patients with Mitochondrial Disease.  
A prominent feature observed in the cerebellum of individuals with mitochondrial 
disease are the observation of axonal torpedoes in the granular cell layer. These 
structures are found proximal to Purkinje cell bodies and are found to be highly 
concentrated with disorganised phosphorylated neurofilaments. Images taken 
from A) (Lax et al., 2012b) (SMI-31) and B) (Mori et al., 2000b) (Bodain stain).  
 
Axonal torpedoes have also been observed in a number of other neurological disorders such 
as Friedreich’s ataxia (Jitpimolmard et al., 1993) and multiple sclerosis (Redondo et al., 
2015). In common neurodegenerative disorders like Alzheimer’s and Parkinson’s disease, 
axonal torpedoes have also been observed, with one study detailing 5 times more axonal 
torpedoes in both diseases compared to controls (Louis et al., 2009a). Axonal torpedoes have 
been shown to be highly prevalent in the cerebellum of patients with essential tremor, 
observed in two studies to be 12 times (Louis et al., 2009a) and 6 times (Louis et al., 2007) 
more prevalent than compared to control tissue. The observation of axonal torpedoes in 
neurological disorders and the lack of correlation between axonal torpedoes and age (Louis et 
al., 2007), indicates that the formation of these structures occurs in injured Purkinje cell 
neurons. 
Along with quantifying the number and level of axonal torpedoes in the cerebellum of 
individuals, a number of early studies have investigated the main constituents that form the 
torpedoes. A study using electron microscopy (EM) found that the axonal torpedoes in a 
patient with Essential tremor are mainly comprised of densely accumulated and disorganised 
neurofilaments which force mitochondria and endoplasmic reticulum to peripheries of the 
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axonal torpedoes (Louis et al., 2009c). As well as the accumulation of neurofilaments, the EM 
images show a lack of myelin sheath around the torpedoes. This lack of myelin was also 
observed with axonal torpedoes in the cerebellum of patients with Friedrich’s ataxia (Kemp et 
al., 2016). 
It has been proposed that following a focal insult, there is a block in anterograde and 
retrograde fast axonal transport resulting in the dis-organisation and accumulation of 
neurofilaments and other proteins in the axon which subsequently over time produces an 
axonal torpedo (Figure 3.2). This block in axonal transport would “starve” the distal regions 
of the neuron and lead to Wallerian degeneration of the distal axon and inevitably cell death. 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 3  Characterisation of Axonal Torpedoes 
72 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Hypothesised sequence of events that lead to the formation of axonal 
torpedoes.  
A focal insult to the axon results in the inhibition of fast axonal transport (A). 
Proteins involved in axonal transport, like amyloid precursor protein, start to 
accumulate causing a focal swelling of the axon further inhibiting axonal 
transport eventually forming an axonal torpedo (B). Ultimately the block in 
transport becomes too significant and initiates Wallerian degeneration of the 
distal axon creating an end bulb (C). This image was modified from Coleman 
(2005). 
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3.1.1.1.Neurofilaments 
Neurofilaments are one of the most abundant intermediate filaments found in the CNS (Lee et 
al., 1993). There are three isomers of the neurofilament protein; Neurofilament L (70 kDa, 
NFL), Neurofilament M (150 kDa, NFM) and Neurofilament H (200 kDa, NFH) (Yuan et al., 
2012). Each isomer is composed of a globular head domain, a α-helical rod domain and a tail 
c-domain that differs in length and amino acid composition, determining the weight of the 
isomer (Figure 3.3A (Yuan et al., 2012)). The globular head domain contains a microtubule 
(MT) polymerisation inhibitory domain that is involved in the regulation of MT 
polymerisation and numbers (Bocquet et al., 2009).  The α-helical domain is a highly 
conserved sequence of 310 amino acids that is vital for the co-assembly with other subunits to 
form filaments and also contains the binding site myosin Va motor protein (Rao et al., 2011). 
In Neurofilament M and Neurofilament H, the c-terminal domains have fine lateral extensions 
that can increase the spacing between the neurofilaments, key for the radial growth of axons 
(Figure 3.3B (Rao et al., 2003)). The three isomers and α- internexin come together to form 
heteropolymers that have an exceptionally long half-life (Millecamps et al., 2007) and are 
extremely elastic allowing for them to maintain the asymmetrical shape of neurons (Wagner 
et al., 2007). These properties allow neurofilaments to regulate axonal calibre and 
subsequently influence the conduction velocities of the axon. Targeted disruption of the 
neurofilament network has shown both a reduction in both axon calibre and conduction 
velocities (Kriz et al., 2000). 
Neurofilaments can be phosphorylated at multiple sites depending on the location of the 
subunits. In the cell body, the globular head domain is non phosphorylated to prevent the 
formation of filaments (Hisanaga et al., 1990). In the c-terminal domain of NFM and NFH, 
there are multiple lysine-serine-proline (KSP) sites that can be phosphorylated (Jaffe et al., 
1998; Veeranna et al., 2011). The level of c-terminal phosphorylation depends on the location 
of the neurofilaments. In the cell body or dendrites the neurofilaments are non-phosphorylated 
while in axons they are highly phosphorylated (Sternberger and Sternberger, 1983). The 
phosphorylation of the c-terminal regulates the transportation of neurofilaments (Ackerley et 
al., 2003), modulates the interaction of neurofilaments with microtubules (Hisanaga and 
Hirokawa, 1989; Hisanaga et al., 1991; Yabe et al., 2000) and also leads to resistance to 
proteolysis (Goldstein et al., 1987; Pant, 1988). 
Aberrant phosphorylation and accumulation of neurofilaments has been associated with a 
number of neurodegenerative disorders. In disorders such as Alzheimer’s disease (AD), 
amyotrophic lateral sclerosis (ALS), giant axonal neuropathy and Parkinson’s disease (PD) 
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phosphorylated neurofilaments have been observed in neuronal cell bodies (Shea et al., 2009; 
Liu et al., 2011). In AD, the phosphorylation of KSP repeats on NFH and NFM was observed 
to be four to eight fold higher in AD patients compared to controls (Rudrabhatla et al., 2011). 
In ALS, the release of phosphorylated NFH into blood serum is seen as a sign of axonal injury 
and as a potential biomarker (Shaw et al., 2005; McCombe et al., 2015). In a mice model, 
where the human variant of NFH was overexpressed, the mice were shown to develop 
neurological defects at the age 3-4 months and abnormal neurofilamentous swellings, similar 
to those observed in ALS (Cote et al., 1993). A study showed that 87% of large axonal 
swellings of the motor neurons which are characteristic of ALS stained heavily for the 
Kinesin, the motor protein essential for anterograde axonal transport (Carpenter, 1968; 
Toyoshima et al., 1998). The entrapment of motor proteins will likely lead to an inhibition of 
axonal transport and a “starvation” of the neuron. 
 
Figure 3.3: Neurofilaments of the central nervous system. 
Neurofilaments are intermediate filaments that are found abundantly in the axons. 
There are three isoforms of neurofilaments; neurofilament heavy (NFH), medium 
(NFM) and light (NFL) polypeptides. Mutations and aberrant phosphorylation of 
neurofilaments is associated with a number of neurodegenerative disorders (A).  
Neurofilaments play an important role in determining the radial growth of axons. 
This is achieved through the projection of a side arm in the c-terminal domain of 
the neurofilaments (B). The image was modified from (Yuan et al., 2012). 
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3.1.1.2. Fast Axonal Transport 
Neurons are highly polarised cells, and as organelles, proteins, lipids, and RNA are 
synthesised in the soma, they rely on axonal transport to direct those molecules to the growth 
cones and synapses. Additionally, damaged molecules undergo retrograde transport from the 
distal regions to the soma to be degraded and recycled.  
Fast axonal transport (FAT) can reach speeds of 0.5-3 mm/s and is utilised to transport 
vesicles, organelles, and RNA to the extremities of the neuron (Maday et al., 2014). FAT 
employs  two motor protein families known as kinesin and dynein, and they are capable of  
hydrolysing one ATP molecule for every 8nm they transport proteins along the axons 
(Gennerich and Vale, 2009). The motor proteins use microtubules as the tracks to move along 
the axon. Microtubules (MT) are polymers composed of α and β tubulin forming a highly 
dynamic component of the cytoskeleton (Salinas et al., 2008).  Microtubules are polarised 
with a fast-growing plus ends directed to the synapse in the axon and a stable minus end 
directed towards the soma (Stepanova et al., 2003). The polarity of the microtubules helps 
direct the motor proteins and the directions of FAT.  
Kinesins are the main motor protein involved in the anterograde movement of cargo from the 
soma to the synapse. Kinesins are a part of a superfamily and have many isoforms but 
Kinesin-1 motors are responsible for the trafficking of the majority of vesicles, organelles, 
proteins, and RNA particles. They are heterotetramers composed of two heavy chains 
(KIF5A–C) and two light chains (KLC1/2). The heavy chains (KIFs) contain the motor 
domain and binding motifs for ATP and microtubule while the light chains (KLC) regulates 
the motor activity and binding of cargo (Wang et al., 2015b).. In addition to Kinesin-1, 
Kinesin-3 has been shown to be involved in the transport of synaptic vesicle precursors and 
dense core vesicles (Lo et al., 2011).  
The transport of molecules from the plus end of microtubules to the negative end is known as 
retrograde transport. Retrograde transport is completed by Dynein, a motor protein consisting 
of two heavy chains, an intermediate, light intermediate and light chain (Hirokawa et al., 
2010). As with Kinesin, the heavy chains of Dynein contains the ATP and microtubule 
binding motifs. The activity of Dynein is dependent on Dynactin, a multi-subunit cofactor, 
which among other cofactors such as lissencephaly-1 and huntingtin, Dynein binds to forming 
a complex (Vale, 2003; Maday et al., 2014). 
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Two proteins that undergo fast axonal transport are Amyloid Precursor Protein (APP) and 
synaptophysin and for the purpose of this chapter I will briefly describe them as their presence 
in axonal torpedoes will be investigated. 
Amyloid Precursor Protein (APP) is a type I orientated membrane protein that it is 
synthesised in the endoplasmic reticulum (ER) and processed in the Golgi network (Haass et 
al., 2012). Once APP had been processed, it travels unidirectionally and constantly in tubular 
vesicles via FAT to the presynaptic terminals reaching speeds up to 10 mm/s with an average 
speed of 4.5 mm/s (Kaether et al., 2000). Once the vesicles reach the pre-synaptic terminal, 
they fuse with the plasma membrane before forming synaptic vesicle. APP has been shown to 
accumulate in the axons (Figure 3.3) in a number of neurological disorders from Alzheimer’s 
disease (Stokin et al., 2005), traumatic brain injury (Gentleman et al., 1993) to multiple 
sclerosis (MS) (Ferguson et al., 1997). The build-up of APP in an end bulb create structures 
that are highly reminiscent of the axonal torpedoes of the Purkinje cells. If APP is present in 
the axonal torpedoes then it would also indicate that axonal transport is blocked and that 
axonal torpedoes may share a similar degenerative mechanism as the one involved in the 
degenerative process observed in axonal transection or demyelination of the axon (Trapp et 
al., 1998).  
Synaptophysin, a calcium binding membrane glycoprotein, is the second-most abundant 
protein at the pre-synaptic terminal accounting for 10% of total vesicle protein (Rehm et al., 
1986; Takamori et al., 2006) . It is found in the membrane of the small presynaptic vesicles 
and plays a role in synaptic vesicle biogenesis, exocytosis and endocytosis (Valtorta et al., 
2004). In patients with Alzheimer’s disease an increase in synaptophysin reactivity was 
observed in diffuse amyloid deposits and dystrophic plaque neurites (Brion et al., 1991). In 
the corticospinal tract of a patient with ALS, numerous axonal spheroids were documented to 
be positive for synaptophysin as well as phosphorylated neurofilaments, ubiquitin and lipid-
laden macrophages (Takahashi et al., 1997). Synaptophysin has been observed to increase in 
concentration distally to the site of injury when an rat optic nerve had been crushed indicating 
a block in axonal transport (Li and Dahlstrom, 1997). The change in expression or distribution 
of these proteins is likely to be indicative of disrupted axonal transport and may be an early 
marker of axonal degeneration. 
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3.2. Aims 
In previous studies that characterised the neuropathology in the cerebellum of patients with 
mitochondrial disease, axonal torpedoes were phenomenon’s that were only observed and 
never quantified or characterised. The formation of axonal torpedoes may be involved in the 
degenerative process caused by respiratory chain deficiency in the cerebellum of patients with 
mitochondrial disease. The aim of this chapter is to further quantify and characterise axonal 
torpedoes in patients with mitochondrial disease to determine if there is a relationship 
between respiratory chain deficiency in Purkinje cells and the presence of axonal torpedoes 
Additionally, the aim of this chapter is to investigate if the formation of axonal torpedoes are 
a by-product of a cessation or block in axonal transport. Therefore, I aim to: 
1. Confirm that axonal torpedoes are more prevalent in patients with mitochondrial 
disease and age-matched controls 
2. Determine if a disruption of fast axonal transport is the cause of axonal torpedo 
formation.  
3. Determine if mitochondria are present within axonal torpedoes and quantify the level 
of respiratory chain deficiency to determine if axonal torpedoes form in Purkinje cells 
that have a high level of respiratory chain deficiency.  
To achieve these aims I will use a combination of immunohistochemistry and 
immunofluorescent assays on formalin fixed paraffin embedded cerebellar sections from 
patients with mitochondrial disease and age matched controls.  
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3.3. Materials and Methods 
3.3.1. Subjects and tissue details 
For this chapter formalin-fixed paraffin-embedded (FFPE) cerebellar brain tissue from ten 
patients (age range: 20-79 years) that were genetically and clinically confirmed to have 
mitochondrial disease and ataxia were used. While for comparison, fourteen age-matched 
control individuals (age range: 25-79 years) with no clinical or pathological evidence of 
neurological disease were used in this study.  The age (t-test, p=0.069) and PMI delay (t-test, 
p= 0.564) of patients and controls showed no statistical difference. Table 3.1 summarises 
details about the individuals used in this chapter.  
3.3.2. Immunohistochemistry and immunofluorescence.  
The immunohistochemistry method described in section 2.2.1 was utilised to quantify the 
number of axonal torpedoes in the cerebellum of patients with mitochondrial disease 
compared to controls as well as further characterising the components of the axonal 
torpedoes.  
To determine the presence of microtubules in the axonal torpedoes, a triple 
immunofluorescent will be used with the following antibodies; anti-SMI-31 ((1:1000) 
488nm), anti-β-tubulin ((1:500 (546nm)) and anti-acetylated α-tubulin (1:100 (647nm)). 
The quantification of respiratory chain deficiency in axonal torpedoes, Purkinje cell bodies 
and their axons was achieved through the development of a triple immunofluorescent assay. 
The immunofluorescent protocol is described in section 2.2.2.  The assay allowed for the 
detection of;  
i. Axonal torpedoes, Purkinje cells, and proximal axons by using anti-
neurofilament H 200 kDa (1:500 (biotinylated 405nm)),  
ii. Mitochondrial mass using anti- cytochrome c oxidase subunit 4 (COX4 
(1:100) (546nm)) 
iii. Complex I marker anti-NADH dehydrogenase [ubiquinone] 1 alpha 
subcomplex subunit 13 (NDUFA13 ((1:100) 488nm)).  
 
The primary antibodies used in this chapter are summarised in table 3.2 while table 3.3 
summarises the secondary antibodies used.  
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Gender Age 
(Years) 
PMI 
(Hours) 
Genetic defect Cause of Death 
Patient 1 F 40 58 m.3243A>G Respiratory Failure 
Patient 2 F 20 187 m.3243A>G Aspiration pneumonia 
with MELAS 
Patient 3 F 36 9 m.3243A>G Myocardial infarction 
Patient 4 M 45 43 m.3243A>G Complications associated 
with MELAS 
Patient 5 M 59 67 POLG 
(p.Gly848Ser 
and 
p.Ser1104Cys) 
Unknown 
Patient 6 M 30 21 m.3243A>G Unknown 
Patient 7 F 42 59 m.8344A>G Respiratory failure 
Patient 8 F 60 10 m.3243A>G Multi-organ failure 
Patient 9 M 58 66 m.8344A>G Unknown 
Patient 
10 
M 79 85 POLG 
(p.Thr251Ile/p.
Pro587Leu;  
p.Ala467Thr) 
Pneumonia due to 
mitochondrial disease 
Control 1 F 69 16  
 
 
 
 
 
 
 
 
 
 
N/A 
Gastric Cancer 
Control 2 F 74 53 Heart Failure 
Control 3 M 55 51 Liver Cancer 
Control 4 F 74 67 Lung Cancer 
Control 5 M 70 72 Metastatic Ovarian 
Cancer 
Control 6 F 77 83 Myocardial Infarction 
Control 7 M 48 46 Coronary Artery 
Atherosclerosis 
Control 8 M 44 83 Coronary Artery 
Atherosclerosis 
Control 9 M 45 44 Complications of 
Bronchopneumia and  
Coronary Artery 
Atherosclerosis 
Control 
10 
M 25 53 Hanging 
Control 
11 
M 61 61 Hanging 
Control 
12 
M 48 43 Coronary Artery 
Thrombosis 
Control 
13 
M 72 17 Oesophageal 
adenocarcinoma 
Control 
14 
F 78 34 Metastatic Ovarian 
Cancer 
Table 3.1: Tissue details of individuals that were used in Chapter 3. 
Tissue details which include age, gender, Post mortem interval (PMI) and cause 
of death about the individuals that were used in this chapter.   
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Table 3.2: Properties of the Primary antibodies used in Chapter 3.  
The properties of primary antibodies used include; target, host, isotype, dilution 
and method of antigen retrieval.   
Table 3.3: Properties of the secondary antibodies used in Chapter 3.  
The properties of secondary antibodies used include; epitope, host, and dilution.   
 
Primary antibody Target Host and 
isotype 
Dilution Antigen Retrieval 
Anti-GAD65/67 Glutamic acid 
decarboxylase   
65–67 
Rabbit IgG 1:1000 1mmol EDTA 
pH 8, 
pressure 
cooking 
Anti-SMI-31R Phosphorylated 
heavy 
subunit of 
neurofilaments 
Mouse IgG1 1:12,000 
 
No Antigen Retrieval 
Anti-SMI-32 Non-
phosphorylated 
heavy subunit 
of 
neurofilaments 
Mouse IgG1 1:6,000 1mmol EDTA 
pH 8, 
pressure 
cooking 
Anti-amyloid 
precursor protein 
Amyloid 
Precursor 
Protein 
Rabbit IgG 1:2500 10mmol 
tri-sodium citrate, 
pH 6, 10 minutes 
microwave 
Anti-
synaptophysin 
Synaptophysin Mouse IgG1 1:150 10mmol 
tri-sodium citrate, 
pH 6, 10 minutes 
microwave 
Anti-beta III 
Tubulin [TUJ-1] 
β-tubulin  
(TUJ-1) 
Mouse IgG2a 1:100 No Antigen Retrieval 
Anti-Acetylated 
alpha Tubulin 
Acetylated 
alpha Tubulin 
Mouse IgG2b 1:100 No Antigen Retrieval 
Anti-complex I 
19 kDa 
NDUFA13 Mouse IgG2b 1:100 1mmol EDTA 
pH 8, 
pressure 
cooking 
Anti-complex IV 
subunit IV 
COX4 Mouse IgG2a 1:100 1mmol EDTA 
pH 8, 
pressure 
cooking 
Secondary Epitope Host Dilution 
Alexa Flour 488nm anti-mouse IgG2b  
 
 
Goat 
 
 
 
1:100 
anti-mouse IgG1 
Alexa Flour 546nm anti-mouse IgG2a 
Alexa Flour 647nm anti-mouse IgG2b 
Alexa Flour 405nm Streptavidin Conjugate 
Biotinylated anti-Rabbit IgG 
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3.3.3. Quantification of Axonal Torpedo and Purkinje Cell Density 
5μM FFPE sagittal cerebellum sections were stained with anti-p-NF-H to quantify the 
densities of both axonal torpedoes and Purkinje cells. Axonal torpedoes were identified as 
large spherical structures with high immuno-reactivity to p-NF-H with no visible nucleolus 
and located in the Purkinje cell layer or granular cell layer. Purkinje cells were defined as 
having a clearly defined nucleolus and cell body. Using a stereological workstation with a 
light microscope (Olympus BX51), motorised stage and CCD colour video with Stereology 
software (StereoInvestigator, MBF Bioscience, USA), the length of the Purkinje cell layer 
was outlined at 2X magnification. Once completed, magnification was increased to 20X and 
the total number of axonal torpedoes and Purkinje cells were counted along the length of two 
superior and two inferior folia. The Axonal torpedo and Purkinje cell counts were then 
divided by the folia length to calculate densities.  
3.3.4. Quantification of Respiratory Chain Deficiency 
The quantification of respiratory chain deficiency using the triple immunofluorescent assay 
was completed using the Nikon A1R confocal microscope with the NIS Elements software. 
Purkinje cells, axonal torpedoes and axons in the granular cell layer as identified by NFH200 
were captured at 60X magnification with 4X electronic zoom under constant gain, offset and 
laser power. Volocity 3D Image Analysis Software (PerkinElmer, UK) was used to 
deconvolve images and then analysed by using Neurofilament 200kDa to identify either the 
cell or axonal torpedo. The pixel intensities for both NDUFA13 labelled with 488nm and 
COX4 labelled with 546nm were quantified.  
Using the statistical software SAS (SAS Institute Inc.) NDUFA13 intensity values were 
corrected to the mitochondrial marker (COX4) intensity values and then the z scores were 
calculated for the NDUFA13 intensity values. The normal range of NDUFA13 expression 
was defined as range of -2 standard deviations (SD) < z < 2 (SD), while high NDUFA13 
expression was defined as z >2 SD, low NDUFA13 expression was z < -2 SD and deficient if 
z < -3 SD.  Therefore any z-score below -3 will be defined as deficient for NDUFA13 
expression. To determine the difference in NDUFA13 expression between neuronal structures 
or patients with different genetic defects, two-sample t-test (for parametric data) and Mann-
Whitney U tests (for nonparametric data) were performed. While looking at paired data, the 
Wilcoxon Signed-Rank test was implemented.  
Graphical representation of the data was generated using GraphPad prism (GraphPad prism, 
Inc.). 
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3.4. Results 
3.4.1. Characterisation of Axonal Torpedoes 
As previous reports have shown that the main constituents of the axonal torpedoes were 
disorganised phosphorylated neurofilaments, I aimed to determine if other proteins are found 
to be accumulated in the axonal torpedoes from controls and patients with mitochondrial 
disease and whether the presence of these proteins can provide information regarding the 
origins of the axonal torpedoes. 
Immunoreactivity of GAD65-67 in axonal torpedoes confirmed that axonal torpedoes are 
formed in the axons of control Purkinje cells (arrow, Figure 3.4a). Immunohistochemistry 
confirmed that phosphorylated neurofilament H (pNFH) was the main constituent of axonal 
torpedoes (figure 3.4Bi). Axonal torpedoes were shown to be negative for non-phosphorylated 
NFH (npNFH) whereas the cell bodies were clearly positive for npNFH (arrowhead, Figure 
3.4Bii). 
 
     Figure 3.4: Characterisation of axonal torpedoes. 
The presence of GAD65/67 in axonal torpedoes (black arrow) confirms that 
axonal torpedoes originate in Purkinje cell axons (A). Phosphorylated 
neurofilament H (pNFH) was shown to be the main component in the Axonal 
Torpedoes (Bi) while non phosphorylated neurofilament H (npNFH) was not 
observed in axonal torpedoes but was present in Purkinje cell bodies (arrow 
heads, Bii). scale bar= 100µm 
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Using phosphorylated neurofilament H (smi-31R, green, Figure 3.5Ai) as a marker for axonal 
torpedoes (white arrow, Figure 3.5Ai-iv) it was shown that both β-tubulin (tuj1, red, Figure 
3.5Aii) and acetylated α tubulin (acetylated α tubulin, cyan, Figure 3.5Aiii) co-localised with 
phosphorylated neurofilaments in an axonal torpedo, confirming the presence of microtubules 
in axonal torpedoes (Figure 3.45iv, white arrow).  
The next question was to determine if the large accumulation of pNFH in axonal torpedoes 
resulted in a block in axonal transport. Using immunohistochemistry it was determined that 
APP was not present in axonal torpedoes since no APP positive axonal torpedoes were 
observed. However positive staining was observed in the deep white matter, confirming that 
the protocol had worked and accumulations of APP were present in swellings in distal axons 
(red arrow, Figure 3.5B). As with APP, there was no immunoreactivity for synaptophysin in 
axonal torpedoes (black arrow, Figure 3.5Ci) while in the deep cerebellar white matter but 
there was an accumulation of synaptophysin in axonal swellings (red arrow, Figure 3.5Cii). 
This observation in conjunction with APP in the axonal swellings, shows that axonal 
swellings and axonal torpedoes are distinct structures. 
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3.4.2. Quantification of Axonal Torpedoes and Purkinje Cell Density 
As axonal torpedoes have been observed in both control individuals as well as patients with 
mitochondrial disease, I aimed to determine if axonal torpedoes were found at a higher 
density in patients compared to controls. Axonal torpedo and Purkinje cell numbers were 
quantified in the same 4 randomly selected cerebellar regions for each individual. The counts 
were then divided by the length of the Purkinje cell layer to calculate a density of axonal 
torpedoes and Purkinje cells.   Quantification of axonal torpedo density showed that patients 
with mitochondrial disease had a significantly higher density of axonal torpedoes compared to 
controls (unpaired t test, p=0.0007) however, patients had a significant decrease in Purkinje 
cell density compared to control subjects (unpaired t test, p<0.001).  
To account for Purkinje cell loss, the density of axonal torpedoes was adjusted to Purkinje cell 
density and it was shown that 7/10 patients had a higher level of axonal torpedoes per 
Purkinje cells compared to controls (Figure 3.6a) The correlation between axonal torpedo 
density and Purkinje cell density was investigated (Figure 3.6b) and it was shown in patients 
there was a non-significant negative relationship (Pearson’s correlation coefficient; R2=0.035, 
p=0.605). In controls there was a statistically significant relationship (R2=0.283, p=0.04), 
indicating that the presence of axonal torpedoes is associated with the loss of Purkinje cells. 
The relationship between age of individuals and axonal torpedoes was assessed (Figure 3.6c), 
where it was shown that was a significant positive correlation in controls, with the number of 
axonal torpedoes increasing with age (R2=0.431, p=0.0147) but no relationship was observed 
in patients (R2=0.027, p=0.648).  
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3.4.3. Quantification of Complex I Deficiency in Purkinje Cells, Axonal Torpedoes 
and Axons  
A Triple immunofluorescent assay was utilised to determine if mitochondria are present in 
axonal torpedoes and if they are respiratory chain deficient. To achieve this both the 
expression of the complex I subunit NDUFA13 and a mitochondrial mass marker, COX4, was 
measured. I chose to look at complex I as a marker of respiratory chain deficiency as previous 
studies in mitochondrial disease have reported a decrease in subunits of complex I (Reeve et 
al., 2013; Grunewald et al., 2014; Chrysostomou et al., 2016; Lax et al., 2016). When 
compared to the expression level in controls, the COX4 expression levels in the axonal 
torpedoes (unpaired t-test p = 0.1058) and Purkinje cells (unpaired t-test p = 0.1871) of 
patients was preserved which is in agreement with previous studies (Lax et al., 2012b; 
Chrysostomou et al., 2016), confirming that COX4 is a suitable protein to be used as a 
mitochondrial mass marker.  
Immunofluorescence reveals that mitochondria (COX4) are found diffusely throughout the 
axonal torpedoes (Figure 3.7-9). The data from control axonal torpedoes show NDUFA13 co-
localising with COX4 confirming that the expression of NDUFA13 remains intact. In patient 
axonal torpedoes, there is a reduction in NDUFA13 expression in the patients with either the 
m.3243A>G point mutation (Figure 3.7) or the mutation in POLG (Figure 3.8). The axonal 
torpedoes in patients with the m.8344A>G point mutation (Figure 3.9) had NDUFA13 
expression that was comparable to the NDUFA13 expression in control axonal torpedoes. In 
Purkinje cells the expression of NDUFA13 and COX4 is equal in control Purkinje cells 
(Figure 3.10). In patients, more specifically those with the m.3243A>G (Figure 3.10) and 
POLG mutations (Figure 3.11), there is a clear reduction in the expression of NDUFA13. 
However, in the patients with m.8344A>G point mutation there was no discernible difference 
in NDUFA13 expression when compared to the controls (Figure 3.12).  This pattern of 
deficiency is also observed in Purkinje cell axons that were imaged from a close proximity to 
the Purkinje cell bodies, with Purkinje cell axons from patients with the m.3243A>G (Figure 
3.13) and POLG mutations (Figure 3.14) displaying a reduction in NDUFA13 expression 
while there the NDUFA13 expression is comparable to controls in the patients with 
m.8344A>G mutation (Figure 3.15).  
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The intensities of NDUFA13 and COX4 were quantified in all 3 regions and from this data z 
scores were derived in order to provide an accurate measure of the difference between patient 
and control subcellular domains. From the z scores, the different domains could be defined by 
the standard deviations (SD) and these are as follows; high NDUFA13 expression (z >2 SD), 
normal NDUFA13 expression (-2SD < z < 2SD), low NDUFA13 expression (z < -2 SD) and 
deficient (z < -3 SD). 
Quantification of z scores revealed that complex I deficiency in the axonal torpedoes was 
most severe in patients 1 and 2, carrying the m.3243A>G mutation. Respectively, 60% and 
66. 667% of the axonal torpedoes, in those patients, displayed a level of NDUFA13 
expression that was deemed as deficient while the remainder of patients displayed a minimal 
level of NDUFA13 deficiency with the majority of axonal torpedoes having normal level of 
NDUFA13 (Figure 3.16A). The Purkinje cell bodies displayed a greater level of NDUFA13 
deficiency in patients, with patient 3 (m.3243A>G) and 6 (m.3243A>G) respectively having 
90% and 80% of the Purkinje cells being deficient in NDUFA13 (Figure 3.16B). 
Interestingly, the majority of the Purkinje cells from the five patients harbouring the 
m.3243A>G mutation (Patient 1, 2, 3, 4, and 6) all displayed a level of NDUFA13 expression 
that was below the normal level. Axons displayed a similar pattern of deficiency with patients 
(Patient 1, 2, 4, and 6) harbouring the m.3243A>G mutation having the greatest reduction in 
NDUFA13 expression (Figure 3.16C). More specifically Patients 1 and 2 had the highest 
level of NDUFA13 deficiency, respectively with 71.429% and 75% of axons having deficient 
NDUFA13 expression and no axons at all displaying a normal range of NDUFA13 
expression. 
The patients with m.3243A>G mutation appeared to demonstrate the greatest level of 
complex I deficiency and this was statistically confirmed, with significant differences 
observed in the Z scores of all of the m.3243A>G structures when compared to controls 
(paired t test, p<0.00001). There was a similar level of complex I deficiency in all the 
neuronal compartments of patient’s harbouring autosomal recessive POLG mutations. 
However there was no evidence of complex I deficiency in in any of the neuronal 
compartments of the patients harbouring m.8344A>G mutations.  
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3.5. Discussion 
Patients with mitochondrial disease are commonly affected by neurological deficits which are 
characterised by progressive decline and have limited treatment options. The poor 
regenerative capacity and complex architecture of neurons combined with dependence on 
mitochondria for oxidative phosphorylation explains the vulnerability of the CNS to 
mitochondrial defects (Attwell and Laughlin, 2001). A common feature in patients with 
mitochondrial disease is cerebellar ataxia, with recent estimations calculating that 68% of 
adult patients are suffering with this problem (Lax et al., 2012b; Nesbitt et al., 2013). Despite 
neuropathological studies confirming the susceptibility of the cerebellum with atrophy, 
Purkinje cell loss and dentate nucleus neuron loss with complex I deficiency in remaining 
cells, the mechanisms which result in the degeneration at this early phase are not known (Lax 
et al., 2012b).  
A common and striking pathological phenomenon observed in the cerebellum of patients with 
mitochondrial disease are axonal torpedoes (Mori et al., 2000b; Lax et al., 2012b). These 
structures are fusiform swellings of Purkinje cell axons proximal to the cell body. This 
chapter aimed to confirm that axonal torpedoes are more prevalent in patients with 
mitochondrial disease than controls, characterise the composition of axonal torpedoes, 
determine the relationship of axonal torpedoes and respiratory chain deficiency in different 
neuronal domains and finally determine if axonal torpedoes formed due to a block in axonal 
transport. I wanted to gain an insight into how they might form, the potential consequence of 
their formation and how this influences degeneration and therefore progression of disease.  
Axonal torpedoes have previously been observed in other disorders with neurological 
involvement such as Friedreich’s ataxia (Jitpimolmard et al., 1993), Creutzfeldt-Jakob disease 
(Ferrer, 2002) and Huntington’s disease (Rub et al., 2013). Where axonal torpedoes have been 
quantified it was shown that there was 5 times more axonal torpedoes in patients with 
Alzheimer’s and Parkinson’s disease compared to controls (Louis et al., 2009a), and patients 
with essential tremor had on average 7 times more axonal torpedoes than control individuals 
(Louis et al., 2006; Louis et al., 2007; Louis et al., 2009a). When quantifying the level of 
axonal torpedoes, the densities of axonal torpedoes were adjusted to Purkinje cell densities 
and 7/10 patients with mitochondrial disease were observed to have higher axonal torpedo 
densities than compared to controls. This is therefore in agreement with those previous studies 
that axonal torpedoes are more prevalent in diseases with neurological involvement.  
Additionally, Purkinje cell density was also quantified and shown to be markedly decreased in    
patients which agrees with previous observations in the cerebellum of patients with 
mitochondrial disease (Lax et al., 2012b). There was no statistically significant relationship 
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between Purkinje cell density and axonal torpedo density in patients with mitochondrial 
disease but there was a trend towards an increase in axonal torpedo density when Purkinje cell 
density was decreased. This observation is similar to results achieved by Louis et al. (2014), 
where a significant negative correlation was observed between axonal torpedo counts and 
Purkinje cell counts in the cerebellum of patients with essential tremor. However Louis et al. 
(2014) also found a positive relationship between axonal torpedo counts and Purkinje cell 
counts in the cerebellum of patients with multiple system atrophy. These differing 
observations suggests it may not be possible to conclude a simple linear relationship between 
Purkinje cell densities and axonal torpedo densities as the cerebellum is likely undergoing 
torpedo formation and loss, Purkinje cell remodelling and Purkinje cell loss simultaneously 
making it difficult to conclude relationships in thin post-mortem cerebellar sections. There 
was no significant relationship between age and axonal torpedo density in patients however in 
controls a significant relationship was observed with axonal torpedo density increasing with 
age. My data does contradict published results by Louis et al. (2009a), however our analysis 
differed as we examined axonal torpedo density whereas the previous study reported absolute 
torpedo counts, therefore this alternative approach may explain our different results. 
Glutamic acid decarboxylase (GAD) 65kDa and 67kDa are isoforms of an enzyme that 
catalyses the decarboxylation of glutamate to GABA and is only found in inhibitory neurons 
as GABA is an inhibitory neurotransmitter. Therefore, the immunoreactivity of GAD65/67 in 
the axonal torpedoes confirms that axonal torpedoes are formed in the axons of Purkinje cells. 
Electron microscopy studies have shown that disorganised pNFH’s were a main component of 
axonal torpedoes (Mann et al., 1980; Louis et al., 2009c) and through immunohistochemistry, 
I can confirm that pNFH are the main constituents of axonal torpedoes in patients with 
mitochondrial disease. The degree at which neurofilaments are phosphorylated is associated 
with their location, as neurofilament in the axons are phosphorylated while npNFH’s are 
located in the cell body (Sternberger and Sternberger, 1983). The observation of npNFH 
accumulation in axons is associated with axonal damage and degeneration as seen in axonal 
end bulbs in the brains of patients with multiple sclerosis (Werner et al., 2001; Trapp and 
Stys, 2009). In the axonal torpedoes, immunohistochemistical analysis showed that there was 
no accumulation of  npNFHs  but there was positive staining of npNHF in the Purkinje cell 
bodies therefore showing the correct distribution of npNFH in the Purkinje cells and 
indicating that there is no axonal damage.  
The accumulation of neurofilaments have been observed in other neurological disorders 
(Quan, 2011), and the accumulation of neurofilament in the perikaryon and axon of motor 
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neurons is a pathological hallmark ALS (Hirano et al., 1984; Robertson et al., 2002).  In mice 
that over express the human form of NFH, neurofilament accumulations occur in the 
perikaryon causing atrophy of motor axons and altered axonal conductance’s (Côté et al., 
1993; Križ et al., 2000). This accumulation of pNFH has been hypothesised to cause a 
“strangulation” of the neuron by causing a physical block to anterograde transport and the 
disruption of microtubule tracks resulting in the “starvation” of the neurons distal regions 
causing death (Cleveland, 1999; Louis et al., 2009b). Neurons have highly polarised 
structures and as all proteins in the neuron are produced in the cell body, they have be 
transported quickly and efficiently via fast axonal transport (FAT) to the distal regions of the 
cell which can be up to 1m away. Microtubules which are polymers of α and β tubulin, forms 
a highly dynamic component of the cytoskeleton and are fundamental for FAT as they are the 
tracks along which the molecular motor proteins move their cargo up and down axons 
(Salinas et al., 2008). Anterograde transport utilise the motor protein Kinesin while retrograde 
transport is achieved through Dynein and both motor proteins hydrolyse one ATP molecule 
for every 8nm they transport proteins along the axons (Gennerich and Vale, 2009). As an 
accumulation of pNFH is thought to disrupt the microtubule network, I investigated the 
presence of microtubules in axonal torpedoes. I was able to show that both β-tubulin and 
acetylated α tubulin, which are monomers in the microtubules, were present in the axonal 
torpedoes indicating that the microtubules are still present in the axonal torpedoes. Two 
proteins that utilise FAT are APP and synaptophysin as they are both located in the 
presynaptic terminal. The accumulation of APP in axons is associated with axonal damage in 
diseases like MS (Ferguson et al., 1997) and an accumulation of synaptophysin was observed 
when the optic nerve had been crushed confirming that these proteins accumulate when FAT 
is inhibited (Li and Dahlström, 1997).  Immunohistochemistry showed a lack of APP and 
synaptophysin accumulation in the axonal torpedoes. Additionally, when neurofilaments are 
transported they are in the non-phosphorylated state, as npNFH have a higher affinity for 
kinesin (Yabe et al., 2000), therefore,  if there was a block in axonal transport you would also 
expect to see an accumulation of npNF’s , which was not seen in axonal torpedoes.  The lack 
of positive staining of APP, npNFH and synaptophysin and the positive staining of 
microtubules in axonal torpedoes infers that fast axonal transport is not inhibited and that the 
strangulation theory might not be relevant to axonal torpedoes.   
In a previous study it had been observed that mitochondria were present in axonal torpedoes 
but had been forced to the periphery (Louis et al., 2009c). However, I have shown using 
immunofluorescent labelling of COX4 in axonal torpedoes that mitochondria are found 
abundantly throughout the axonal torpedoes. Respiratory chain deficiency was then 
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investigated in the mitochondria found in the axonal torpedoes, as well as those in the 
Purkinje cell bodies and proximal Purkinje cells axons, to determine if respiratory chain 
deficiency was a main cause in axonal torpedo formation. A triple immunofluorescent assay 
was used to measure complex I expression relative to a mitochondrial mass marker.  Previous 
studies have shown that expression of complex I subunits (19kDa 20kDa) were reduced in 
patients with mitochondrial disease (Lax et al., 2012b; Reeve et al., 2013; Grunewald et al., 
2014), therefore a complex I subunit would be a good marker for determining respiratory 
chain deficiency. Complex IV was used as a mitochondrial mass marker as previous studies 
have not documented any reduction in complex IV expression in Purkinje cell bodies (Lax et 
al., 2012b; Chrysostomou et al., 2016). The triple immunofluorescent assay has provided 
quantified evidence that there is a decrease in NDUFA13 expression in axonal torpedoes, 
Purkinje cell bodies and axons in the majority of patients with mitochondrial diseases. In line 
with previous studies by Chrysostomou et al. (2016) and Lax et al. (2016), this study has 
shown that patients harbouring the m.3243A>G mutation displayed the greatest reduction in 
complex I deficiency.  In the same group of patients, the Purkinje cell body is observed to 
have the greatest reduction in NDUFA13 expression compared to the other structural 
domains. This observation differs to data from patients harbouring autosomal recessive POLG 
mutations which suggests that the complex I deficiency is comparable throughout all 
structural domains of the neuron. In stark contrast, patients harbouring the m.8344A>G 
mutations displayed no evidence of complex I deficiency in any of the structural 
compartments. This is somewhat surprising as both patients were observed to have axonal 
torpedo densities higher than controls and Purkinje cell density in both patient 7 
(m.8344A>G) and patient 9 (m.8344A>G) was reduced compared to controls. The 
observation that the level of complex I deficiency is greater in Purkinje cell bodies than 
axonal torpedoes, indicates that axonal torpedoes do not form in the most impaired and 
affected neurons. 
Originally the formation of axonal torpedoes were hypothesised to be a pathological 
phenomenon that represented the axon dying through a “strangulation” mechanism. However, 
the characterisation of the axonal torpedoes in this chapter has shown that axonal transport 
does not appear to be impaired and that axonal torpedoes are more likely to form in “healthy” 
neurons than sick neurons that harbour a high level of deficiency. If axonal torpedoes were to 
be involved in a degenerative process, than it would be expected that they would show the 
greatest level of complex I deficiency but this was not the case. These observations in 
addition to the high density of axonal torpedoes observed  in essential tremor (Louis et al., 
2009c), which is not viewed as a neurodegenerative disease (Rajput et al., 2012),  suggests  
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that a variety of stressors can induce the formation of axonal torpedoes but axonal torpedoes 
are not involved in a degenerative process.  The formation of axonal torpedoes in “healthier” 
neurons suggests that they may be involved in a process of remodelling of the cerebellar 
circuitry following Purkinje cell loss, explaining the observed trend of increased axonal 
torpedo density when there is a decrease in Purkinje cell density, in an attempt to maintain 
efficient functioning of the cerebellum. Understanding the remodelling of Purkinje cell axons 
following Purkinje cell loss remains an important area of research for understanding and 
treating patients with ataxia. However, to achieve this utilising thin sections is impossible. 
Therefore, in the next chapter I will optimise a recently published technique that will enable 
the use of thicker tissue sections and allow for 3 dimensional visualisation of axonal 
torpedoes to help determine the level of Purkinje cell axon remodelling in patients with 
mitochondrial disease compared to controls.  
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Chapter 4. Three-Dimensional Reconstruction of the Cerebellum: 
Development of CLARITY technique 
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4.1. Introduction 
Typically, histological studies have relied upon imaging of thin sections in order to 
investigate the cytoarchitecture and cellular compositions of tissues. This approach has 
numerous limitations as they only convey fragmented information about structures, spatial 
arrangements and the relationship between neurons (Figure 4.1). Therefore, to be able to 
investigate the 3 dimensional (3D) structure of complex cells such as neurons, several groups 
have depended on the use of serial thin sections for 3D reconstructions. Although very useful, 
the process of cutting the tissue is extremely laborious and can result in artefacts from tissue 
distortion, tears, folds or compression leading to a substandard reconstruction of the tissue or 
organ. An alternative approach is now to use thicker volumes of tissue and image at higher 
spatial resolutions, but due to several constrains, for a long time, this was not possible. 
The first issue related with imaging large volumes of tissue with a traditional epifluorescent 
microscope was the distortion of the plane of imaging due to the fluorescence emitted by the 
structures above and below the plane of focus - effect known as out-of-focus.  However, the 
advent of confocal microscopy and the further development of laser scanning microscopes has 
permitted the filtering and removal of the out of focus light and enabled optical sectioning of 
the volume to produce a stacked 3D reconstruction of the volume. With advances in 
microscopy now allowing thicker sections to be imaged at faster rates with higher resolutions, 
the only limitation restricting the use of thicker sections, was the intrinsic properties of tissues 
which causes light scattering. A main cause of light scattering in tissue is due to the variable 
refraction indexes (RI) of components within the tissue, and as RIs across the tissue are not 
uniformly distributed, the light scattering properties are amplified. In addition to the 
heterogeneity of RIs within the tissue, the hydrophobicity of the tightly packed lipid bi-layer 
of the plasma membrane prevents both the chemical penetration of molecular probes and 
prevention of photon emittance, resulting in further scattering and disruption of the lights 
pathway. 
Recently, a number of methods have been developed aiming at reducing the level of light 
scattering by either matching the RI throughout the tissue or by removing the molecules that 
cause the light scattering. This method of tissue clearing was first described by Spatleholtz, 
where by using organic solvents, the tissue underwent dehydration, tissue bleaching and 
clearing (Spalteholz, 1914; Richardson and Lichtman, 2015a). Even though this produced 
unprecedented images in its time, it was found that this original method caused damage to the 
first few centimetres of tissue ultimately leaving it only useful for large or full organs (Steinke 
and Wolff, 2001). Since then, clearing methods have evolved and became more refined; some 
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keep true to the original Spalteholtz method and utilise tissue dehydration and solvent-based 
clearing while methods that are more recent are aqueous-based. 
 
 
 
 
 
 
  Figure 4.1: The limitations of using 5µm thick sections. 
The use of 5µm thick sections (black boxes) limits the amount of information 
captured. For example, one 5µm thick section might present a neuronal cell 
body and a axon, however, due to the small thickness of the section it is not 
possible to control if both cell body and axons belong to the same neuron.  
Therefore, if thicker volumes are used (red box) then the complete 3D 
architecture of the neurons and their connections can be visualised.  
 
 
 
 
 
 
 
 
 
 
 
 
v
v
v
v
250µm 
5µm 
5µm 
5µm 
5µm 
Chapter 4  Development of CLARITY technique 
107 
 
4.1.1. Solvent Based Clearing Methods 
Solvent-based clearing of tissue is typically composed of two steps; the first step involves 
tissue dehydration using methanol, which sometimes can be mixed with hexane or 
tetrahydrofurane to remove all the water and some lipids. The second step is to incubate in a 
clearing solvent to further remove lipids and homogenise RIs across the tissue (Becker et al., 
2012). However, one of the major limitation of this technique is the total removal of water 
molecules which results in fluorescence quenching, as commonly-used fluorescent proteins 
require water molecules to maintain photon emission (Richardson and Lichtman, 2015b).  In 
addition to fluorophore quenching, the use of solvents in tissue clearance can also cause up to 
50% tissue shrinkage, as previously been observed by Becker et al. (2012). The combination 
of tissue shrinkage, toxic nature of some of the solvents used and fluorophore quenching 
limits the ease and usefulness of the technique. 
4.1.2. Aqueous Based Clearing Methods 
To overcome the problems associated with solvent-based techniques, a number of clearing 
techniques use an aqueous-based method to either increase the RI of the tissue or combine the 
removal of lipids together with RI increment. In simple immersion techniques, the tissue is 
placed in a solution that has a higher RI, therefore displacing water and clearing the section. 
As these sections still contain lipids, the clearing solution requires a RI higher than 1.45 
which can be achieved by using molecules such as sucrose (Tsai et al., 2009), fructose (Ke et 
al., 2013), glycerol (Meglinski et al., 2004)and  2,2’-thiodiethanol (TDE) (Aoyagi et al., 
2015). The benefits of using this method is that it takes relatively short incubation periods, the 
molecules are inexpensive and they are compatible with lipophilic dyes (Ke et al., 2013). 
However, as these solutions are needed at high concentrations resulting in a very viscous 
solution and an increased risk of precipitation, it is difficult to clear large pieces of tissue. 
Additionally, as antibodies are applied before the clearing process, the fluorophores are more 
likely to become quenched at the high temperatures (37˚C) that are used to help with the 
clearing method in the SeeDB technique (Ke et al., 2013).  
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4.1.3. Immersion Clearing Methods 
While simple immersion techniques aim to average the RI across the section, a method first 
described by Hama et al. (2011), by removing the lipids then reducing the RI through 
incubation in a clearing solution. The Scale method, combines a detergent (triton x) to remove 
the lipids with both urea and glycerol for hydration and lowering of the RI (Hama et al., 
2011). As the urea is able to penetrate and hydrate the most hydrophobic regions of proteins, 
this can result in the expansion of protein complexes (Hua et al., 2008), as shown by the 
overall expansion of the tissue section. Therefore, stereological measurements from the 
sections are not accurate when using this approach. 
4.1.4. Clear Lipid-exchanged Acrylamide-hybridized Rigid Imaging compatible 
Tissue hYdrogel (CLARITY)   
The number of limitations associated with the simple immersion method: use of only small 
sections, hyperhydration is slow and can cause tissue expansion, and the use of solvents and 
detergents can lower protein content, led to the development of a novel protocol first 
described by Chung et al. (2013). This technique known as Clear Lipid-exchanged 
Acrylamide-hybridized Rigid Imaging compatible Tissue hYdrogel (CLARITY) overcomes 
these limitations by embedding the tissue within a nanoporous hydrogel matrix, through the 
covalent binding of acrylamide monomers to primary amine groups of molecules in the tissue. 
The lipids from the tissue are then removed actively by electrophoresis or passively through 
incubation in a detergent (8% SDS). The principles of the method is summarised in figure 4.2.  
Following the clearing step, the tissues are then incubated in either FocusClear (Chung et al., 
2013) or a Refractive Index Matching Solution (RIMS) (Yang et al., 2014). The benefit of 
using an acrylamide based hydrogel is that it crosslinks with biological molecules within the 
sections and reduces protein loss, with only 0.05 mg per mg gross weight protein loss (Yang 
et al., 2014).  Due to the high level of protein retention, the compatibility with normal 
immunolabelling techniques and its versatility, CLARITY can be applied to a number of 
different organs from brain to liver and kidney (Lee et al., 2014), and therefore has become 
very popular for clearing tissue.   
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Figure 4.2: The principles of the Clear Lipid-exchanged Acrylamide-hybridized 
Rigid Imaging compatible Tissue hYdrogel (CLARITY) technique.  
The heterogeneous nature of the CNS and its high lipid content results in 
the                          scattering of emitted light, limiting the thickness of 
tissue that can be used (A). Sections are incubated with the monomers of 
the hydrogel (Formaldehyde and acrylamide) at 4ºC for 3 days (B). When 
the monomers are polymerised in addition to forming a rigid hydrogel they 
covalently bond to amine groups to the native molecules incorporating 
those molecules into the hydrogel (C). The removal of lipids can be 
achieved by passive of active clearing but in both cases the lipids in the 
section are removed via SDS michelles present in the clearing solution (D). 
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With the removal of lipids there is reduced light scattering increasing the 
thickness of tissue that can be used (E). 
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A number of different groups have utilised the technique to understanding neuron 
vulnerability in neurodegenerative disorders. For instance, by assessing 500µm thick sections 
of formalin-fixed frontal cortex from two controls and five patients with Alzheimer’s disease, 
Ando et al. (2014) were the first group to 3D image Amyloid β (Aβ) and tau plaques in 
human sections. They observed a large axon deflected by a Aβ plaque and, interestingly, a 
neuron containing a neurofibrillary tangle was shown to have no axonal projections (Ando et 
al., 2014). Also, the original paper showed that the technique is also suitable for sections that 
have been fixed in formalin for long periods of time. The investigation of a 500µm thick 
section from the frontal cortex (fixed in formalin for 6 years) of an infant with autism 
demonstrated parvalbumin-labelling of interneurons in the deep cellular layers with evidence 
of isoneuronal and heteroneuronal dendritic bridges, which was not observed in age-matched 
controls (Chung et al., 2013). Along with human studies documenting changes in neuronal 
connectivity, CLARITY has been applied to Thy1-YFP mice that have undergone 
experimental autoimmune encephalomyelitis (EAE). In this study by Spence et al. (2014), 
they followed axons in the spinal cord that traversed over 5mm in length, and found that 61% 
of axons in the dorsal corticospinal tract of  EAE mice displayed ovoids whereas virtually 
none were observed in the control mice. While in the cerebral cortex they were able to 
accurately count the number of layer V pyramidal neurons, something that before could only 
be achieved as an estimate through serial sections, as well as determining the length of apical 
dendrites, of which both were shown to be reduced compared to control animals (Spence et 
al., 2014). These studies highlight that CLARITY permits the visualisation and quantification 
of axonal pathology associated with neurons in 3D volume in mouse and human post-mortem 
brain tissues. This methodology provides a wealth of information which is hugely 
advantageous for elucidating the mechanisms of neuronal vulnerability and connectivity in the 
human brain associated with different neurodegenerative disorders, and particularly in 
mitochondrial disease. Therefore, in this chapter, I will describe how I developed CLARITY 
techniques to allow imaging of large-volumes of cerebellar tissue from patients with 
mitochondrial disease.  
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4.2. Aims 
The CLARITY method described by Chung et al. (2013) has been successfully completed on 
human tissue and has the novel property of allowing the sections to undergo multiple staining 
cycles. The aim of this study is to develop and optimise this technique for use on both human 
and mouse cerebellar sections. The successful completion of this study would allow for the 
more comprehensive investigation of changes to Purkinje cell axon morphology in patients 
with mitochondrial disease compared to controls than was previously achievable in the 5µm 
thick FFPE sections. Therefore, the aims of this work are: 
1. To achieve transparent mouse and human cerebellar sections through the use of the 
CLARITY method. 
2. To optimise a reliable immunolabelling method on the cleared sections that 
consistently labels Purkinje cell axons, mitochondrial proteins and for the first time 
attempt a quadruple immunofluorescent assay on cleared sections.  
3. To replicate previous findings that it is possible to stain a cleared section, image, 
remove the previous staining and restain and image the sections with no presence of 
the original stain.  
4. To optimise the imaging of the labelled cleared sections to produce 3D images of the 
connectivity in the cerebellum.  
I will complete the optimisation of mouse cerebellar sections first before completing the 
protocol on human cerebellar sections. 
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4.3. Methods 
4.3.1. Mice 
Five wild type 12 month old C57-BL6 mice were used for this chapter. The mice were 
sacrificed using cervical dislocation before the brain was excised. Following excision the 
brains were incubated in 4% Paraformaldehyde at 4ºC overnight and then washed in PBS.  All 
animal experimental procedures were conducted in accordance with the guidelines of the UK 
home office guidelines. 
4.3.2. Human tissue 
 Formalin-fixed cerebellar brain tissue was obtained from six deceased patients (age range: 
55-79years) with genetically and clinically confirmed mitochondrial disease and two control 
individuals (age: 72 years and 77 years) with no clinical or pathological evidence of 
neurological disease were used in this study (Table 4.1). The tissue was obtained through the 
Newcastle Brain Tissue Resource (NBTR) and was approved by the Newcastle and North 
Tyneside Local Research Ethics Committee. 
 
 
 
 
 
 
 
 
 
 
Table 4.1: Tissue details of individuals that were used in the optimisation of 
the CLARITY technique.  
The details which include age, gender, post mortem interval (PMI) and cause of 
death from tissue that was supplied by NBTR. N/A – Not applicable 
 
 
 
Gender Age 
(Years) 
Fixation 
(years) 
PMI 
(Hours) 
Genetic defect 
Control 
15 
F 72 7 27 N/A 
Control 
16 
F 58 8 39 N/A 
Patient 
6 
M 30 6 21 m.3243A>G 
Patient 
9 
M 58 3 66 m.8344A>G 
Patient 
10 
M 79 4 85 POLG 
(p.Thr251Ile/p.Pro587Leu;  
p.Ala467Thr) 
Patient 
11 
M 55 3 112 POLG (p.Trp748Ser and 
p.Arg1096Cys) 
Patient 
12 
F 60 4 39 Unconfirmed multiple mtDNA 
deletions due to a nDNA defect  
Patient 
13 
M 47 2 76 m.3243A>G 
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4.3.3. SeeDB 
The SeeDB method is fully described in chapter 2.2.3 and is based on the method detailed in 
the study by Ke et al. (2013). Cerebellar sections from wild type 12 month old C57BL/6 mice 
were used. Sections were stained with anti-Neurofilament H 200kDa (Neurofilament H, 
1:200) and anti-SMI-94 (Myelin Basic Protein, 1:1000). 
4.3.4. CLARITY Protocol 
Once the tissue had been acquired and processed, the tissue underwent the CLARITY 
protocol which is described in detail in chapter 2.2.4. The basis of the protocol is depicted in 
figure 4.3 and a number of factors were adjusted and optimised throughout the chapter and 
they are explained further in the results section.  
Once the tissue had been incubated in the hydrogel solution, both mouse and human 
cerebellum sections were sectioned to 250µm using a vibratome (Frequency:70Hz, 
Amplitude:0.7m). 
A number of negative consequences have been associated with the active clearing process 
which include blackening and expansion of the sections as well as the formation of 
destructive bubbles within the sections (http://forum.CLARITYtechniques.org/). A number of 
recent publications have concentrated on the optimisation of the conditions used for the active 
clearing step, to attempt to prevent the destructive consequences (Lee et al., 2014; 
Poguzhelskaya et al., 2014), However due to those negative consequences and the apparent 
success of other authors using passive clearing (Spence et al., 2014; Tomer et al., 2014; Yang 
et al., 2014) the passive clearing method was chosen as the preferred method of clearing to be 
completed on both mouse and human cerebellar sections.  
The primary antibodies and secondary antibodies used in this chapter are summarised in table 
4.2 and 4.3. The Refractive Index Matching Solution (RIMS) was the imaging solution used 
throughout the project. It was first proposed by Yang et al. (2014), it has similar properties to 
FocusClear but is a more affordable option. 
4.3.5. Imaging 
The cerebellar sections were imaged (Z-stack volume, 250 µm) using confocal laser 
microscopy (Nikon A1R, Nikon instruments) with the Galfano settings at excitation 
wavelengths of 488nm, 546nm and 647nm with an 20X objective (0.70 numerical aperture). 
Post image 3D projection was viewed using the NIS Elements viewer software (Nikon 
instruments) while 3D rendering was completed using Imaris software (Andor Technology 
plc) 
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Figure 4.3: A flow diagram of the original CLARITY protocol.  
The basic flow of steps that were applied to the sections of cerebellum tissue. 
Prepare tissue 
Incubate in hydrogel for 3 days (mice) 
or 7 days (human) at 4˚C. 
Polymerisation of hydrogel at 37˚C. 
Incubate sections in clearing solution 
for 1 week (mice) or 4 weeks (Human) 
Apply immunofluorescent protocol 
Overnight incubation in imaging 
solution (Refractive Index Matching 
Solution (RIMS)) 
10% Normal Goat Serum incubation for 
1hour 30mins 
Image 
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Table.4.2: Description of Primary antibodies used .  
A summary of the different primary antibodies that have been used on passively 
cleared sections of both human mouse cerebellar tissue.  
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Target Host Isotype Dilution 
Anti-neurofilament 
H 200kDa 
neurofilament H (200 kDa) Rabbit IgG 1:200 
Anti-NDUFA13 NDUFA13 Mouse IgG2b 1:100 
Anti-SMI-94 Myelin Basic Protein Mouse IgG1 1:500 
Anti-Porin porin Mouse IgG2b 1:100 
Anti-MTCO1 Cytochrome C Oxidase 
subunit I (COX1) 
Mouse IgG2a 1:100 
Anti-COX4 + 
COX4L2 
cytochrome C oxidase 
subunit IV (COX4) 
Mouse IgG2a 1:100 
Anti-SMI-31 Phosphorylated neurofilam
ent H & M 
Mouse IgG1 1:1000 
Anti-glut-1 Glut-1 (endothelial) Rabbit IgG 1:100 
Anti-SDHA Succinate Dehydrogenase 
Complex, Subunit A 
(SDHA) 
Mouse IgG1 1:100 
Anti-myelin basic 
protein 
Myelin Basic Protein Chicken IgY 1:100 
Anti-GAD 65/67 
Glutamic Acid 
Decarboxylase 65/67 
Rabbit IgG 
1:100 
Anti-neurofilament 
H 200kDa 
Neurofilament H (200 
kDa) 
Chicken IgY 1:100 
Anti-α smooth 
muscle actin 
α smooth muscle actin Mouse IgG2a 1:100 
Anti-parvalbumin Parvalbumin Mouse IgG1 1:100 
Anti-calbindin D-
28k 
Calbindin D-28k Mouse IgG1 1:100 
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Table.4.3: Description of secondary antibodies used in the optimisation of the  
CLARITY technique.  
A summary of the different secondary antibodies that have been used on 
passively cleared sections of both human mouse cerebellar tissue. All secondary 
antibodies were raised in goat and the dilution used was 1:100µl 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Antibody Target 
Alexa Fluor 633 anti-mouse IgG1 Mouse IgG1 
Alexa Fluor 633 anti-mouse IgG2a Mouse IgG2a 
Alexa Fluor 647nm anti-mouse IgG1 Mouse IgG1 
Alexa Fluor 405nm anti-rabbit IgG Rabbit IgG 
Alexa Fluor 488nm anti-mouse IgG1 Mouse IgG1 
Alexa Fluor 488nm anti-mouse IgG2b Mouse IgG2b 
Alexa Fluor 488nm anti-mouse IgG2a Mouse IgG2a 
Fluorescein Goat Anti-Chicken IgY Chicken IgY 
Alexa Fluor 546nm anti-mouse IgG1 Mouse IgG1 
Alexa Fluor 546nm anti-rabbit IgG Rabbit IgG 
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4.4. Results 
Throughout this section I will describe the processes and results I achieved when optimising 
the different aspects of the CLARITY technique.  
4.4.1. SeeDB 
Before optimising the CLARITY protocol, I attempted the SeeDB method on the cerebellum 
taken from wild type 12 month old C57BL/6 mice. The SeeDB method uses increasing 
concentrations of fructose to match the RI of the sections (Ke et al., 2013) and is a simpler 
and faster method than the CLARITY technique. However, as the antibodies must be applied 
before the clearing process, there was no successful staining of targets and a substantial 
increase in the volume of tissue was observed (results not shown). Through these 
observations, it was decided to persist with the CLARITY technique.  
4.4.2. Applying CLARITY to mouse sectioning 
The mouse brains were processed and incubated with hydrogel solution that underwent 
polymerisation at 37˚C to provide a firm and defined hydrogel matrix around and within the 
section. Polymerised hydrogel forms a strong and durable structure so removing the whole 
cerebellum from the excess hydrogel was easy. However, the pre-sectioned tissues proved 
difficult to remove from the hydrogel and were more prone to damage following the physical 
removal. Therefore, the whole cerebellum was embedded in the hydrogel before sectioning to 
the required thickness (250µm) using a vibratome. Following sectioning on the vibratome, the 
sections were incubated in clearing buffer at 37˚C until the sections were visually determined 
as transparent. For mouse sections, it took 7 days for the sections to become fully clear 
(Figure 4.4). 
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Figure 4.4: Before and after images of a passively cleared wild type mouse brain 
sections.  
Wild type mouse cerebellar sections had undergone passive clearing in clearing 
solution at 37˚C for 7 days. 
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4.4.3. Immunofluorescent staining 
Once the tissue was successfully cleared, the next step was to optimise the immunofluorescent 
protocol in order to label the different neuronal structure and mitochondrial proteins of 
interest. In order to determine the optimal conditions for immunofluorescent staining, the 
following reliable antibodies were used:  
 Porin (to label mitochondria; 488nm),  
 Neurofilament H (to label neurons and their neuritic processes; 546nm) 
 Myelin basic protein (to label myelin; 633nm).  
The first set of conditions to be tested for immunofluorescent staining was first described in 
the original study by Chung et al. (2013), where both the primary and secondary antibody 
solutions were diluted in a sodium borate buffer (SBB) and then incubated at 37˚C for 
24hours for each (Figure 4.5A). The results with this condition were rather underwhelming, 
with only neurofilament H producing positive staining.  
Despite increasing the temperature to 37˚C to improve antibody penetration and decrease the 
incubation time, the higher temperature reduced the specificity of the staining. Therefore, the 
staining was repeated using different experimental conditions: the temperature was decreased 
to 4˚C to increase the specificity of antibody binding while the length of the incubation was 
extended to 6 days for primary antibodies and 4 days for secondary antibodies (Figure 4.5B). 
The incubation length was increased to account for the decrease in diffusion rates of the 
antibodies due to the cold temperature. This resulted in specific staining of all three markers, 
including the mitochondrial marker porin (488nm).  However, it was also observed that at 4˚C 
the SBB formed crystals both in the solution and on the sections, which most likely affected 
the quality of staining. Therefore the experiment was repeated using PBS instead of SBB, 
which produced strong positive staining of porin, neurofilament H and MBP, that was of 
higher quality than captured with SBB (Figure 4.5C). Due to the superior quality of staining, 
the dilution of antibodies in PBS at 4˚C with a prolonged incubation was used as the method 
of choice for immunostaining from here onwards. An un-cleared section underwent the most 
successful immunofluorescent protocol to show the benefits of using the CLARITY method 
(Figure 4.5D).  
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Figure 4.5: Optimisation of immunofluorescent protocol conditions on passively cleared 
250µm thick wild type mouse cerebellar section.  
Passively cleared wild type mouse cerebellum sections were stained with porin 
(488nm), neurofilament H 200kDa (546nm) and myelin basic protein (633nm) 
under various different conditions; A) sodium borate buffer at 37˚C for 24 hours 
B) sodium borate buffer at 4˚C for 6 days for the primary antibodies, then at 4˚C 
for 4 days for secondary antibodies. C) PBS at 4˚C for 6 days for the primary 
antibodies, then at 4˚C for 4 days for secondary antibodies. D) An uncleared 
cerebellar section was also stained for porin, neurofilament H 200kDa and 
myelin basic protein using protocol C. Scale=100µm 
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4.4.4. Antibody penetration  
When completing the staining of serial sections with increasing thickness, it became apparent 
that there was a lack of antibody penetration into the thicker sections. It was observed that 
sections with a thickness greater than 300µm, there was strong positive staining at the edges 
of the section but reduced intensities towards the centre of the tissue. This is exemplified in 
figure 4.6, where a highly dense network of myelin can be seen in the extremities of the 
section and reduced intensities in the middle. 3D rendering of the section, however, shows 
that the myelin staining is present at the centre but the intensity is reduced compared to that of 
the section edges, suggesting lower penetration of antibodies. 
In an attempt to increase the depth of antibody penetration by improving the permeability of 
the tissue, a proteinase K (10 mg/ml) incubation for 10 minutes following the hydrogel 
incubation was applied (Gleave et al., 2013). Following the application of proteinase K, the 
tissue lost structural integrity and slowly disintegrated, making it impossible to image.  
 
    Figure 4.6: Poor antibody penetration in 500µm thick in mouse cerebellum section. 
Positive labelling of myelin basic protein can clearly be observed in the first 
and last 150µm of the section. However, in the middle of the section the 
intensity reduces. This is exemplified once the image has undergone 3D 
rendering using the Imaris software. The dense complex myelin structure can 
be observed at the surfaces/edges however in the middle there is still staining 
but nowhere as strong. Scale 100µm 
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4.4.5. Testing of various antibodies 
In order to investigate axonal and circuitry pathology in the cerebellum of mitochondrial 
diseased patients, the next step was to trial a number of antibodies that would label Purkinje 
cells, either their cell bodies or projections, as well as labelling mitochondria to help 
determine the level of respiratory chain deficiency in the a single neuron. 
Unfortunately there was no positive staining associated with the GAD65/67 antibody which 
labels glutamic decarboxylase 65/67, an enzyme only found in inhibitory neurons like 
Purkinje cells. However, the Purkinje cell bodies were clearly labelled with both parvalbumin 
(Figure 4.7A) and calbindin (Figure 4.7B). The axons were clearly labelled with the 
neurofilament H (Figure 4.7C) and SMI-31 antibody (Figure 4.7D) while the MBP (IgY) 
antibody produced non-specific staining and no specific staining of the myelin. There were 
mixed results with the mitochondrial antibodies, as there was no specific or positive labelling 
of mitochondria associated with the SDHA, NDUFA13 and COX4 antibodies, while there 
was partial positive staining with porin. The most success was observed with the COX1 
antibody (Figure 4.7E).  
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4.4.6. Microscopy 
To begin with, imaging was completed using the Nikon A1R confocal microscope with the 
10X objective as this had the greatest working distance of the objectives available (Figure 
4.8A). Once it had become apparent that thinner sections were going to be used to overcome 
the lack of antibody penetration depth, it was possible to use the 20X objective (Figure 4.8B) 
which has a greater numerical aperture and improves the resolution of the images acquired 
compared to the 10X objective. This is shown by the increased detail of both neurofilament H 
and myelin basic protein, as well as observing punctate mitochondria in the Purkinje cell 
body. 
Another useful tool for analysing axonal pathology is the ability to produce large field images 
of the section (Figure 4.9A). This image was achieved by taking 180 images at 20X 
magnification and then stitching together the individual tiles. The benefit of large field images 
at a higher magnification is that it is possible to zoom into any region and retain the high 
resolution (20X). This is exemplified in figure 4.9B where it is possible to see the intricate 
network of the axons in granular cell layer of a folia. 
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4.4.7. Human Tissue 
After successfully clearing mouse tissue and devising a successful immunofluorescent 
protocol, the next step was to optimise the method for human tissue. I had started by 
completing the method on tissue obtained from control 15 and patient 6. As expected, the 
human tissue took longer to fully clear, with 250µm thick sections taking 4 weeks to clear 
(Figure 4.10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10: Before and after images of a passively cleared 250µm thick control human 
cerebellar section.  
Human cerebellar sections had undergone passive clearing in clearing solution 
at 37˚C for 4 weeks. 
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4.4.8. Antibody staining conditions 
Following the successful clearing of the human tissue, the conditions used on the mouse 
tissue were repeated on the human sections (Figure 4.11 and Figure 4.12). As before, the 
antibodies used to evaluate the efficacy of the subsequent conditions were: porin (488nm), 
neurofilament H (546nm) and myelin basic protein (633nm). The results observed were 
similar to those from the mouse tissue, with a lack of staining in both the control 15 and 
patient 6 sections when the antibodies were incubated in SBB (Figure 4.11A) or PBS (Figure 
4.11B) at 37˚C for 24 hours. However, when using the previously successful protocol where 
the temperature was reduced to 4˚C with a prolonged incubation time, there was a lack of 
positive staining in the section from patient 6 but positive staining of all three antibodies in 
the 250µm cerebellar section from control 15 (Figure 4.12A). In the white matter, the 
neurofilament H and MBP co-localised confirming that the staining was specific. An 
uncleared 250µm cerebellar section from control 15 underwent the protocol of PBS at 4˚C, 
which produced minimal positive staining and confirmed the benefits of using cleared 
sections (Figure 4.12B).  
A no primary antibody panel was completed and showed a high level of autofluorescence in 
the 405nm channel, where blood vessels (white arrows) can be observed, and slight 
autofluorescence in the 488nm channel (Figure 4.13). 
 
 
 
 
 
 
  
Chapter 4  Development of CLARITY technique 
130 
 
 
Figure 4.11: Optimisation of immunofluorescent protocol conditions on passively 
cleared 250µm human cerebellar sections.  
Passively cleared cerebellum sections from control 15 and mitochondrial 
patient 6 were stained with porin (488nm), neurofilament H 200kDa (546nm) 
and myelin basic protein (633nm) under different conditions; A) sodium borate 
buffer at 37˚C for 24 hours B) PBS at 37˚C for 24 hours Scale bar=100µm   
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4.4.9. Completion of CLARITY protocol on new sections 
Now the clearing of human cerebellar sections and the immunofluorescent protocol to 
successfully label axons and myelin sheathes has been optimised, the next step was to 
complete the process on new cases. These were carefully chosen based on the criteria that 
they had been fixed in formalin for a maximum length of 6 years, which produced 6 new 
cases to trial (1 control and 5 patients with mitochondrial disease). As before, I used an 
antibody that labels a mitochondrial protein (COX1), neuronal marker (neurofilament H) and 
a myelin sheath maker (myelin basic protein) to determine the viability of the tissue to be 
used in the protocol. 
The new cases were incubated in the hydrogel and following hydrogel polymerisation, 
sectioned to 250µm thickness. The sections were then passively cleared for 4 weeks before 
undergoing the immunofluorescent staining protocol and imaged on the Nikon A1 confocal 
microscope. It is clearly visible in control 16 and patient 13 that the staining has failed, with 
no positive labelling of either the axons or myelin sheath (Figure 4.14). In addition to the lack 
of staining, a large vascular vessel can be observed in the 488nm channel of control 16, 
indicating that there is a problem with auto fluorescence or non-specific staining of the 
antibodies, as  a similar structure was observed in the no primary antibody control section 
(Figure 4.13).  
Patients 9, 10, 11 and 12 had specific and positive labelling of both axons and myelin in 
cerebellum, making it possible to visualise the Purkinje cell axons running from the Purkinje 
cell layer into the white matter (Figure 4.15 and Figure 4.16). Along with the original control 
I successfully cleared and stained (figure 4.12), I can confirm that it is also possible to 
successfully clear and stain cerebellar human tissue from both control individuals and 
mitochondrial patients.  
 
 
 
 
 
 
 
 
  
Chapter 4  Development of CLARITY technique 
134 
 
 
Figure 4.14: A lack of positive immunolabelling in newly cleared 250µm thick 
cerebellum sections from control 16 and patient 13 with mitochondrial 
disease. 
There was a lack of positive immunolabelling in control 16 and patient 13 with 
no positive labelling of mitochondria, axons or myelin sheath. In control 13 there 
is aggregation of the secondary antibodies along with non-specific staining of the 
vascular network (white arrow) in the 488nm channel. Scale=100µm 
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4.4.10. Quadruple Immunofluorescence 
The end goal of this project is to determine respiratory chain deficiency in a single neuron 
from dendrites to synapse on a global scale and its effects on the connectivity of the neuron 
circuitry. To achieve this a quadruple immunofluorescent assay was attempted on cleared 
sections to visualise; 
 NDUFA13 (to label complex I; 546nm) 
 COX4 (to label mitochondria; 488nm),  
 Neurofilament H (to label neurons and their neuritic 
processes; 405nm)  
 Myelin basic protein (to label myelin; 633nm).  
COX4 and MBP had strong positive staining in the cases shown (Figure 4.17). When 
comparing the staining of NDUFA13 between patients, there was variability in intensity 
which would be expected in patients with mitochondrial disease. However, as the quality of 
NDUFA13 staining in control 15 was variable, an increased number of controls will be 
needed to confirm the specificity of NDUF13 staining and to be able to confidently quantify 
respiratory chain deficiency.  
In the 405nm channel, the observation of blood vessels reveals a high level of 
autofluorescence, which is similar to the observation in the no primary antibody control 
(Figure 4.13). This auto fluorescence in the 405nm channel currently prevents the use of the 
channel.  
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4.4.11. Length of clearing on tissue  
As expected, the duration of the clearing time is very important for the quality of the resulting 
staining procedure. Typically, the clearing method was kept to 4 weeks (Figure.18A) which 
produced strong and specific staining of both neurofilament H (488nm) and myelin basic 
protein (546nm). However, when the clearing incubation was only 2 weeks, there was 
minimal staining of neurofilament H, myelin basic protein or COX1 (Figure 4.18B). 
4.4.12. Re-staining of the sections. 
One of the main benefits of using the CLARITY technique is that hydrogel incorporates all 
macromolecules by forming covalent bonds between them. Therefore, it was proposed that 
the sections could be stained, imaged and then undergo another step of clearing before 
undergoing another round of staining and imaging. Here I originally stained a cerebellum 
section from control 15 with α-smooth muscle actin (633nm), a chicken anti-neurofilament H 
(488nm) and a GLUT-1 (546nm) antibody to look at the microvessels (Figure 4.19A). Both 
the α-smooth muscle actin and GLUT-1 produced specific staining of the vascular system in 
the cerebellar section, while the chicken anti-neurofilament H produced non-specific staining 
of vessels as well as a high level of background noise in the 488nm channel (Figure 4.18A).  
Once the sections had been imaged, they were incubated in the clearing solution for 1 week at 
37˚C, with the solution changed every other day. The sections were then re-stained with 
COX1 (633nm), rabbit anti-Neurofilament H (488nm) and myelin basic protein (546nm) 
(Figure 4.18B). This round of staining produced specific and positive labelling of both axons 
(neurofilament H) and the myelin sheath (myelin basic protein), with both co-localising and 
showing the complex connectivity of the cerebellum. There was no visible labelling of the 
vascular system (Glut-1) in the 546nm channel, which would be expected if the original 
staining was still present, therefore confirming that the clearing process is sufficient to 
remove antibodies.  
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4.4.13. Imaging of structures in the cerebellum of passively cleared sections 
In addition to the visualisation of Purkinje cells soma and mitochondria in passively cleared 
human sections, I have also shown it is possible to visualise the dendrites, axons and the 
vascular network (Figure 4.20).  The dendrites were labelled by neurofilament H (Figure 
4.20A) while a combination of neurofilament H and myelin basic protein label myelinated 
axons (Figure 4.20B). Visualisation of the blood vessels was achieved through the use of 
antibodies targeting α smooth muscle actin and Glut-1 (Figure 4.20C). The lack of co-
localisation between Glut-1 and α smooth muscle actin indicates that the labelling of α 
smooth muscle actin failed.   
One of the main forms of axonal pathology are axonal torpedoes. By using this method and 
labelling neurofilament H and myelin basic protein, I have been able to observe the full 
structure of axonal torpedoes, and therefore I am aiming to provide more insights on the 
morphology of the axons entering and exiting the axonal torpedoes as well as determining if 
they are myelinated (Figure 4.20D).  
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Figure 4.20: Visualising of structures in passively cleared control human cerebellum 
sections. 
Visualisation of dendrites, axons, vascular network and axonal torpedoes was 
achieved in 250µm thick tissue passively cleared cerebellum of post-
mortem human brain tissue. neurofilament H (488nm) clearly labels the dendritic 
tree (white arrow (A)) The combination of myelin basic protein (633nm) and 
neurofilament H (546nm) labels myelinated axons (white arrow head) projecting 
from the Purkinje cell layer to the deep cerebellar white matter (B). Positive 
staining of Glut-1 (546nm) has labelled the vascular network in the cerebellar 
sections (C). neurofilament H (488nm) and myelin basic protein (546nm) allow 
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for the visualisation of axonal torpedoes. While Axonal branching can be 
observed on the axons that are exiting the axonal torpedoes (D). Scale=100µm 
4.5. Discussion 
With the advent of confocal microscopy and the ability to scan a single focal plane in a 
section, the desire to use thicker sections to visualise the 3D structure of cells like neurons has 
increased. However, the light scattering properties of tissues was a major confounder for this, 
making this approach not possible for many years. To overcome this problem, a number of 
protocols have recently been developed to match the refractive indexes throughout the tissue 
and/or remove lipids, a main culprit for light scattering.  One of those methods was Clear 
Lipid-exchanged Acrylamide-hybridized Rigid Imaging / Immunostaining / in situ-
hybridization-compatible Tissue hYdrogel (CLARITY), which uses a combination of lipid 
removal and refractive index matching, to produce transparent tissue (Chung et al., 2013). 
Due to previous successful application of CLARITY to human tissue (Chung et al., 2013; 
Ando et al., 2014; Liu et al., 2016), this work aimed at applying the CLARITY protocol to 
both mouse and human cerebellar sections. Following this, optimising an immunofluorescent 
protocol in order to investigate the changes to Purkinje cell connectivity in the cerebellum of 
patients with mitochondrial disease. 
CLARITY works by embedding sections in a hydrogel composed of acrylamide and PFA 
which forms covalent bonds with amine groups in the native molecules in the tissue, 
preventing the protein loss that is associated with lipid removal using solvents or detergents 
(Chung et al., 2013; Yang et al., 2014). Once the hydrogel has been polymerised, the sections 
can be either actively cleared using electrophoresis or passive clearing through immersion in a 
detergent at 37˚C. Since clearing via electrophoresis has problems with reproducibility and 
degradation of tissue (http://forum.CLARITYtechniques.org/), and passive clearing methods 
have been successfully validated (Tomer et al., 2014; Yang et al., 2014), the passive clearing 
step was used to create transparent cerebellar sections. Although the clearing length is 
extended, as the length of time to clear a section is dependent on both the rate of lipid 
solvation by the detergent and the diffusion rate of the detergent within the tissue (Hoffman, 
2012), the preservation of tissue is increased. It was found that the time needed to clear mouse 
tissue (ranging from 250µm to 500µm thickness) was longer than active clearing, but only 
taking seven days. By contrast, clearance of human cerebellum sections (250µm thickness), 
took substantially longer requiring at least 4 weeks. 
As expected, the appropriate/full clearing, which is dependent on the clearing length, is 
fundamental for producing quality immunofluorescent images. When sections were stained 
after 2 weeks of passive clearing, the staining was poor with very little labelling of the axons 
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or myelin sheath. However, when staining sections cleared for 4 weeks, both the axons and 
myelin sheath were positively labelled and co-localised, and mitochondria were labelled in the 
Purkinje cell bodies. The extended length of time needed to clear human sections, when 
compared to mouse sections, is likely to be caused by the longer formalin-fixation period for 
the human sections. Nevertheless, I show that it is possible to clear and stain formalin-fixed 
sections from both control individuals and patients with mitochondrial disease. 
Once the sections had been cleared, the next step was to optimise an immunofluorescent 
protocol to produce the best quality images with the greatest depth of antibody penetration. A 
number of immunofluorescent protocols had been used on cleared CLARITY tissue. The 
original paper by Chung et al. (2013) incubated the cleared sections with the antibodies 
diluted in sodium borate buffer (pH8) at 37˚C with for 24hours followed by 12h washes. 
While this method was modified by Lee et al. (2014), who extended the length of incubation 
to 3 weeks for primary antibody incubation, 1 week washes and 2 weeks secondary 
antibodies, it produced variable staining of Purkinje cell bodies in the mouse cerebellum. The 
increased temperature aims at improving the rate of antibody diffusion and increasing binding 
affinity, therefore increasing the antibody penetration depth. However, the same increase in 
binding affinity leads to a decrease in specificity. These methods do diverge from the 
traditional immunofluorescent techniques that use PBS. Yang et al. (2014) tried for instance a 
more traditional method incubating passively cleared sections with a cocktail of antibodies 
diluted in PBS at room temperature for 2-5 days for each step. From these previously 
published protocols, I trialled the sodium borate buffer or PBS at 37˚C for 24 hour 
incubations or sodium borate buffer or PBS at 4˚C for 6 days of primary antibody incubation 
then a 4 day secondary antibody incubation with 12 hour washes in between. 4˚C was tested 
as the experience from previous immunofluorescent work I have completed showed that 
lowering the temperature to 4˚C increased the specificity of antibody binding. Indeed, I found 
that completing the immunolabelling at the higher temperature failed to produce any specific 
staining of either porin, neurofilament H or myelin basic protein. When the temperature was 
reduced to 4˚C with increased incubation lengths, positive labelling of porin, neurofilament H 
and myelin basic protein was achieved and myelinated axons from the Purkinje cell layer 
through the granular cell layer could be traced. One issue with reducing the temperature to 
4˚C was the precipitation of sodium borate out of solution and formation of crystals on the 
sections. Therefore, the experimental conditions providing superior immunofluorescent 
images were: incubating sections with antibodies diluted in PBS, at 4˚C with longer 
incubation periods.  
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As the immunofluorescent technique used in this work utilises a combination of primary and 
secondary antibodies which are incubated at low temperatures (therefore low diffusion rates), 
the depth of antibody penetration needed to be checked. It was found that there was an initial 
penetration of ~150µm either side of the section before the staining started to lose its 
intensity. This loss of intensity through the sections was also observed by Ando et al. (2014) 
when they were investigating Aβ and tau plaques in cleared frontal cortex of patients with 
Alzheimer’s disease. Following this observation, it was determined that only 250µm sections 
would be used for future usage of CLARITY,  to ensure uniform labelling throughout the 
section and still maintain enough tissue volume to visualise large portions of Purkinje cell 
axons. 
The sample size was then increased by applying the same methodology to cerebellar sections 
from five more patients with mitochondrial disease. Whereas 4 of these patients were 
successfully cleared and stained allowing the investigation of changes in axonal morphology, 
this was not observed in one of the patients (patient 6). It is unlikely that post mortem interval 
(PMI) influences the clearing and staining procedures, as patient 6 had a PMI of 21 hours and 
patient 11, which had a PMI of 112 hours, was successfully cleared and labelled. The same 
could be said for the length of fixation; patient 13, in which labelling failed, had a fixation of 
2 years whereas successful labelling was achieved in control 15 with a fixation length of 7 
years.  
To expand the use of the technique, a quadruple immunofluorescent stain was attempted on 
successfully cleared tissue to be able to investigate respiratory chain deficiency in neuronal 
axons as well as the changes in both axonal projections and level of myelination. The 
quadruple assay contained two mitochondrial antibodies, one to determine the mitochondrial 
mass (COX4) and one to quantify the level of complex one deficiency (NDUFA13), while the 
axons were labelled by neurofilament H and the myelin sheath labelled by myelin basic 
protein. Out of the four markers, myelin basic protein produced the best stain, clearly 
labelling all the myelin sheath in the granular cell layer and appearing comparable across all 
the cases. With regards to the mitochondrial antibodies, the COX4 antibody positively 
labelled mitochondria in each of the cases, whilst the NDUFA13 antibody produced varying 
labelling among the cases, as exemplified by the lack of complex I staining in the section 
from control 15. Therefore, it is not be possible to confidently quantify the level of complex I 
deficiency at the current time. Regarding neurofilament H, there was a high level of 
autofluorescence and a lack of specific staining of the Purkinje cell axons. Indeed, the no 
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primary antibody section showed bright levels of autofluorescence in the 405nm channel, 
which is used to visualise the vascular network. It is known that brain tissue has a high level 
of autofluorescence and for that reason I have been using an incubation of 0.2M glycine for 
15mins(Ando et al., 2014) to eliminate autofluorescence. However,  it does not appear 
sufficient and therefore other alternative protocols such as 0.1M Ammonium chloride in PBS 
for 20 min prior to immunolabelling needs to be further attempted 
(http://forum.CLARITYtechniques.org/).  
As the sections are embedded in a hydrogel that crosslinks to the native biological molecules, 
it effectively eliminates protein loss that is associated with lipid solvation steps (Chung et al., 
2013; Yang et al., 2014). As a result, one of the main advantages of the CLARITY technique 
is that the sections can be reused post immunolabelling through a repeated incubation in the 
clearing solution (Chung et al., 2013). I was able to confirm that sections originally stained 
for a number of markers can undergo antibody removal via the clearing solution to then be 
stained with other of neuronal markers. The imaging of the re-stained sections showed no 
remnants of the original vasculature markers and there was positive staining of the axons and 
myelin sheath, validating this procedure. This is a highly attractive feature as it allows for 
sections to be used multiple times, therefore being able to image multiple cell types within the 
same section and location, as well as making a finite and rare resource such as brain tissue 
from individuals with rare disorders stretch further. 
Through the work completed in this chapter, I have been able to confirm that it is possible to 
passively clear sections of both mouse and human cerebellum that have been embedded with 
an acrylamide based hydrogel.  In addition, I have produced a protocol (Figure 4.21) that 
consistently labels the axons and myelin of Purkinje cells, as well as multitude of other 
mitochondrial components. Some antibodies require further optimisation as the lack of 
antigen retrieval and depth of penetration limit their use. However, at the current time, I have 
shown that it is possible to use thicker tissue sections to look at the changes in axonal 
pathology such as axonal torpedoes in patients with mitochondrial disease compared to 
controls, for which I will investigate further in the next chapter. 
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Figure 4.21: The final CLARITY protocol to consistently produce quality 
immunofluorescent images from passively cleared sections. 
The steps in red are those that were optimised in this chapter and were added to 
the basic protocol to improve the quality and repeatability of the 
immunolabelling of the passively cleared sections. 
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Chapter 5. Quantifying Axonal Changes in the Cerebellum of Patients with 
Mitochondrial Disease 
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5.1. Introduction 
The structure of the cerebellum is highly organised, whereby the Purkinje cell soma resides in 
the Purkinje cell layer with its dendrites projecting into the molecular layer. As described in 
section 1.11, the fully myelinated Purkinje cell axon is the final output from the cerebellar 
cortex. It projects from the Purkinje cell body on the parasagittal plane through the granular 
cell layer into deep cerebellar white matter before finally synapsing onto the deep cerebellar 
nuclei such as the dentate nucleus (Hamilton, 1973). In addition to projecting into the DCN, 
after the first node of Ranvier, the axons project a recurrent collateral at an acute angle that 
synapse on to neighbouring Purkinje cell soma and dendrites, basket cell projections, Golgi 
cells and Lugaro cells, forming the infranganglionic plexus in the upper granular cell and 
Purkinje cell layer (Babij et al., 2013). The vast distances that axons project and the complex 
connections they form are exemplified by the Purkinje cell projections. Perturbations to 
neuronal homeostasis within these structures, for instance, lack of ATP or morphological 
abnormalities of the axons, may be an early sign of neuronal degeneration following an insult. 
5.1.1. Purkinje cells response to injury 
The response of Purkinje cells following an insult, such as axotomy, has been well 
documented. Studies have shown that the Purkinje cell’s response to axotomy is very different 
to the accepted neuronal response. The accepted neuronal response being that the cellular and 
molecular changes are normally reactive or compensatory to the insult. Eventually turning 
regressive and leading to atrophy or cell death (Lieberman, 1971). Purkinje cells are unique in 
that the axotomized axon undergoes a number of morphological changes that include: (i) the 
formation of axonal torpedoes on the transected axon in the granular cell layer; (ii) the initial 
neuritic segment and recurrent collaterals becomes hypertrophic; (iii) finally there is 
progressive atrophy of the corticofugal axons. Initially there is no sign of retraction or 
regeneration at the transected stump and these end bulbs can reside for up to 18 months 
(Dusart et al., 1999). Purkinje cells have been shown to lose their ability to regenerate by the 
end of the first post-natal week (Dusart et al., 1997; Ghoumari et al., 2000; Gianola and Rossi, 
2001). Following a number of months, the transected stump is observed to begin spontaneous 
sprouting, in what is believed to be an attempt to maintain the individuals integrity by either 
creating new connections to maintain function or to access growth factors (Gianola and Rossi, 
2002). One study investigated these morphological changes in the cerebellum of individuals 
with essential tremor in comparison to control individuals and found that changes in axonal 
shape, presence of axonal torpedoes and changes in axonal connectivity such as axonal 
recurrent collaterals, axonal branching and terminal axonal sprouting, were more prevalent in 
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the cerebellums of patients with essential tremor cases versus controls (Babij et al., 2013). In 
addition to morphologically changes, Purkinje cell soma are highly resistant to death, 
surviving multiple months after injury. This survivability has been contributed to a lack of 
cell body response to injury, whereby genes associated with injury or regeneration such as c-
Jun, I-NOS ad GAP-43 are only minimally upregulated (Zagrebelsky et al., 1998). This 
results in the Purkinje cell remaining after injury but limits its ability to regenerate the axon, 
therefore resulting in the axonal sprouting to attempt to retain connectivity.  
5.1.2. Molecular changes to axonal torpedoes 
In addition to the changes in axonal morphology, it has been observed through electron 
microscopy that the myelin sheath around the axonal torpedo has been disrupted in a number 
of axonal torpedoes (Louis et al., 2009c). Additionally, immunohistochemical analysis of 
axonal torpedoes in Friedreich Ataxia (FRDA) cases has shown axonal torpedoes with 
varying degrees of myelin fragmentation (Kemp et al., 2016). In the CNS, it is the 
oligodendrocytes that ensheath the axons by wrapping their plasma membrane around the 
axons, forming a compact, multi-layered stack of membranes (Baumann and Pham-Dinh, 
2001; Hartline, 2008). Each myelin segment is approximately 150µm in length, creating a 
defined structural boundary. A gap is present between each myelin segment, known as the 
nodes of Ranvier. Each node of Ranvier accommodates a high number of voltage gated 
sodium ion channels. The insulating properties of myelin increases the electrical resistance 
and decreases the capacitance across the axons membrane. This allows the action potential to 
jump from one node of Ranvier to the other, a process known as saltatory conduction, 
allowing for the fast and efficient transmission of action potential (Hille, 2001). The myelin 
sheath has a high lipid content with 73%-81% of the total dry weight of myelin being lipids 
(Chrast et al., 2011) with cholesterol accounting for 25% of that (Saher et al., 2005). In 
addition to the lipids, myelin is composed of about 19%-27% of membrane proteins which 
include proteolipid protein, myelin oligodendrocyte glycoprotein, myelin-associated 
glycoprotein and myelin basic protein (MBP). MBP is the most abundant protein in the 
myelin sheath, accounting for 30% of the total protein (Braun, 1984; de Ferra et al., 1985), 
and is essential for myelination. This is exemplified in mouse models, such as the shiverer 
mouse, where MBP has been disrupted, resulting in hypomyelination of the CNS, while in 
axons there is an increase in slow axonal transport, alterations to the cytoskeleton and a 
shortened life span (Rosenbluth, 1980; Brady et al., 1999). As mentioned, the importance of 
MBP, and its abundance in the myelin sheath, make it an ideal protein to target via an 
immunofluorescent assay in order to investigate the level of axonal torpedo myelination. 
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As mentioned, the gaps between the myelin segments leaves regions of exposed axonal 
membrane where nodes of Ranvier are formed. Nodes of Ranvier are characterised by the 
high density of voltage gated sodium channels, which are essential for the propagation of 
action potentials in saltatory conduction. Voltage gated sodium channels are large, multimeric 
complexes composed of a 260 kDa α subunit (Nav1.1-Nav1.9) and one or more auxiliary β 
subunits (β1, β2 and/or β3) of 33-36 kDa (Hartshorne and Catterall, 1981; Hartshorne et al., 
1982) (Yu and Catterall, 2003). The α subunit contains the ion-conducting pore, as well as 
being responsible for channel opening, ion selectivity, and rapid inactivation (Yu and 
Catterall, 2003). In the mature CNS, the main sodium channel clustered at the node of 
Ranvier are the Nav1.6 channels, with a density of ~1000/µm2. However, they can also be 
found at a lower density of 25/µm2 along the myelinated portion of the axon (Ritchie and 
Rogart, 1977; Caldwell et al., 2000)). Nav1.2 and Nav1.8 channels are also found at the nodes 
of Ranvier, with Nav1.2 being highly expressed during development but is replaced by 
Nav1.6 as the CNS matures (Kaplan et al., 2001; Arroyo et al., 2002). Nav1.6 is not only 
restricted to axons, it is also located at dendrites, synapses, and the soma of Purkinje cells 
(Caldwell et al., 2000). Nav1.6 channels predominantly produce a persistent current, but can 
also generate rapidly activating and inactivating currents (Smith et al., 1998). Studies carried 
out within Experiment Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS), 
where axonal demyelination within the CNS is observed, show that Nav1.6 is 
uncharacteristically expressed along the length of a demyelinated axon (Craner et al., 2003; 
Craner et al., 2004b). As axonal torpedoes appear to show a lack of myelination, it would be 
important to understand if they reacted like normal demyelinated axons by increasing the 
expression of Nav1.6 channels in an attempt to maintain electrical conductance.  
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5.2. Aims 
As axonal torpedoes are much larger than normal axons, and there is a lack of myelin around 
them (Louis et al., 2009c). The aim of this work was to determine if the presence of axonal 
torpedoes within the mitochondrial disease patients was accompanied by the loss of myelin 
when compared to control patients. The loss of myelin would adversely affect the 
connectivity of the neurons. Furthermore, neurons that have already become demyelinated 
exhibit increased expression of Nav1.6, enabling the neuron to continue generating action 
potentials. Therefore, I further aim to determine whether Nav1.6 channels are present within 
axonal torpedoes, and if so, this would add weight to the hypothesis that there is a 
compensatory attempt to maintain electrical conductance within individual Purkinje cell.  
Additionally, Babij et al. (2013) showed that there is an increase in axonal morphology 
changes, such as axonal branching and recurrent axons, associated with axonal torpedoes. The 
increase in axonal changes has been credited to a change in Purkinje cell connectivity. Using 
the CLARITY technique I developed in chapter 4, I aim to determine if there is an increase in 
axonal morphological changes as this may be indicative of Purkinje cells compensating for 
the loss of neighbouring Purkinje cells by increasing axonal branching, thereby maintaining 
neuronal connectivity. This work has the potential to delineate whether or not axonal 
torpedoes represent a compensatory mechanism to maintain connectivity rather than a 
detrimental pathological phenomenon.  
In order to complete the aims of this chapter I will; 
 Visualise and quantify the level of myelination around axonal torpedoes and compare 
to normal appearing axons. 
 Utilise the recently developed CLARITY technique to quantify morphological 
changes to the Purkinje cell axons in mitochondrial patients versus controls. 
 Determine if axonal torpedoes that have undergone demyelination have expression of 
Nav1.6 channels in an attempt to maintain electrical function. 
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5.3. Methods 
The methods to be used in this chapter are immunofluorescence (chapter 2.2.2) and 
CLARITY (chapter 2.2.4). Immunofluorescent staining was completed on 5µm thick FFPE 
cerebellar sections while CLARITY was completed on 250µm thick cerebellar sections. 
Control and patients’ details used in this chapter are summarised in table 5.1. The details 
about the specific antibodies used in this chapter are summarised in table 5.2.  
5.3.1. Quantification of myelin volume around the axonal torpedoes and normal 
appearing axons.  
5µm thick FFPE cerebellar sections from 10 patients with clinically defined mitochondrial 
disease and 12 control individuals were stained with Anti-SMI-94 (myelin basic protein) and 
Anti-neurofilament H 200kDa (neurofilament H). The quantification of myelin volume and 
axonal torpedo volume was completed using the Nikon A1R confocal microscope with the 
NIS Elements software. Axonal torpedoes and Purkinje cells axons in the granular cell layer 
were identified by neurofilaments H and were captured at 60x magnification with 4x 
electronic zoom under constant gain, offset and laser power. Using Volocity 3D Image 
Analysis Software (PerkinElmer, UK) a region of interest was drawn around either the axonal 
torpedoes or normal appearing axons using neurofilaments H. The volumes of axonal 
torpedoes and axons were calculated while only the volume of myelin that was touching the 
axonal torpedoes or normal appearing axons was calculated.  
Using the statistical software SAS (SAS Institute Inc.), the myelin and axonal torpedo volume 
data underwent Box-Cox transformation to determine the appropriate method of 
transformation to normalise the data. The most appropriate transformation was for the data to 
undergo a Log10 transformation. To determine the difference between axonal torpedo 
myelination in controls and patients, either the unpaired t test or Mann Whitney tests were 
completed, the same was done for axonal myelination. To confirm that axonal torpedoes are 
demyelinated, Wilcoxon signed rank tests were completed to determine a difference between 
myelin volumes of axon and axonal torpedoes within an individual. Pearsons correlations was 
completed to determine a relationship between myelination volume and axonal torpedo 
volume or axon volume.  
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5.3.2. Quantification of axonal morphology in passively cleared 250µm thick human 
cerebellum sections 
Passively cleared 250µm thick human cerebellum sections were labelled with Anti-
neurofilament H 200kDa (neurofilament H) and Anti-SMI-94 (myelin basic protein). The 
sections were imaged on Nikon A1R confocal microscope, where through the NIS Elements 
software, large 3x3 field images of 10 randomly selected regions with a Z step of 10µm were 
captured for each case. Once the large image was captured, any axonal torpedoes 
(neurofilament H) that were present in the large field image were captured using an additional 
1.5X of electronic magnification with a Z step of 5µm. Once all the images were captured, 
they were imported into ImageJ (National Institutes of Health) where a grid was place over 
the image and each form of axonal morphology was counted in each of the grid squares with 
the aid of the ImageJ counter add on.  
5.3.3. Analysis of NaV1.6 Channels in Axonal Torpedoes and Normal Appearing 
Axons.  
5µm thick FFPE cerebellar sections from 10 patients with clinically defined mitochondrial 
disease and 12 control individuals were stained with Anti-SMI-99 (myelin basic protein), 
Anti-NaV1.6 (Type VI Sodium Channels), and Anti-SMI-31R (Phosphorylated heavy subunit 
of neurofilaments). The visualisation of Type VI Sodium Channel in axonal torpedoes and 
normal appearing axons was completed using the Nikon A1R confocal microscope with the 
NIS Elements software. Axonal torpedoes and Purkinje cells axons in the granular cell layer 
were identified by smi-31R immunoreactivity and were captured at 60x magnification with 4x 
electronic zoom under constant gain, offset and laser power. Once the images had been 
captured, regions of interest were drawn around the axonal torpedoes or Purkinje cell axons 
using SMI-31R as a marker in Volocity 3D Image Analysis Software. Once the region of 
interest was drawn, counts of Type VI Sodium Channels were made and the volume of myelin 
touching the structures was calculated. As with the myelination data, SAS was used to 
complete a Box-Cox transformation to determine that Log10 was the most appropriate 
method to transform the data. Depending on the normality of the data, either unpaired t test or 
Mann Whitney tests were used to determine if there is was a difference between the NaV1.6 
concentration in control axonal torpedoes and axons and patient’s axonal torpedoes and 
axons. Spearman’s ranks order correlations were used to determine a relationship between 
NaV1.6 concentration and myelin volume of axonal torpedoes or Purkinje cell axons in both 
controls and patients.  Graphical representation of the data in all sections was completed using 
GraphPad prism (GraphPad prism, Inc.). 
Chapter 5                                                      Quantification of Purkinje Cell Axon Morphology 
156 
 
Table 5.1: Patient and control details used in the quantification of axonal changes.  
Patient and control details include age, gender, Post Mortem Interval (PMI) and 
defined genetic defect. N/A – Not applicable 
 
Gender Age 
(Years) 
PMI 
(Hours) 
Genetic defect 
Individuals used in immunofluorescent analysis 
Patient 1 F 40 58 m.3243A>G 
Patient 2 F 20 187 m.3243A>G 
Patient 3 F 36 9 m.3243A>G 
Patient 4 M 45 43 m.3243A>G 
Patient 5 M 59 67 POLG (p.Gly848Ser and p.Ser1104Cys) 
Patient 6 M 30 21 m.3243A>G 
Patient 8 F 60 10 m.3243A>G 
Patient 7 F 42 59 m.8344A>G 
Patient 9 M 58 66 m.8344A>G 
Patient 10 M 79 85 POLG (p.Thr251Ile/p.Pro587Leu; 
p.Ala467Thr) 
Control 1 F 69 16  
 
 
 
 
 
 
 
N/A 
Control 2 F 74 53 
Control 3 M 55 51 
Control 4 F 74 67 
Control 5 M 70 72 
Control 6 F 77 83 
Control 7 M 48 46 
Control 8 M 44 83 
Control 9 M 45 44 
Control 11 M 61 61 
Control 13 M 72 17 
Control 14 F 78 34 
Individuals used in the CLARITY technique 
Control 15 F 72 27  
N/A Control 16 F 58 39 
Patient 9 M 58 66 m.8344A>G 
Patient 11 M 55 112 POLG (p.Trp748Ser and p.Arg1096Cys) 
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Table 5.2: Properties of antibodies used in the quantification of axonal changes.  
Properties of the antibodies used to quantify the molecular and morphological 
changes in Purkinje cell axons.  
 
 
 
  
Antibody Target Host and 
isotype 
Dilution 
Primary antibodies 
Anti-SMI-31R Phosphorylated heavy 
subunit of 
neurofilaments 
Mouse 
IgG1 
1:1000 
Anti-SMI-94 Myelin Basic Protein Mouse  
IgG1 
1:1000 
Anti-SMI-99 Myelin Basic Protein Mouse  
IgG2b 
1:500 
Anti-neurofilament H 
200kDa 
neurofilament H       
(200 kDa) 
Rabbit  IgG 1:200 
Anti-NaV1.6 Type VI Sodium 
Channel 
Rabbit IgG 1:100 
Secondary antibodies 
Alexa Fluor 488nm 
anti-Rabbit IgG 
Rabbit IgG  
 
 
Goat IgG 
 
 
 
1:100 
Alexa Fluor 546nm 
anti-Rabbit IgG 
Rabbit IgG 
Alexa Fluor 488nm 
anti-mouse IgG1 
Mouse IgG1 
Alexa Fluor 546nm 
anti-mouse IgG1 
Mouse IgG1 
Alexa Fluor 633 anti-
mouse  IgG2b 
Mouse  IgG2b 
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5.4. Results 
5.4.1. Myelination of Axonal Torpedoes 
Immunofluorescent staining was carried out on sections from twelve controls and ten patients 
with mitochondrial disease to label axons, axonal torpedoes and the myelin sheath (Figure 
5.1). In comparison to the normal appearing axon, which was fully myelinated (figure 5.1A), 
the axonal torpedoes were observed to be myelinated to varying degrees (Figure 5.1B-D).  
The level of axonal torpedo and axon myelination was quantified (Figure 5.2A-B). The level 
of myelination associated with axonal torpedoes was comparable in both controls and patients 
with mitochondrial disease (unpaired t-test, p=0.452 (Figure 5.2A)), with patient 3 
(m.3243A>G) showing the only observable increase in axonal torpedo myelination. The level 
of axonal myelination was also comparable between controls and patients with mitochondrial 
disease (unpaired t-test, p=0.582 (Figure 5.2B)). There was no statistical difference in the 
volume of axonal torpedoes between controls and patients with mitochondrial disease 
(unpaired t test, p=0.617). However, the volume of control axons was significantly increased 
compared to the volume of patient axons (unpaired t test, p=0.018). 
When comparing axonal torpedo myelination to axonal myelination in each patient, there was 
a signification reduction of axonal torpedo myelination in all cases (Wilcoxon signed rank 
test, (Control (p<0.0001), patients 2, 4, 5, 6, 7, 8 and 10 (Wilcoxon signed rank test, 
(p=0.002)), patient 3 and 9 (Wilcoxon signed rank test, (p=0.004)) and patient 1 (Wilcoxon 
signed rank test, (p=0.016)), confirming that axonal torpedoes are demyelinated in 
comparison  to normal appearing axons. 
The relationship between axonal torpedo volume and myelin volume was investigated (Figure 
5.3A). A significant positive relationship was observed between myelin volume and axonal 
torpedo volume in the patients with mitochondrial disease (Pearsons correlation, R2=0.618, 
p=0.007). A similar relationship was observed in controls, however this was not significant 
(Pearsons correlation, R2=0.340 p=0.0505).  
In the axons of controls, there was a significant positive relationship between axon volume 
and myelin volume whereby as the axonal volume increased so did the myelin volume 
(Pearsons correlation, R2=0.400, p=0.027). A positive relationship between axon volume and 
myelin volume was observed in the patient cohort, but this was not significant (Pearsons 
correlation, R2=0.2216, p=0.170)  
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Figure 5.1: Myelination of axons and axonal torpedoes in the cerebellum.  
Normal appearing axon (A) are fully myelinated (green) while axonal torpedoes 
display a varying level of myelination, with some being fully myelinated (B), 
partially myelinated (C) or completely devoid of a myelin sheath (D). 
Scale=10μm 
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Figure 5.2: Quantification of myelin sheath around axonal torpedoes and normal 
appearing Purkinje cell axons in the cerebellum.  
A) The level of axonal torpedo myelination in control was comparable to the 
level of axonal torpedo in patients with mitochondrial disease (unpaired t-test, 
p=0.452). B) As observed in axonal torpedoes, there was no statistical difference 
in the level of axonal myelination between controls and patients with 
mitochondrial disease (unpaired t-test, p=0.582). m.3243A>G- red diamonds, 
m.8344A>G-orange circles and POLG-crosses
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Figure 5.3: The relationship between myelin volume and the volume of axonal torpedoes 
or normal appearing Purkinje cell axons in the cerebellum. 
A) In axonal torpedoes from patients with mitochondrial disease there was a 
significant positive relationship between myelin volume and axonal torpedo 
volume (Red line, Pearsons correlation, R2=0.618, p=0.007). The relationship in 
controls was comparable to patients but was not significant (Green line, Pearsons 
correlation, R2=0.340 p=0.0505). B) A significant positive relationship between 
control axon volume and control myelin volume was observed whereby as the 
axonal volume increased so did the myelin volume (Green line, Pearsons 
correlation, R2=0.400, p=0.027). In the patient cohort a positive relationship 
between axon volume and myelin volume was observed but this was not 
significant (Red line, Pearsons correlation, R2=0.2216, p=0.170). Each dot 
represents the mean data from each case. m.3243A>G- red diamonds, 
m.8344A>G-orange circles and POLG-crosses 
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5.4.2. Changes in axonal morphology 
Following the development of the CLARITY protocol, two control and two patient 
cerebellums were rendered transparent using the CLARITY protocol and were stained for 
neurofilament H (488nm) and myelin basic protein (546nm). Using the Nikon A1 confocal 
microscope and NIS:elements software, ten large field images were captured from the 
controls (Figure 5.4) and patients with mitochondrial disease (Figure 5.5). The changes in 
axonal morphology to be quantified are axonal torpedoes (Figure 5.6A), thickened axons 
(Figure 5.6B), recurrent axonal collaterals (figure 5.6C) and axonal branching (Figure 5.6D). 
In addition to the morphological changes, the number of Purkinje cells were counted in each 
section (Figure 5.6E).  
The quantification of changes to axonal morphology are shown in figure 5.7. Both patients 
were shown to have a reduction in Purkinje cell density compared to controls, with patient 9 
(m.8344A>G) having the greatest reduction in Purkinje cell density. Axonal torpedo densities 
in patient 11 (POLG) and controls were comparable, whereas in patient 9 there was an 
increase in axonal torpedo densities compared to controls.  The density of thickened axons 
was more prevalent in both patients compared to controls, with patient 11 having the greatest 
increase in density. There was no difference in the prevalence of recurrent axons in patients 
compared to controls. The largest difference was observed in the occurrence of axonal 
branching, with both patient 9 and patient 11 having a greater density of axonal branching 
compared to that observed in controls.  
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Figure 5.6: Visualisation of axonal morphology in 250µm passively cleared cerebellar 
sections. 
Immunofluorescent staining of passively cleared cerebellum sections allows for 
the visualisation of morphological changes that include axonal torpedoes (A), 
thickened axons (B), recurrent axonal collaterals (C), axonal branching (D) and 
Purkinje cell soma (E). Scale=100µm 
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Figure 5.7: Quantification of morphological changes to Purkinje cell axons projecting 
through the granular cell layer.  
The different types of Purkinje cell axon morphology were quantified in the 
granular cell layer of each large field scan and corrected to the volume (mm3) of 
the region quantified.  
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5.4.3. Morphology of axons relating to axonal torpedoes.  
The benefit of using CLARITY has allowed for the full visualisation of axonal torpedoes and 
associated axons. Using neurofilament H (488nm) axonal torpedoes were imaged using 1.5X 
electronic magnification in conjunction with X20 objective on the Nikon A1R (Figure 5.8). 
The percentage of axons entering and exiting the axonal torpedoes was calculated (Figure 
5.9A), and it was shown that in the controls 94.75% of the axonal torpedoes had an axon 
entering, while 81.25% of axonal torpedoes had an axon exiting distally. Patient 9 was shown 
to have 95% of axonal torpedoes with an entering axon, and 100% of torpedoes displaying an 
exiting axon. All of the axonal torpedoes of patient 11 displayed an axon entering, while 
66.67% of the torpedoes had an axon exiting.  
Following the confirmation that the majority of axonal torpedoes project an axon distally, the 
morphology of those axons were investigated (Figure 5.9B). A small number of proximal 
axonal torpedo axons were shown to display axonal branching, with 0% of proximal axons in 
patient 4, 5% in patient 2, and 7% in controls displaying axonal branching. Recurrent axon 
collaterals projecting distally from the axonal torpedoes were more prominent than axonal 
branching with 23% of controls, 35% of patient 2 and 50% of patient 4 having recurrent 
axons. A number of distal axonal torpedo axons were both recurrent and had axonal branches, 
and the quantification showed that 23% of control distal axons, 55% of patient 2 distal axons 
and 50% of patient 4 distal axons were both recurrent and had axonal branching. Only the 
control cohort had any proximal axonal projections that was not either recurrent or have 
axonal branching (47%).  
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Figure 5.8: Visualisation of axonal torpedoes in 250µm passively cleared cerebellum sections.  
Labelling of neurofilament H (green) and myelin basic protein (red) has allowed 
for the visualisation of axonal torpedoes and the axons projecting both to and 
from the structures. Scale=100µm 
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Figure 5.9: Quantification of the morphology of axonal torpedo projections.  
A) The percentage of axons entering and exiting the axonal torpedoes was 
quantified, showing that the majority of axonal torpedoes had both an axon 
entering and exiting it. B) The morphology of the axons exiting distally from the 
axonal torpedoes was quantified. Both patients displayed a higher level of 
morphological change in the distal axon of the axonal torpedo compared to the 
controls.  
A) 
B) 
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5.4.4. Expression of sodium channels in axonal torpedoes 
A triple immunofluorescent assay was utilised to investigate if the axonal torpedoes retained 
the potential to be functional by looking at the presence of sodium channels (Nav1.6) in both 
axons and axonal torpedoes. Punctate staining of sodium channels (NaV1.6, 488nm) can be 
observed in the axonal torpedoes (neurofilament H, 546nm) irrespective of the level of 
myelination ((myelin basic protein, 633nm) Figure 5.10). As with the axonal torpedoes, 
Nav1.6 can be observed in normal appearing axons that are traversing the granular cell layer 
(Figure 5.11).  
The expression of Nav1.6 in both axonal torpedoes (Figure 5.12A) and normal appearing 
axons (Figure 5.12B) was quantified. In the axonal torpedoes, no statistically significant 
difference in the expression of Nav1.6 was observed between controls and patients with 
mitochondrial disease (Mann Whitney, p=0.869). As with axonal torpedoes, Nav1.6 density 
was comparable in patients and controls (unpaired t test, p=0.213).  
The relationship between Nav1.6 density and volume of myelin associated with either axonal 
torpedoes (Figure 5.13A) or normal appearing axons (Figure5.13B) was investigated. In 
control axonal torpedoes there was no relationship observed between Nav1.6 density and 
myelin volume (Spearman's Rank-Order Correlation, R2=0.1373, p=0.129). However, in 
patients, a significant relationship was observed, with Nav1.6 density decreasing as myelin 
volume increased (Spearman's Rank-Order Correlation, R2=0.465, p=0.03). In the normal 
appearing axons, neither the patients (Pearsons correlation, R2=0.442, p=0.574) or controls 
(Pearsons Correlation, R2=0.215, p=0.129) displayed a significant relationship between 
sodium channel expression and myelin volume.  
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Figure 5.12: Quantification of sodium channels (Nav1.6) in axonal torpedoes and normal 
appearing Purkinje cell axons.  
A) There was no statistical difference in Nav1.6 density between the axonal 
torpedoes from controls and patients with mitochondrial disease (Mann 
Whitney, p=0.869). B)  Nav1.6 density was comparable in Purkinje cell axons 
from patients with mitochondrial disease and those from controls (unpaired t 
test, p=0.213). m.3243A>G- red diamonds, m.8344A>G-orange circles and 
POLG-crosses   
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Figure 5.13: The relationship between Nav1.6 density and the myelin volume in either 
axonal torpedoes or normal appearing Purkinje cell axons in the 
cerebellum.  
A) There was no relationship observed between Nav1.6 density and myelin 
volume in control axonal torpedoes (Spearman's Rank-Order Correlation, 
R2=0.1373, p=0.129). However, Nav1.6 density was observed to decrease as 
myelin volume increased in patient axonal torpedoes and this was a significant 
relationship (Spearman's Rank-Order Correlation, R2=0.465, p=0.03). No 
significant relationship between Nav1.6 density and myelin volume was 
observed in the normal appearing axons from either the patients (Pearsons 
Correlation, R2=0.442, p=0.574) or controls (Pearsons correlation R2=0.215, 
p=0.129). Each dot represents the mean data from each case. 
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5.5. Discussion 
Purkinje cells are unique in that they react differently to stress or injury than any other 
neuronal populations. For instance, there is no sign of retraction or regeneration following 
transection with the end bulbs residing for up to 18 months (Dusart et al., 1999). Following an 
insult, the Purkinje cells reaction can be characterised by the structural remodelling of the 
axons and intracortical branches, with minimal cell body changes (Rossi et al., 2006). Even 
though Purkinje cells are highly resistant to axotomy, this property is made redundant by their 
inability to regenerate axons, even in permissive environments (Dusart et al., 1997). The 
structural remodelling of axons in an injured cerebellum include the formation of axonal 
torpedoes, hypertrophy of initial neurotic segment and recurrent collaterals and finally 
progressive atrophy of the corticofugal axons. The formation of recurrent collaterals from 
axons of Purkinje cells has been suggested to provide a feedback system, either through the 
inhibition of Golgi II cells resulting in the depression of their inhibitory activity on 
surrounding granule cells, or increasing the activity of Purkinje cells by inhibiting the basket 
cells (Chan-Palay, 1971).  
Using the optimised CLARITY technique, it was possible to use passively cleared 250μm 
thick cerebellar sections from two controls and two patients with mitochondrial disease. This 
allowed the investigation into the axonal changes that can occur following a stress, such as 
respiratory chain deficiency. Quantification of the structural changes showed that the most 
significant changes in mitochondrial disease patients was the increased prevalence of 
thickened axons and axonal branching, with both patients exhibiting a significant increase in 
axonal branching. While an increase in thickened axons was observed in both patients, only 
patient four was found to be significant. The increase in structural changes in a diseased 
cerebellum is in agreement with a previous study where an increase in structural changes was 
observed in the cerebellum of patients with essential tremor (Babij et al., 2013). Babij and 
colleagues also observed that axons projecting from the axonal torpedoes were more likely to 
display a structural change. When I investigated the axonal morphology associated with 
axonal torpedoes, I was firstly able to confirm, through the use of CLARITY, that the 
majority of axonal torpedoes had both an axon entering and exiting the axonal torpedoes. 
When focusing on the morphology of the axons leaving distally from the axonal torpedo, it 
was observed that the axons were more likely to be recurrent or exhibit both axonal branching 
and be recurrent, indicating that the presence of axonal torpedoes was associated with an 
increase in axonal remodelling. This observation is in agreement with that observed in the 
study conducted by Babij et al. (2013). 
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In addition to the remodelling of the axons, it has been observed via electron microscopy and 
immunohistochemistry that there is myelin fragmentation and loss to axonal torpedoes (Louis 
et al., 2009c; Kemp et al., 2016). Myelination of an axon enables the neuron to transmit 
information extremely quickly and efficiently by increasing the resistance and decreasing the 
capacitance of the axons as well as creating structural boundaries which enables saltatory 
conduction through nodes of Ranvier. Using an immunofluorescent assay, it was shown that 
the level of axonal torpedo myelination was variable, with some axonal torpedoes fully 
demyelinated while others were partially or fully myelinated. The quantification of axonal 
torpedo myelination showed that there was no difference between controls and patients. There 
was also no significant difference in the volume of axonal torpedoes between controls and 
patients. As with axonal torpedoes, there was no significant difference between the 
myelination of normal axons in controls and patients, confirming that mitochondrial disease 
does not cause demyelination of Purkinje cell axons. Unlike the axonal torpedoes, there was a 
significant difference in volume of Purkinje cell axons from patients and controls, with the 
Purkinje cell axons in patients being smaller in volume than those in controls. The reduction 
in axonal volume would likely reduce the conduction velocities in the cerebellum, as the 
axonal calibre is a large factor in determining the conduction velocity of a neuron (Boyd and 
Kalu, 1979; Waxman, 1980). 
When comparing the level of myelination between axonal torpedoes and normal axons, there 
was a significant difference in the level of myelination, confirming that axonal torpedo 
formation results in the loss of myelin sheath around the axonal torpedo. As the axonal 
torpedoes are proximal to the Purkinje cell body, they may form in the axon initial segment 
(AIS). The AIS is a region of the axon that is not myelinated, if the axonal torpedoes were 
formed in the AIS, then I would not expect myelin to be present around the axonal torpedoes. 
It is unlikely that that the axonal torpedoes form in the AIS as I observed axonal torpedoes 
with myelin fragmentation, as has Kemp et al. (2016) when they were investigating axonal 
torpedoes in the cerebellum of FRDA patients. To fully conclude that axonal torpedoes do not 
form in the AIS, I would complete a immunofluorescent assay that would label the AIS 
(ankyrinG or neurofascin-186) in conjunction with markers of axonal torpedoes 
(neurofilament H). If the AIS marker was found to co-localise with axonal torpedo marker 
then this would indicate axonal torpedoes do form in the AIS and would explain the lack of 
myelination around the axonal torpedoes.  
The increase in axonal calibre associated with axonal torpedo formation could disrupt the 
myelin/axon interaction which initiates axonal sprouting and remodelling as it has been 
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observed that the myelin-neurite interaction is inhibitory to axonal growth. Myelin is known 
to contain inhibitory growth factors, and the inhibition of these growth factors through 
experimental application of antibodies increased the expression of several axotomy-associated 
genes in Purkinje cells that are needed for axonal regrowth as well as neurite sprouting along 
the intracortical segment of Purkinje cell axons (Zagrebelsky et al., 1998; Foscarin et al., 
2009). Therefore, the removal of myelin by the formation of an axonal torpedo may remove 
this interaction and promote axonal plasticity.  
Following demyelination of the axonal torpedoes, I have shown that there is expression of 
sodium channels in the axonal torpedoes. The expression of sodium channels in axonal 
torpedoes was comparable to normal appearing axons. The relationship between Nav1.6 
density and myelin volume in both axons and axonal torpedoes from patients with 
mitochondrial disease differed from the one observed in controls. This may indicate that the 
function of axonal torpedoes differs in patients and controls. In demyelinated axons there is an 
increase in the expression of NaV1.6 channels in an attempt to maintain normal function 
(Craner et al., 2003; Craner et al., 2004b). However, in the acute plaques in MS patients, the 
increase in expression of NaV1.6 and its co-localisation with the sodium calcium exchanger 
(NCX) has been proposed as a method for degeneration (Craner et al., 2004a). As the NaV1.6 
channel can produce substantial persistent current (Rush et al., 2005), it can result in the 
reversal of NCX, causing an influx of calcium ions and activating calcium dependent caspases 
(Craner et al., 2004a). Typically, the co-localisation between NaV1.6 and NCX was observed 
in axons immunopositive for APP, a marker for axonal damage, indicating that this process 
may only occur in damaged axons. Regarding axonal torpedoes, I have shown in chapter 3.4.1 
that axonal torpedoes are not immunoreactive for APP, inferring that they are not involved in 
a degenerating process in the axonal torpedoes. Additionally, the change in Nav1.6 density in 
the patients may be associated with an attempt to modulate the firing ability of the Purkinje 
cell.  
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In summary, I have provided evidence of increased Purkinje cell axon remodelling in patients 
with mitochondrial disease than in the cerebellum of control individual. I have also shown 
that there is myelin fragmentation and loss due to axonal torpedoes in both patients and 
controls. Whereas, the density of NaV1.6 channels in axonal torpedoes was observed to be at 
a comparable level to normal appearing axons following the loss of myelin. The combination 
of these findings suggest that axonal torpedoes are not part of a pathological and degenerative 
process as previously suggested, but are part of a process that attempts to remodel and 
reorganise the connections and circuitry in order to prevent cell death and maintain normal 
neuronal function.  
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Primary mtDNA mutations, or mutations in nuclear DNA affecting mtDNA maintenance and 
expression, intra-organelle protein synthesis or mitochondrial dynamics lead to respiratory 
chain dysfunction and a group of disorders known as mitochondrial diseases. Mitochondrial 
diseases are a very heterogeneous group of disorders as demonstrated by the variability in 
their age of onset, severity and disease progression. One of the main characteristics of 
mitochondrial disease is the involvement of the central nervous system resulting in 
progressive and severe neurological deficits. These are varied and typically dependent on the 
brain region affected but symptoms can include ataxia, dementia, migraine, neural deafness, 
central and peripheral neuropathy and stroke-like episodes (DiMauro et al., 2013). 
Affecting 70% of adult patients recruited to the UK MRC Mitochondrial Disease Patient 
Cohort, cerebellar ataxia is one of the most frequently observed neurological deficits in 
patients with mitochondrial disease (Lax et al., 2012b; Nesbitt et al., 2013). Cerebellar ataxia 
causes progressive disability through an inability to coordinate balance, gait, extremity and 
eye movements (Ferrarin et al., 2005). As cerebellar ataxia is such a common feature, the 
cerebellum has been heavily investigated to help understand its susceptibility to perturbed 
OXPHOS function. Neuroradiological imaging of patients with mitochondrial defects showed 
that abnormalities in the cerebellum were a primary feature (Scaglia et al., 2004; Bindu et al., 
2015), while neuropathological studies have shown cerebellar atrophy, Purkinje cell loss and 
a reduction in complex I expression in surviving cells in  post mortem tissue (Tanji et al., 
2001; Lax et al., 2012b; Chrysostomou et al., 2016).  
A frequently observed phenomenon in the neuropathological studies is the presence of axonal 
torpedoes in the granular cell layer of the cerebellum (Mori et al., 2000a; Lax et al., 2012b). 
Axonal torpedoes are fusiform swellings of the Purkinje cell axon and previous studies have 
shown that the main constituents of the axonal torpedoes are phosphorylated neurofilaments 
(Louis et al., 2009c). Originally it had been hypothesised that the formation of axonal 
torpedoes was part of a degenerative process that “strangled” the neuron and resulted in 
neuronal death (Figure 6.1). It was speculated that a stress stimuli would initiate a pathway 
resulting in the accumulation of phosphorylated neurofilaments which would eventually block 
fast axonal transport (FAT). The block in FAT would prevent vital proteins, organelles and 
metabolites from reaching the distal end of the neuron subsequently “starving” and 
“strangling” the neuron, eventually causing the neuron to die back and form an end bulb or in 
the case of Purkinje cells, an axonal torpedo.  
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Studies in patients with mitochondrial disease have only described axonal torpedoes 
superficially, therefore the original aim of this project was to investigate the role axonal 
torpedoes play in the loss of Purkinje cells in patients with mitochondrial disease and how this 
relates to respiratory chain deficiency. The project involved the quantification and 
characterisation of axonal torpedoes in both patients with mitochondrial disease, and age 
matched controls, leading to the optimisation of a clearing technique CLARITY in order to 
further characterise axonal morphology changes in the cerebellum of patients with 
mitochondrial disease.  
 
Figure 6.1: Proposed mechanism of axonal torpedo formation.  
A) The axon receives a focal insult resulting in the cessation of fast axonal 
transport (A). B) The inhibition of fast axonal transport results in the 
accumulation of proteins like amyloid precursor protein and causes a focal 
swelling of the axon and ultimately forms a axonal torpedo. C) Eventually the 
block in transport becomes too severe and initiates Wallerian degeneration of the 
distal axon creating an end bulb. Image modified from Coleman (2005). 
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6.1. Characterisation of axonal torpedoes in patients with mitochondrial disease.  
As axonal torpedoes were viewed as a pathological phenomenon, the first aim was to confirm 
that they were more prevalent in patients with mitochondrial disease compared to age 
matched controls. To complete this, immunohistochemical techniques were applied that 
enabled a quantitative comparative analysis of axonal torpedo and Purkinje cell density in 
patients with mitochondrial disease and age-matched controls.  This work confirmed that 
Purkinje cell density is lower in patients with mitochondrial disease which is in agreement 
with previous studies (Lax et al., 2012b), while there is a higher density of axonal torpedoes 
in patients, especially those harbouring the m.3243A>G mutation relative to controls cases. 
The observation that there is a high axonal torpedo density in other neurodegenerative 
disorders like Alzheimer’s disease and Parkinson’s disease (Louis et al., 2009a) along with 
the increased density of axonal torpedoes in patients with mitochondrial disease indicates that 
the formation of axonal torpedoes is a response to a toxic stimuli causing neurodegeneration, 
with different factors causing their formation. Thus, it is unlikely that respiratory chain 
deficiency is the sole cause but it may be the primary cause for torpedo formation in patients 
with mitochondrial disease 
As axonal torpedoes were observed in control individuals, the relationship between age and 
axonal torpedo density was investigated. It was shown that there was no relationship in the 
patients but in the controls, axonal torpedo density increased with age. The observation of a 
correlation in the control individuals but not the patients, indicates that in control individuals, 
age is the primary factor in axonal torpedo formation where as in the patients it is a different 
factor, most likely respiratory chain deficiency as a result of the mitochondrial disease that 
causes the formation of axonal torpedoes. The correlation between age and axonal torpedo 
density does contradict previous evidence (Louis et al., 2009a), however the quantification 
methods employed in this study are different to those that were used by Louis et al. (2009a). 
Louis and colleagues only counted axonal torpedoes from a 3 × 20 × 25 mm parasagittal 
section, whereas my data was corrected to the Purkinje cell density.  Additionally, the 
correlation between age and axonal torpedo density I saw was in a disease free control cohort 
whereas the control group used by Louis et al. (2009a) contained both disease free controls 
and individuals with essential tremor, AD, and PD, potentially distorting the relationship with 
age 
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It is difficult to conclude definitive relationships between axonal torpedoes and other 
observations such as Purkinje cell densities since the cerebellum is dynamic and is likely to be 
undergoing torpedo formation and loss, Purkinje cell remodelling and Purkinje cell loss 
simultaneously, making it difficult to conclude relationships in thin post-mortem cerebellar 
sections which are only representative of changes at the end-stage of disease. 
Originally, as mentioned above, it was postulated that the mis-accumulation of neurofilaments 
in the axonal torpedoes would lead to the “strangulation” of the neuron by inhibiting both 
anterograde and retrograde transport in the axon, ultimately leading to degeneration (Louis et 
al., 2009c). Components of FAT were investigated to determine if they were present or if 
there is was abnormal accumulation of FAT proteins in the axonal torpedoes. Microtubules 
are essential for FAT, as they provide the tracks for the motor proteins, dynein and kinesin to 
move along. Using an immunofluorescent assay I confirmed that the monomers of 
microtubules were present in the axonal torpedoes. As the microtubule network was still 
intact, Synaptophysin, a protein that undergoes fast axonal transport to the synapse which 
would accumulate in the axon or axonal torpedo if there was a block in FAT, was 
investigated. Using immunohistochemistry there was no accumulation of synpatophysin in the 
axonal torpedoes. A similar observation was made of APP, which is an indicator of axonal 
degeneration when it is found accumulated in axons. The absence of synaptophysin and APP 
immunoreactivity in the axonal torpedoes suggests that axonal transport is not blocked and 
that there is no axonal degeneration happening. These findings do not support the proposed 
theory of axonal torpedo formation through a block in FAT and indicates that axonal 
torpedoes may not be involved in a degenerative process.   
Axonal torpedoes were originally viewed as a pathological phenomenon involved in the 
degeneration of a Purkinje cell, initiated by a toxic or stress stimuli, which in the case of 
patients with mitochondrial disease, would be respiratory chain deficiency. Therefore, it 
would be expected that the axonal torpedoes would form in Purkinje cell axons which 
displayed the greatest level of respiratory chain deficiency. To confirm this, a triple 
immunofluorescent assay was used to investigate the presence of mitochondria in the axonal 
torpedoes and determine the level of respiratory chain deficiency in those mitochondria as 
well as mitochondria in adjacent Purkinje cell bodies and normal appearing axons. To 
quantify respiratory chain deficiency, complex I subunit NDUFA13 was used a marker as a 
decrease in the protein expression of NDUFA13 protein has been previously observed in 
patients with mitochondrial disease (Lax et al., 2012b). The protein expression of NDUFA13 
was corrected to a mitochondrial mass marker (COX4). Even though COX is a multi-subunit 
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enzyme complex that has 3 subunits encoded by the mtDNA, it has been shown that there is 
no loss of COX expression in the cerebellum of patients with mitochondrial disease (Lax et 
al., 2012b; Chrysostomou et al., 2016), making COX4 an adequate mitochondrial mass 
marker. Mitochondria were shown to be localised throughout the axonal torpedoes in both 
controls and patients with mitochondrial disease. Quantification of NDUFA13 expression in 
axonal torpedoes, Purkinje cell soma and normal appearing axons, revealed that respiratory 
chain deficiency exists in all three neuronal compartments and that Purkinje cell soma had the 
greatest loss of NDUFA13 expression compared to other neuronal compartments. If axonal 
torpedoes were to be involved in a degenerative process it would be expected that the 
mitochondria in the axonal torpedoes would have the greatest level of complex I deficiency as 
that Purkinje cell would be the most affected and most vulnerable to degeneration. However,  
this data indicates that the axonal torpedoes are forming in the ”healthier” neurons and, rather 
than being a part of a degenerative process, are involved in the remodelling process of a 
surviving neuron to compensate for loss of neighbouring neurons due to respiratory chain 
deficiency. Unfortunately, 5µm thick sections are too thin to be able to comprehensively 
investigate changes to Purkinje cell morphology. Therefore, the next step was to optimise a 
recently published tissue clearing technique (Chung et al., 2013) that would allow for the 
morphology of Purkinje cell axons to be investigate changes in the cerebellum by permitting 
the use of thicker tissue sections (~250µm). 
6.2. Optimisation of CLARITY 
As mentioned before a main limitation of the standard immunofluorescent technique is that 
only extremely thin (5μm) sections can be used. This is extremely problematic when looking 
at structures that have expansive processes like axons as only small region can be visualised.   
The use of thicker sections is limited due to the heterogeneous nature of tissue, as there are 
different cell types each with a differing refractive index and the high lipid content of the 
brain which further scatters and blocks light during imaging. Therefore, the light emitted from 
fluorophores is severely scattered, a process which increases with increasing section 
thickness. A recent novel technique known as Clear Lipid-exchanged Acrylamide-hybridized 
Rigid Imaging compatible Tissue hYdrogel (CLARITY) was devised by Chung et al. (2013) 
that allowed for thicker sections to be used. This protocol involved the incorporation of the 
biological molecules within the sample into a matrix and then removed the lipids through a 
clearing process while the important biological material is retained. Once the lipids are 
removed, the samples are incubated in an imaging solution that matches the refractive indexes 
throughout the section, further reducing the level of light scattering. 
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One of the aims of my project was to optimise the CLARITY technique and a subsequent 
immunofluorescent protocol to use on post mortem tissue from patients with mitochondrial 
disease. The development of a consistent and reliable clearing and staining method would 
allow for the use of thicker sections and provide the opportunity to further investigate changes 
to the morphology of Purkinje cell axons. I decided to develop passive clearing process rather 
than an active clearing process as the experience of others had indicated that the tissue is more 
likely to survive this process (http://forum.CLARITYtechniques.org/), thus preserving a finite 
resource of patient tissue. I have shown that it is possible to passively clear both mouse and 
human cerebellum sections. As expected, due to the length of fixation that the human sections 
had undergone, human sections took considerably longer to clear (four weeks) compared to 
the mouse sections (seven days). Once the sections had been cleared, the next step was to 
determine the best immunofluorescent staining protocol. I used the original method described 
by Chung et al. (2013) and one that I devised which included a prolonged incubation at 4˚C 
(Phillips et al., 2016). The protocol I developed produced significantly better results than 
other previously reported methods (Chung et al., 2013; Lee et al., 2014; Poguzhelskaya et al., 
2014). The staining protocol I developed was more successful than those previously published 
is due to the lower temperatures used, 4ºC compared to is 37ºC. The higher temperature 
results in less antibody specificity as there is more kinetic energy in the system meaning that 
less energy is required for the antibody to bind to an antigen increasing the probability of the 
antibody binding to the incorrect antigen, resulting in non-specific binding and an increase in 
background fluorescence. Although the decrease in temperature does reduce the diffusion 
rates of the antibodies I addressed this issue by increasing the incubation length from hours to 
days. Following the staining, it was found that the antibody penetration at best was 150μm, 
this had also been observed by (Ando et al., 2014). Therefore, the section thickness used was 
limited to 250μm, however there was a benefit to this as it decreased the length of time 
needed to clear the sections. The development of the immunofluorescent protocol allowed for 
the reliable visualisation of Purkinje cell axons in the cerebellum of both control individuals 
and patients with mitochondrial disease providing the opportunity to investigate changes to 
the morphology of Purkinje cell axons.  
6.3. Axonal morphology changes in mitochondrial disease 
Due to the issue of antibody penetration, the section thickness was limited to 250μm but this 
still allowed for the complete visualisation of axonal torpedoes and the investigation of 
morphology changes to Purkinje cell axons in the cerebellum of patients with mitochondrial 
disease compared to control individuals.  A previous study used immunohistochemistry on 
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100μm thick sections from patients with essential tremor to investigate both axonal torpedoes 
and axonal morphology (Babij et al., 2013). In comparison to the study byBabij et al. (2013), 
the benefit of using passively cleared sections is that thicker sections are able to be used 
(250μm > 100μm) and secondly where they only used a single antibody (calbindin 28kDa), I 
was able to use two antibodies (Neurofilament H and Myelin basic protein). I have also 
shown it is possible to complete triple immunofluorescence on tissue that has undergone 
CLARITY, further expanding the possible applications that can be utilised. For example, it 
would allow for the investigation of respiratory chain deficiency in the cleared sections as 
well.  Unfortunately, quadruple immunofluorescent labelling of cleared sections was 
unsuccessful as there was a significant level of autofluorescence in the 405nm channel. Even 
though I applied a 0.2M glycine incubation step at the end of the immunolabelling protocol to 
reduce the level of autofluorescence this was not adequate in reducing the level of 
autofluorescence in the 405nm channel. There are some alternative methods that are used to 
quench autofluorescence and I can attempt these in the future, in an attempt to reduce the 
405nm channel autofluorescence and make quadruple immunofluorescence achievable.  
The development of CLARITY and a reliable immunofluorescent labelling protocol allowed 
for the investigation into morphology changes to the Purkinje cell axon. Even though, there 
was a small sample size (2 controls vs 2 patients with mitochondrial disease), it was shown 
that there was a difference in Purkinje cell morphology, especially the observation of an 
increase in thickened axons and axonal branching in the cerebellum of patients with 
mitochondrial disease compared to control individuals, however a significance could not be 
applied to this.. The changes observed in Purkinje cell morphology is in line with previous 
observations by Babij and colleagues in patients with essential tremor.  
In combination with the observation of axonal morphology changes in the GCL, a significant 
reduction in the volume of Purkinje cell axons was also observed in patient with 
mitochondrial disease. As the axonal caliber is known to be a determining factor in 
conduction velocity (Boyd and Kalu, 1979; Waxman, 1980), this reduction in volume along 
with the general loss of Purkinje cells could severely affect the signal output of the cerebellar 
circuitry and could be a potential mechanism behind cerebellar ataxia.  
With the use of CLARITY it was possible to visualise entire axonal torpedoes as well as the 
projecting axons. It was shown that the majority of axonal torpedoes studied had both an 
entering and exiting axon. The axons exiting the torpedo were observed to be more complex 
than normal axons, as recurrent axons in axonal torpedoes were very common and the 
observation of axonal branching on a recurrent axon was not uncommon. 47% of axons 
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exiting axonal torpedoes from the controls were observed to have no morphological changes. 
The observation that axons with axonal torpedoes have more morphological features indicates 
that the formation of axonal torpedoes is more likely to be involved in a remodelling process 
than a degenerative process. 
Recurrent Purkinje cell axons have been shown to synapse on to other Purkinje cells, Lugaro 
cells and molecular layer interneurons (MLI) within a narrow (<100µm) parasagittal plane 
(Witter et al., 2016). It has been hypothesised that the recurrent Purkinje cell axons allow for 
the cerebellar output to modulate and control the gain of the cerebellar cortex. As the Purkinje 
cells are inhibitory and are the main output neurons of the cerebellum, it is possible for the 
gain to be controlled by the output neurons (Brown et al., 2014). The formation of recurrent 
axons could have a number of consequences depending on where they synapse. If the 
connection is between a Purkinje cell and a MLI, then there would be a positive feedback on 
the circuit as the MLI inhibition of Purkinje cells would be decreased. However, negative 
feedback would be initiated if the connection was between two Purkinje cells as there would 
there would be an increase in output inhibition. Additionally, through modelling, Purkinje cell 
to Purkinje cell connections have been proposed to cause fire-rate changes (Maex and 
Steuber, 2013). The observation of recurrent axons and axonal branching in the axons 
projecting from the axonal torpedo indicates that the formation of axonal torpedoes may be 
involved in a compensatory process that increases the number of recurrent axons following 
the loss of neighbouring Purkinje cells to enhance the feedback loop in the cerebellum to 
regulate the cerebellar output in an attempt to maintain a normal cerebellar output.  
As axonal torpedoes reach a considerable size and evidence suggests that there is no myelin 
sheath around the axonal torpedoes (Mann et al., 1980; Louis et al., 2009c), I aimed to 
confirm that there is a lack of axonal torpedo myelination. With the use of 
immunofluorescence I was able to confirm that axonal torpedoes become demyelinated 
compared to normal axons. There was no difference in the level of myelination of axonal 
torpedoes between controls and patients with mitochondrial disease, the same was true for 
normal appearing axons. 
As I have shown that axonal torpedoes loose myelination compared to normal axons, I then 
looked at the distribution of sodium channels in axonal torpedoes. It has been shown in axons 
that have become demyelinated that there is an increase in the expression of sodium channels, 
Nav1.6 and Nav1.2, in an attempt to main electrical conductivity (Craner et al., 2004b). 
Through immunofluorescent staining, I have shown that the sodium channel Nav1.6 is present 
in the axonal torpedoes and that the level of expression is comparable to that observed in 
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axons. It has been proposed that the presence of Nav1.6 and its persistent current in 
demyelinated axons causes degeneration through the reversal of the sodium calcium 
exchanger (Craner et al., 2004a). In the case of axonal torpedoes it is unlikely that the 
presence of Nav1.6 channels is indicative of degeneration since the expression of Nav1.6 is 
comparable in both axonal torpedoes and axons. My data indicates that the presence of 
Nav1.6 maintains electrical conductivity, however this would need further work to confirm, 
such as determining if there is a difference in the co-localisation of Nav1.6 channels and NCX 
in axonal torpedoes compared to normal appearing axons.  
6.4. Conclusion 
Through the work I have completed in the characterisation of axonal torpedoes and the 
optimisation of the CLARITY technique for use in humans, I have shown that; A) torpedoes 
are more prevalent in patients with mitochondrial disease, B) there appears to be no disruption 
or inhibition to axonal transport, C) respiratory chain deficient mitochondria are found in 
axonal torpedoes but a higher degree of deficiency is observed in the Purkinje cell soma, D) 
axonal torpedoes are demyelinated, E) a comparable expression of Nav1.6 channels are found 
in axons and axonal torpedoes and finally F) there is an increase in complex axonal 
morphology observed in the cerebellum of patients with mitochondrial disease compared to 
controls, especially the axons exiting axonal torpedoes.  
The prevailing theory about axonal torpedoes is that the accumulation of phosphorylated 
neurofilaments results in a blockade of axonal transport resulting in the “strangulation” of the 
neuron leading to distal degeneration of the Purkinje cell (Louis et al., 2009c).  However, 
following the results obtained in this project I do not agree with this theory. Specifically, if 
there was a block in transport and “strangulation” of the neuron, I would expect to observe an 
accumulation of proteins that undergo fast axonal transport and I did not observe an 
accumulation of either APP or synaptophysin in the axonal torpedoes. In addition 
microtubules were observed in the axonal torpedoes and therefore were not displaced by the 
accumulated neurofilament. Furthermore, the use of CLARITY has shown that the axonal 
torpedoes are not merely just axonal end bulbs as they have axons projecting distally and 
those axons are complex structures with recurrent collaterals and multiple branching points 
that project back towards the Purkinje cell layer.   
Therefore, I propose that axonal torpedoes are likely a phenomenon that forms during a period 
of stress in a process of remodelling to maintain functionality rather than as a part of a 
degenerative process (Figure 6.2). For example, in patients with mitochondrial disease, 
respiratory chain deficiency results in an inadequate supply of ATP and consequently the 
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Purkinje cells degenerate and are lost. As the Purkinje cell, is the main output neuron in the 
cerebellum, any significant loss in Purkinje cell numbers will affect the pattern of activity 
exiting the cerebellum. This work suggests that the formation of axonal torpedoes in surviving 
Purkinje cell axons is involved in the remodelling of the axons, resulting in an increase in 
recurrent axons to form plexuses in the molecular and granular layers to provide a feed-back 
mechanism. This feedback or inhibition results in the modulation of Purkinje cell activity in 
an attempt to maintain homeostatic balance. The exact role of axonal torpedoes in this process 
is not known and would be difficult to determine in post-mortem tissue as it only provides an 
insight at the end-stage point.  
Returning to the larger picture of respiratory chain deficiency in the cerebellum and what is 
the primary site of degeneration, I have shown that axonal changes are present in the 
cerebellum of individuals with mitochondrial disease but these are probably secondary 
changes. Additionally, Chrysostomou et al. (2016) have shown changes to the Purkinje cell 
synapse in patients with mitochondrial disease but evidence suggest these are not primary 
either. My data shows that the Purkinje cell soma had the highest level of respiratory chain 
deficiency. Hence, the main respiratory deficiency hit is to the Purkinje cell soma but it’s not 
sufficient to cause neuronal loss. However, the effects of respiratory chain deficiency is also 
sensed throughout the neuron resulting in alterations to the axons and synapses in an attempt 
to maintain normal function. The neuron may be able to survive one change or stress at a time 
but the cumulative effect of multiple stresses results in Purkinje cell death. As each Purkinje 
cell is lost, neighbouring neurons are put under more stress since they increase their function 
in order to compensate for the loss exacerbating the problem. Even though Purkinje cells are 
the main output neurons from the cerebellar cortex and their loss has been quantified, I do 
believe the generation of cerebellar ataxia is multifactorial, and investigating other neurons in 
the cerebellar circuitry and the effects of respiratory chain deficiency on them would be most 
beneficial, in determining the mechanisms behind cerebellar ataxia. 
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Figure 6.2: Proposed purpose of axonal torpedo formation.  
A) In the healthy cerebellum the Purkinje cells (PC) receive indirect input from 
mossy fibres (MF) via granule cells (GrC) and Golgi cells (GoC) or directly 
through climbing fibres that originate in the inferior olive (Not shown). The main 
target of the PC’s are neurons in the deep cerebellar nuclei (DCN). B) When 
there is a loss of Purkinje cells (red) due to an insult such as respiratory chain 
deficiency as seen in patients with mitochondrial disease,  the inhibitory output 
from the PC’s is reduced and the excitability of the DCN is increased. In the 
surviving PC’s, an axonal torpedo will form as a part of the PC axon remodelling 
process that involves the increase in recurrent collaterals projecting towards 
either neighbouring PC’s or interneurons (stellate (SC) and basket cells (BC)). 
These collaterals will create a feedback or inhibition of interneurons resulting in 
the modulation of Purkinje cells activity in an attempt to return in it to a normal 
signal by decreasing the DCNs excitability.  
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6.5. Limitations 
As the human samples that can qualify for use in the optimised CLARITY method need to 
have been in formalin for less than 6 years, it restricts the number of possible cases available 
to be used. Additionally, I was constrained by time to include more individuals in the study as 
it takes roughly 7 weeks from collection of wet tissue to visualisation of passively cleared 
tissue. This limitation is apparent in the study investigating the axonal morphology in axons 
and axonal torpedoes where there was a limited sample size with only two controls and two 
patients with mitochondrial disease. At the moment, the study shows the differences between 
patients with mitochondrial disease and controls however, the sample size is not large enough 
to make statistically robust conclusions.  
One of the major limitations of the project is that the tissue used in the project is post-mortem. 
Post-mortem tissue does allow for the investigation of both structural and molecular changes 
happening in individuals with disease compared to control individuals but this is at the 
terminal stage of disease. Therefore, making it difficult to delineate what are the primary 
drivers of degeneration and which signs are secondary. This limitation is exemplified by the 
neuropathological studies in the cerebellum of patients with mitochondrial disease where 
changes are seen in the axons, synapses  (Chrysostomou et al., 2016) and Purkinje cell soma 
(Lax et al., 2012b) but as post-mortem tissue is not dynamic and is fixed at the end-point of 
the disease it makes it difficult to determine what is the primary cause.  
6.6. Future work 
6.6.1. Axonal torpedoes 
As axonal torpedoes are found in numerous neurological disorders including essential tremor, 
Alzheimer’s disease, Parkinson’s disease (Louis et al., 2007) and multiple sclerosis (Redondo 
et al., 2015), it would be interesting to characterise those axonal torpedoes to determine if 
they have a similar composition and to understand the mechanism of their formation. 
Using confocal microscopy, it was shown that the monomers of microtubules were present in 
the axonal torpedoes. However, light microscopy does not provide the resolution and detail to 
determine if the microtubules are correctly arranged to facilitate FAT. There have not been 
any extensive studies of axonal torpedoes using electron microscopy, therefore, completing 
said study would both allow for the confirmation of whether microtubules are properly 
arranged, and also allow for investigation into the mitochondria present in the axonal 
torpedoes. This would be particularly pertinent to axonal torpedoes found in patients with 
mitochondrial disease, as results here have shown that mitochondria are present in the axonal 
Chapter 6  Final Discussion 
192 
 
torpedoes but election micrographs would provide insight into the quality of mitochondria and 
determine if there were any structural abnormalities to those mitochondria.  
It was shown that the expression of Nav1.6 was comparable in the axonal torpedoes when 
compared to the normal appearing axons in both the controls and patients with mitochondrial 
disease. However in the patients with mitochondrial disease, the trend between Nav1.6 and 
myelin volume was reversed in comparison to controls and may allude to a role of Nav1.6 in 
degeneration in the patients. As previously stated, co-localisation of Nav1.6 with the sodium 
calcium ion exchanger (NCX) is indicative of axonal degeneration. Investigating if Nav1.6 
co-localises with NCX in the axonal torpedoes in patients with mitochondrial will help 
determine if the axonal torpedoes are undergoing axonal degeneration. Additionally, if 
Nav1.6 and NCX  co-localisation differs between patient and control axonal torpedoes, it 
would suggest that the outcome of their formation in patients would differ to the mechanisms 
in controls.   
The data obtained in this work was achieved through work completed on post mortem human 
cerebellar sections. This is a limitation as it only allows for an investigation into the end point 
of the disease and does provide any insight into time course and progression of axonal 
changes in the cerebellum of patients with mitochondrial disease. As axonal torpedoes have 
been identified in normal aging mice (Baurle and Grusser-Cornehls, 1994), a mouse model 
would be sufficient to further research axonal torpedoes formation by taking cerebellar 
sections at different time points which would hopefully allow for the visualisation of  axonal 
torpedoes forming. Additionally, if there was a model of mitochondrial disease caused by a 
mitochondrial defect specifically to the Purkinje cell, it would also allow for the investigation 
into how mitochondrial dysfunction alters the Purkinje cell axon morphology and determine if 
Purkinje cell loss due to mitochondrial dysfunction causes a remodelling of the Purkinje cell 
circuitry. CLARITY could be used on 250µm cerebellar sections from different time points, 
for example P28, P84, P126 and P168, in both the wild type mice and mice with 
dysfunctional mitochondria in the Purkinje cells.  Using Purkinje cell markers such as 
parvalbumin and calretinin, large areas of Purkinje cells could be imaged using a confocal 
microscope. The recurrent axons and axonal torpedoes would then be reconstructed and 
analysed using software such as Matlab and a neurite tracer module on ImageJ (Longair et al., 
2011) . A similar method was used by Witter et al. (2016)  which showed that the recurrent 
axons are confined to a parasagittal plane and the recurrent axons make contact with contact 
Purkinje cells, Lugaro cells, and MLI. If this experiment was carried out in conjunction with 
ex vivo electrophysiological recordings of the same cerebellar sections, then the electrical 
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activity of the cerebellum in could be recorded. This would show the effects of mitochondrial 
dysfunction on the electrical activity of the cerebellum and in combination with the 
immunofluorescent study mentioned above, it would be possible to determine how the 
physical changes and remodelling relate to changes in electrical activity.  
6.6.2. CLARITY 
As mentioned in section 6.5, the sample size in the study investigating axonal morphology 
was too small. To address that issue, I would look at including more controls and patients in 
that study and I have already acquired samples from two patients with mitochondrial disease. 
Additionally, I have started the CLARITY protocol on a control sample that had been fixed in 
PFA and frozen in order to determine if sections fixed and stored in this manner would be a 
viable source of tissue for further experiments using CLARITY.  
An issue that arose with the use of CLARITY was the lack of antibody penetration which 
restricted the thickness of the tissue to 250μm. This issue has been experienced by other 
authors and they have tried to address the issue. One paper utilised the polarity of antibodies 
and applied an electrical current to increase the penetration into the antibodies (Li et al., 
2015). Whereas, Lee et al. (2016) used centrifugal force both spinning the sections at 600 x g 
for 3 hours for each antibody incubation. This was shown to successfully increase the depth of 
specific labelling and also reduced the length of incubation. Both methods utilise a simple set 
up which could be applied to the cleared tissue used in this project. To determine if the 
methods were an improvement, I would simultaneously stain sections with the protocol I 
developed while staining different sections with the methods described above to allow for a 
direct comparison. Alternatively, Fragment antigen-binding F(ab) antibodies conjugated with 
a fluorophore could be used instead of a whole IgG antibody. F(ab) antibodies are produced 
when whole IgG antibodies undergo pepsin digestion which removes the majority of the Fc 
region while leaving the antigen binding intact some of the hinge region. F(ab) antibodies 
have a molecular weight of 110kDa, compared to 160kDa of a whole IgG antibody. The 
smaller and lighter F(ab) antibodies would diffuse into the tissue far easier as there would be 
less steric hindrance increasing the depth and rate at which they will diffuse into the tissue. 
In addition to improving the penetration of antibodies, a final important step of optimisation 
in the CLARITY method is to optimise the use of mitochondrial antibodies in the passively 
cleared human sections so that I can confidently quantify the level of respiratory chain 
deficiency in those sections. Once that has been completed, it would allow for the 
investigation into the distribution of dysfunctional mitochondria in the different neuronal 
compartments of the same neuron.  
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The observation of reduced Purkinje cell axon volume was made in 5µm sections, therefore I 
would like to complete a more comprehensive study of individual Purkinje cell axon volume 
in the CLARITY sections. Using CLARITY would allow for a larger portion of the complete 
axon to be measured making the observation of a reduction in axonal volume more robust. As 
Purkinje cell axon volume was found to be significantly reduced in the granular cell layer of 
patients with mitochondrial disease compared to controls, it would be worthwhile looking at 
axons in other regions of the brain where there is a reduction in conduction velocities or white 
matter abnormalities to determine if a reduction in axon is present there.  
In mitochondrial disease, the grey matter has typically gained the most attention when 
understanding the role of respiratory chain deficiency in neurodegeneration.  The 
development of the CLARITY techniques provides an important tool for understanding 
changes in the connectivity and white matter in other brain region. MRI studies have observed 
deep white matter changes in the frontal and occipital lobe in patients with MELAS (Fujii et 
al., 1990) hence, using CLARITY in those regions can determine what those changes are 
microscopically and will provide further insights into how respiratory chain deficiency affects 
the neuronal connectivity.  
An additional application of the CLARITY technique would be to compare the vascular 
network between areas with stroke-like cortical lesions and neighbouring non-lesioned 
regions. Using markers such as Glut-1 and α-smooth muscle actin will help determine the 
density and morphology of arterioles and capillaries in these regions. This work would help 
determine if dysfunction and degeneration of small arteries, arterioles and capillaries is the 
primary cause of stroke-like lesions as proposed by the mitochondrial angiopathy theory 
(Koga et al., 2010).
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